<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users - Baandrup, L - 2018 | Cochrane Library</title> <meta content="Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users - Baandrup, L - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011481.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users - Baandrup, L - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011481.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011481.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users" name="citation_title"/> <meta content="Lone Baandrup" name="citation_author"/> <meta content="lone.baandrup@regionh.dk" name="citation_author_email"/> <meta content="Bjørn H Ebdrup" name="citation_author"/> <meta content="Mental Health Centre Glostrup, Mental Health Services of the Capital Region" name="citation_author_institution"/> <meta content="Jesper Ø Rasmussen" name="citation_author"/> <meta content="Jane Lindschou" name="citation_author"/> <meta content="Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Christian Gluud" name="citation_author"/> <meta content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Birte Y Glenthøj" name="citation_author"/> <meta content="Mental Health Centre Glostrup, Mental Health Services of the Capital Region" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD011481.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/03/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011481.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011481.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011481.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Withholding Treatment; Antidepressive Agents [therapeutic use]; Aspartic Acid [therapeutic use]; Benzodiazepines [administration &amp; dosage, *adverse effects]; Buspirone [therapeutic use]; Carbamazepine [therapeutic use]; Ethylamines [therapeutic use]; Flumazenil [therapeutic use]; Homeopathy; Imidazoles [therapeutic use]; Lithium Compounds [therapeutic use]; Melatonin [therapeutic use]; Paroxetine [therapeutic use]; Pregabalin [therapeutic use]; Progesterone [therapeutic use]; Pyridines [therapeutic use]; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome [*drug therapy]; Sulfides [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011481.pub2&amp;doi=10.1002/14651858.CD011481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6XSHdtL3";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011481\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011481\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ms","zh_HANS","fa","ru"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011481.pub2",title:"Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users",firstPublishedDate:"Mar 15, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Drugs and Alcohol Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6XSHdtL3&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011481.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011481.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011481.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011481.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011481.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011481.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011481.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011481.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011481.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011481.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11350 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011481.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-sec-0116"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-sec-0073"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-sec-0110"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/appendices#CD011481-sec-0121"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/table_n/CD011481StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/table_n/CD011481StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/information#CD011481-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Lone Baandrup</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/information#CD011481-cr-0003">Bjørn H Ebdrup</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/information#CD011481-cr-0004">Jesper Ø Rasmussen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/information#CD011481-cr-0005">Jane Lindschou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/information#CD011481-cr-0006">Christian Gluud</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011481.pub2/information#CD011481-cr-0007">Birte Y Glenthøj</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/information/en#CD011481-sec-0130">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 March 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011481.pub2">https://doi.org/10.1002/14651858.CD011481.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011481-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011481-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011481-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011481-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011481-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011481-abs-0001" lang="en"> <section id="CD011481-sec-0001"> <h3 class="title" id="CD011481-sec-0001">Background</h3> <p>Prolonged treatment with benzodiazepines is common practice despite clinical recommendations of short‐term use. Benzodiazepines are used by approximately 4% of the general population, with increased prevalence in psychiatric populations and the elderly. After long‐term use it is often difficult to discontinue benzodiazepines due to psychological and physiological dependence. This review investigated if pharmacological interventions can facilitate benzodiazepine tapering. </p> </section> <section id="CD011481-sec-0002"> <h3 class="title" id="CD011481-sec-0002">Objectives</h3> <p>To assess the benefits and harms of pharmacological interventions to facilitate discontinuation of chronic benzodiazepine use. </p> </section> <section id="CD011481-sec-0003"> <h3 class="title" id="CD011481-sec-0003">Search methods</h3> <p>We searched the following electronic databases up to October 2017: Cochrane Drugs and Alcohol Group's Specialised Register of Trials, CENTRAL, PubMed, Embase, CINAHL, and ISI Web of Science. We also searched ClinicalTrials.gov, the WHO ICTRP, and ISRCTN registry, and checked the reference lists of included studies for further references to relevant randomised controlled trials. </p> </section> <section id="CD011481-sec-0004"> <h3 class="title" id="CD011481-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials comparing pharmacological treatment versus placebo or no intervention or versus another pharmacological intervention in adults who had been treated with benzodiazepines for at least two months and/or fulfilled criteria for benzodiazepine dependence (any criteria). </p> </section> <section id="CD011481-sec-0005"> <h3 class="title" id="CD011481-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane.</p> </section> <section id="CD011481-sec-0006"> <h3 class="title" id="CD011481-sec-0006">Main results</h3> <p>We included 38 trials (involving 2543 participants), but we could only extract data from 35 trials with 2295 participants. Many different interventions were studied, and no single intervention was assessed in more than four trials. We extracted data on 18 different comparisons. The risk of bias was high in all trials but one. Trial Sequential Analysis showed imprecision for all comparisons. </p> <p>For benzodiazepine discontinuation, we found a potential benefit of valproate at end of intervention (1 study, 27 participants; risk ratio (RR) 2.55, 95% confidence interval (CI) 1.08 to 6.03; very low‐quality evidence) and of tricyclic antidepressants at longest follow‐up (1 study, 47 participants; RR 2.20, 95% CI 1.27 to 3.82; low‐quality evidence). </p> <p>We found potentially positive effects on benzodiazepine withdrawal symptoms of pregabalin (1 study, 106 participants; mean difference (MD) ‐3.10 points, 95% CI ‐3.51 to ‐2.69; very low‐quality evidence), captodiame (1 study, 81 participants; MD ‐1.00 points, 95% CI ‐1.13 to ‐0.87; very low‐quality evidence), paroxetine (2 studies, 99 participants; MD ‐3.57 points, 95% CI ‐5.34 to ‐1.80; very low‐quality evidence), tricyclic antidepressants (1 study, 38 participants; MD ‐19.78 points, 95% CI ‐20.25 to ‐19.31; very low‐quality evidence), and flumazenil (3 studies, 58 participants; standardised mean difference ‐0.95, 95% CI ‐1.71 to ‐0.19; very low‐quality evidence) at end of intervention. However, the positive effect of paroxetine on benzodiazepine withdrawal symptoms did not persist until longest follow‐up (1 study, 54 participants; MD ‐0.13 points, 95% CI ‐4.03 to 3.77; very low‐quality evidence). </p> <p>The following pharmacological interventions reduced symptoms of anxiety at end of intervention: carbamazepine (1 study, 36 participants; MD ‐6.00 points, 95% CI ‐9.58 to ‐2.42; very low‐quality evidence), pregabalin (1 study, 106 participants; MD ‐4.80 points, 95% CI ‐5.28 to ‐4.32; very low‐quality evidence), captodiame (1 study, 81 participants; MD ‐5.70 points, 95% CI ‐6.05 to ‐5.35; very low‐quality evidence), paroxetine (2 studies, 99 participants; MD ‐6.75 points, 95% CI ‐9.64 to ‐3.86; very low‐quality evidence), and flumazenil (1 study, 18 participants; MD ‐1.30 points, 95% CI ‐2.28 to ‐0.32; very low‐quality evidence). </p> <p>Two pharmacological treatments seemed to reduce the proportion of participants that relapsed to benzodiazepine use: valproate (1 study, 27 participants; RR 0.31, 95% CI 0.11 to 0.90; very low‐quality evidence) and cyamemazine (1 study, 124 participants; RR 0.33, 95% CI 0.14 to 0.78; very low‐quality evidence). Alpidem decreased the proportion of participants with benzodiazepine discontinuation (1 study, 25 participants; RR 0.41, 95% CI 0.17 to 0.99; number needed to treat for an additional harmful outcome (NNTH) 2.3 participants; low‐quality evidence) and increased the occurrence of withdrawal syndrome (1 study, 145 participants; RR 4.86, 95% CI 1.12 to 21.14; NNTH 5.9 participants; low‐quality evidence). Likewise, magnesium aspartate decreased the proportion of participants discontinuing benzodiazepines (1 study, 144 participants; RR 0.80, 95% CI 0.66 to 0.96; NNTH 5.8; very low‐quality evidence). </p> <p>Generally, adverse events were insufficiently reported. Specifically, one of the flumazenil trials was discontinued due to severe panic reactions. </p> </section> <section id="CD011481-sec-0007"> <h3 class="title" id="CD011481-sec-0007">Authors' conclusions</h3> <p>Given the low or very low quality of the evidence for the reported outcomes, and the small number of trials identified with a limited number of participants for each comparison, it is not possible to draw firm conclusions regarding pharmacological interventions to facilitate benzodiazepine discontinuation in chronic benzodiazepine users. Due to poor reporting, adverse events could not be reliably assessed across trials. More randomised controlled trials are required with less risk of systematic errors ('bias') and of random errors ('play of chance') and better and full reporting of patient‐centred and long‐term clinical outcomes. Such trials ought to be conducted independently of industry involvement. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011481-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011481-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011481-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011481-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011481-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011481-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011481-abs-0011">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011481-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011481-abs-0003" lang="en"> <h3>Medications for discontinuation of long‐term benzodiazepine use</h3> <p><b>Background</b> </p> <p>Benzodiazepines are widely prescribed for long‐term use despite recommendations of only short‐term use. It is often difficult to discontinue benzodiazepines after more than a few weeks of treatment due to the development of physical and psychological dependence. This review aimed to assess the effect and safety of medications to facilitate benzodiazepine discontinuation in chronic benzodiazepine users. </p> <p><b>Search date</b> </p> <p>The evidence is current to October 2017.</p> <p><b>Study characteristics</b> </p> <p>We identified 38 randomised controlled trials involving 2543 participants who had either been treated for more than two months with benzodiazepines, or who had been diagnosed with benzodiazepine dependence. We included studies irrespective of whether benzodiazepines were prescribed for anxiety, insomnia, or any other condition. </p> <p>The average age of participants was around 50 years, and the majority of participants were women in most studies. Twenty‐four trials were conducted in Europe; eight trials in the US or Canada; and six trials in Asia. The trials involved a wide range of medications to facilitate reduction or discontinuation of benzodiazepine use. Fourteen of the 38 included studies were partly funded by the drug manufacturer; nine studies were funded by government agencies; and 15 studies did not state the source of funding. The duration of the trials ranged between 1 and 24 weeks; the average trial duration was 9 weeks. </p> <p><b>Key results</b> </p> <p>We extracted data on 18 different comparisons in a total of 2295 participants. We are uncertain whether valproate and tricyclic antidepressants increase the chance of discontinuing benzodiazepines, and whether benzodiazepine withdrawal symptoms are reduced by pregabalin, captodiame, paroxetine, tricyclic antidepressants, and flumazenil, as we assessed the quality of the evidence as very low. We are uncertain as to whether symptoms of anxiety after withdrawal of benzodiazepines are reduced by carbamazepine, pregabalin, captodiame, paroxetine, and flumazenil, as we assessed the quality of the evidence as very low. The effects of the evaluated medications were too uncertain to inform clinical practice due to risk of bias (systematic errors with overestimation of benefits and underestimation of harms) and risk of chance occurrence (random errors giving any result). Tolerability and safety were poorly reported across the included studies, making it impossible to assess the balance between possible benefits and adverse effects. Consequently, no conclusions can be drawn about the effectiveness of the interventions. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence was generally low or very low due to the small number of trials including a limited number of participants for each comparison; dissimilar results across studies; poor study design; and pronounced financial involvement of the pharmaceutical industry. Randomised controlled trials are therefore needed without risk of bias and random significant results involving long‐term assessments of participants conducted without involvement of industry. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011481-sec-0116" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011481-sec-0116">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011481-sec-0187">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011481-sec-0116"></div> <h3 class="title" id="CD011481-sec-0117">Implications for practice</h3> <section id="CD011481-sec-0117"> <p>The current systematic review with meta‐analysis and Trial Sequential Analysis could not find any pharmaceutical add‐on to facilitate the withdrawal process. Some drugs seem to be associated with beneficial effects, but the quality of the evidence was too low to lead to any clinical recommendations. </p> </section> <h3 class="title" id="CD011481-sec-0118">Implications for research</h3> <section id="CD011481-sec-0118"> <p>Future research of the potential of pharmacological agents to facilitate benzodiazepine withdrawal should focus on drugs with a potential to benefit the patients according to the results of the current meta‐analysis and limit the different pharmacological interventions evaluated. Such randomised controlled trials should be assessed versus adequate placebo or nocebo to provide proper blinding and be designed according to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines (<a href="./references#CD011481-bbs2-0071" title="ChanAW , TetzlaffJM , AltmanDG , LaupacisA , GotzschePC , Krle A‐JericK , et al. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Revista Panamericana de Salud Publica(Pan American Journal of Public Health)2015;38(6):506‐14. [PUBMED: 27440100] ">Chan 2015</a>), and reported according to the CONSORT guidelines (<a href="./references#CD011481-bbs2-0108" title="SchulzKF , AltmanDG , MoherD . CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. International Journal of Surgery (London, England)2011;9(8):672‐7. [PUBMED: 22019563] ">Schulz 2011</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011481-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011481-sec-0029"></div> <div class="table" id="CD011481-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Valproate compared with placebo or no intervention for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Valproate compared with placebo or no intervention for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> valproate<br/> <b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Valproate</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.55</b> <br/> (1.08 to 6.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The required information size of 1918 participants was not met.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>679 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b><br/> (142 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.57</b> <br/> (0.80 to 3.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>785 per 1000</b><br/> (400 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean benzodiazepine withdrawal symptoms in the intervention groups was<br/> <b>0.15 standard deviations lower</b><br/> (0.68 lower to 0.37 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.15 (‐0.68 to 0.37).</p> <p>As a rule of thumb, 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio: <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No details provided regarding random sequence generation, allocation concealment, and blinding, leading to unclear risk of selection bias, performance and detection bias (downgraded one level).<br/> <sup>2</sup>Required information size not met (downgraded two levels due to serious imprecision: the sample size is far from the required one).<br/> <sup>3</sup>Unclear risk of selection bias, attrition bias, reporting bias and high risk of performance bias (downgraded one level).<br/> <sup>4</sup>Required information size not met (downgraded two levels due to serious imprecision). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011481-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Carbamazepine compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Carbamazepine compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> carbamazepine<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Carbamazepine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.33</b> <br/> (0.99 to 1.8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>147<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis showed that only 7.0% of the required information size (2109) was reached, indicating that insufficient information has been obtained. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>480 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>638 per 1000</b><br/> (475 to 864) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.41</b> <br/> (0.86 to 2.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>40<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>524 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>739 per 1000</b><br/> (450 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean benzodiazepine withdrawal symptoms in the intervention groups was<br/> <b>1.14 standard deviations lower</b><br/> (2.43 lower to 0.16 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐1.14 (‐2.43 to 0.16).</p> <p>As a rule of thumb, 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio: <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection bias. One study with high risk of attrition, reporting, and other bias (downgraded one level).<br/> <sup>2</sup>Required information size not met (downgraded one level due to imprecision).<br/> <sup>3</sup>Unclear risk of selection and attrition bias (downgraded one level).<br/> <sup>4</sup>Required information size not met, and 95% CI includes both no effect and appreciable benefit (downgraded two levels due to imprecision).<br/> <sup>5</sup>Required information size not met (downgraded one level for imprecision).<br/> <sup>6</sup>Significant heterogeneity (downgraded one level for inconsistency). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011481-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Lithium compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lithium compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> lithium<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Lithium</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.05</b> <br/> (0.86 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>230<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The required information size of 1918 participants was not met.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>617 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>648 per 1000</b><br/> (531 to 790) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection, attrition, and reporting bias (downgraded one level).<br/> <sup>2</sup>The required information size of 1918 participants was not met (downgraded one level due to imprecision). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011481-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Pregabalin compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pregabalin compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> pregabalin<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Pregabalin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.44</b> <br/> (0.92 to 2.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>106<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The required information size of 1918 participants was not met.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>360 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>518 per 1000</b><br/> (331 to 810) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, Physician Withdrawal Checklist (PWCL), end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean benzodiazepine withdrawal symptoms, PWCL, end of intervention in the intervention group was<br/> <b>3.10 lower</b><br/> (3.51 to 2.69 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐3.10 (‐3.51 to ‐2.69)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection bias and high risk of attrition and other bias (downgraded two levels).<br/> <sup>2</sup>Required information size not met (downgraded one level due to imprecision). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011481-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Captodiame compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Captodiame compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> captodiame<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Captodiame</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ), end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean benzodiazepine withdrawal symptoms, BWSQ, end of intervention in the intervention group was<br/> <b>1.00 lower</b><br/> (1.13 to 0.87 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐1.00 (‐1.13 to ‐0.87)</p> <p>The required information size of 229 participants was not met.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection and reporting bias. High risk of other bias (downgraded one level).<br/> <sup>2</sup>Required information size not met (downgraded two levels due to imprecision). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011481-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Paroxetine compared with placebo or no intervention for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Paroxetine compared with placebo or no intervention for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> paroxetine<br/> <b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Paroxetine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.45</b> <br/> (0.88 to 2.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>221<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis showed that only 2.34% of the required information size (9448) was reached, indicating that insufficient information has been obtained. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>504 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>731 per 1000</b><br/> (444 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, BWSQ, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean benzodiazepine withdrawal symptoms, BWSQ, end of intervention in the intervention groups was<br/> <b>3.57 lower</b><br/> (5.34 to 1.8 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐3.57 (‐5.34 to ‐1.8). Trial Sequential Analysis showed that the required information size of 229 participants was not reached. However, the alpha‐spending boundaries for benefit were crossed, indicating that sufficient information was obtained, and the result was not due to random error. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, BWSQ, longest follow‐up: 6 months</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean benzodiazepine withdrawal symptoms, BWSQ, longest follow‐up: 6 months in the intervention group was<br/> <b>0.13 lower</b><br/> (4.03 lower to 3.77 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.13 (‐4.03 to 3.77)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BWSQ:</b> Benzodiazepine Withdrawal Symptom Questionnaire; <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection and attrition bias. High risk of performance, detection, reporting, and other bias (downgraded two levels).<br/> <sup>2</sup>Required information size not met (downgraded one level due to imprecision).<br/> <sup>3</sup>Unclear risk of selection bias. High risk of performance, detection, reporting, and other bias (downgraded two levels).<br/> <sup>4</sup>The required information size was not met (downgraded one level due to imprecision).<br/> <sup>5</sup>Unclear risk of selection bias. High risk of reporting and other bias (downgraded one level).<br/> <sup>6</sup>Required information size not met (downgraded two levels due to imprecision). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011481-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Tricyclic antidepressants compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tricyclic antidepressants compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> tricyclic antidepressants<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tricyclic antidepressants</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.82</b> <br/> (0.52 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>105<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis showed that only 7.82% of the required information size (1343) was reached, indicating that insufficient information has been obtained. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>451 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>370 per 1000</b><br/> (235 to 577) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.2</b> <br/> (1.27 to 3.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>47<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>375 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>825 per 1000</b><br/> (476 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, Physician Withdrawal Checklist, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean benzodiazepine withdrawal symptoms in the intervention group was<br/> 19.78<b>lower</b><br/> (20.25 lower to 19.31 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐19.78 (‐20.25 to ‐19.31)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection bias and high risk of attrition and other bias (downgraded one level).<br/> <sup>2</sup>Required information size not met (downgraded one level due to imprecision).<br/> <sup>3</sup>Unclear risk of selection and attrition bias (downgraded one level).<br/> <sup>4</sup>Required information size not met (downgraded two levels due to imprecision).<br/> <sup>5</sup>High risk of performance, detection, and reporting bias (downgraded two levels). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011481-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Alpidem compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Alpidem compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> alpidem<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Alpidem</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.41</b> <br/> (0.17 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>25<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The required information size of 1918 participants was not met.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>750 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>308 per 1000</b><br/> (128 to 743) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawal syndrome (clinical diagnosis), end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 4.86</b> <br/> (1.12 to 21.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>145<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b><br/> (33 to 622) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Required information size not met (downgraded two levels due to imprecision).<br/> <sup>2</sup>Required information size not met (downgraded one level due to imprecision). </p> <p><sup>3</sup>Unclear risk of selection and other bias, high risk of attrition bias (downgraded one level) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011481-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Buspirone compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Buspirone compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> buspirone<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Buspirone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.82</b> <br/> (0.49 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>143<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis showed that only 4.23% of the required information size (3381) was reached, indicating that insufficient information has been obtained. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>563 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>462 per 1000</b><br/> (276 to 772) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.60</b> <br/> (0.34 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>23<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>917 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>550 per 1000</b><br/> (312 to 962) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean benzodiazepine withdrawal symptoms, end of intervention in the intervention groups was<br/> <b>4.69 higher</b><br/> (14.47 lower to 23.85 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 4.69 (‐14.47 to 23.87)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean benzodiazepine withdrawal symptoms, longest follow‐up in the intervention groups was<br/> <b>1.34 lower</b><br/> (14.31 lower to 11.63 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐1.34 (‐14.31 to 11.63)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection, performance, and reporting bias. High risk of attrition and other bias (downgraded one level).<br/> <sup>2</sup>Required information size not met (downgraded one level due to imprecision).<br/> <sup>3</sup>Unclear risk of selection and reporting bias. High risk of attrition bias (downgraded one level).<br/> <sup>4</sup>Reguired information size not met (downgraded two levels due to serious imprecision). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011481-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Melatonin compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Melatonin compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients (3 studies), outpatients in methadone maintenance treatment (1 study)<br/> <b>Intervention:</b> melatonin<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Melatonin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.20</b> <br/> (0.73 to 1.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>219<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis showed that only 6.37% of the required information size (3438) was reached, indicating that insufficient information has been obtained. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>417 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b><br/> (304 to 817) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.03</b> <br/> (0.47 to 2.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>38<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>389 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>401 per 1000</b><br/> (183 to 883) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazpine withdrawal symptoms, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection, attrition, and reporting bias. High risk of other bias (downgraded one level).<br/> <sup>2</sup>Required information size not met, and the 95% CI includes both no effect and appreciable benefit (downgraded two levels due to imprecision).<br/> <sup>3</sup>Unclear risk of selection and reporting bias (downgraded one level).<br/> <sup>4</sup>Required information size not met (downgraded two levels due to imprecision). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011481-tbl-0011"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Flumazenil compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Flumazenil compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients in methadone maintenance treatment (2 studies), outpatients (1 study)<br/> <b>Intervention:</b> flumazenil<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Flumazenil</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean benzodiazepine withdrawal symptoms, end of intervention in the intervention groups was<br/> <b>0.95 standard deviations lower</b><br/> (1.71 to 0.19 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.95 (‐1.71 to ‐0.19)</p> <p>As a rule of thumb, 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection bias and high risk of performance, detection, and other bias (downgraded one level).<br/> <sup>2</sup>Required information size not met (downgraded two levels due to imprecision). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011481-tbl-0012"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Progesterone compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progesterone compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> progesterone<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Progesterone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.15</b> <br/> (0.52 to 2.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>35<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The required information size of 1918 participants was not met.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>417 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>479 per 1000</b><br/> (217 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection and attrition bias (downgraded one level).<br/> <sup>2</sup>Required information size not met, and the 95% CI includes both no effect and appreciable benefit (downgraded two levels due to imprecision). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011481-tbl-0013"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Magnesium aspartate compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Magnesium aspartate compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> magnesium aspartate<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Magnesium aspartate</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.80</b> <br/> (0.66 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>144<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The required information size of 1918 participants was not met.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>853 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>683 per 1000</b><br/> (563 to 819) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection, detection, and attrition bias (downgraded one level).<br/> <sup>2</sup>Required information size not met (downgraded two levels due to imprecision). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011481-tbl-0014"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 14.</span> <span class="table-title">Homéogène 46/Sedatif PC (homeopathic drugs) compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Homéogène 46/Sedatif PC (homeopathic drugs) compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> Homéogène 46/Sedatif PC (homeopathic drugs)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Homéogène 46/Sedatif PC (homeopathic drugs)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.79</b> <br/> (0.36 to 1.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>51<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The required information size was not met.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>381 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>301 per 1000</b><br/> (137 to 648) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection, attrition, and other bias (downgraded one level).<br/> <sup>2</sup>Required information size not met, and the 95% CI includes both no effect and appreciable benefit (downgraded two levels due to imprecision). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011481-tbl-0015"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 15.</span> <span class="table-title">Carbamazepine compared with tricyclic antidepressant for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Carbamazepine compared with tricyclic antidepressant for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> carbamazepine<br/> <b>Comparison:</b> tricyclic antidepressant </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tricyclic antidepressant</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Carbamazepine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.00</b> <br/> (0.78 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>48<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The required information size was not met.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>833 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>833 per 1000</b><br/> (650 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection, detection, and attrition bias (downgraded one level).<br/> <sup>2</sup>Required information size not met (downgraded one level due to imprecision). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011481-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011481-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011481-sec-0138">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD011481-sec-0030"></div> <section id="CD011481-sec-0031"> <h3 class="title" id="CD011481-sec-0031">Description of the condition</h3> <p>Benzodiazepines are widely prescribed, and consumption remains high despite a modest overall decline during the last couple of decades (<a href="./references#CD011481-bbs2-0090" title="IslamMM , ConigraveKM , DayCA , NguyenY , HaberPS . Twenty‐year trends in benzodiazepine dispensing in the Australian population. Internal Medicine Journal2014;44(1):57‐64. ">Islam 2014</a>; <a href="./references#CD011481-bbs2-0116" title="TsimtsiouZ , AshworthM , JonesR . Variations in anxiolytic and hypnotic prescribing by GPs: a cross‐sectional analysis using data from the UK Quality and Outcomes Framework. British Journal of General Practice2009;59(563):e191‐8. ">Tsimtsiou 2009</a>). A US national survey indicated a prevalence of benzodiazepine consumption of 3.8% among non‐institutionalised adults (<a href="./references#CD011481-bbs2-0105" title="Paulose‐RamR , SafranMA , JonasBS , GuQ , OrwigD . Trends in psychotropic medication use among U.S. adults. Pharmacoepidemiology and Drug Safety2007;16(5):560‐70. ">Paulose‐Ram 2007</a>), and the prevalence approached 8% in a Dutch survey of elderly people (<a href="./references#CD011481-bbs2-0111" title="SonnenbergCM , BiermanEJ , DeegDJ , ComijsHC , vanTilburgW , BeekmanAT . Ten‐year trends in benzodiazepine use in the Dutch population. Social Psychiatry and Psychiatric Epidemiology2012;47(2):293‐301. ">Sonnenberg 2012</a>). Another US survey reported an increase in the percentage of adults filling a benzodiazepine prescription from 4.1% in 1996 to 5.6% in 2013 (<a href="./references#CD011481-bbs2-0063" title="BachhuberMA , HennessyS , CunninghamCO , StarrelsJL . Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996‐2013. American Journal of Public Health2016;106(4):686‐8. [PUBMED: 26890165] ">Bachhuber 2016</a>). A survey in a New Zealand psychiatric outpatient setting documented that one‐third of the patients were prescribed benzodiazepines or benzodiazepine‐like drugs, and the majority of prescriptions were long‐standing (<a href="./references#CD011481-bbs2-0086" title="HuthwaiteMA , AnderssonV , StanleyJ , RomansSE . Hypnosedative prescribing in outpatient psychiatry. International Clinical Psychopharmacology2013;28(4):157‐63. ">Huthwaite 2013</a>). </p> <p>Benzodiazepines are indicated for short‐term treatment of anxiety and insomnia, but prescriptions are often prolonged due to the development of dependence and a lack of knowledge of non‐pharmacological management of anxiety, insomnia, and similar symptoms (<a href="./references#CD011481-bbs2-0061" title="AshtonH . The diagnosis and management of benzodiazepine dependence. Current Opinion in Psychiatry2005;18(3):249‐55. [PUBMED: 16639148] ">Ashton 2005</a>; <a href="./references#CD011481-bbs2-0086" title="HuthwaiteMA , AnderssonV , StanleyJ , RomansSE . Hypnosedative prescribing in outpatient psychiatry. International Clinical Psychopharmacology2013;28(4):157‐63. ">Huthwaite 2013</a>; <a href="./references#CD011481-bbs2-0102" title="O'BrienCP . Benzodiazepine use, abuse, and dependence. Journal of Clinical Psychiatry2005;66 Suppl 2:28‐33. ">O'Brien 2005</a>). Gradual dose reduction of benzodiazepines is recommended above abrupt discontinuation to minimise withdrawal symptoms, including the risk of withdrawal seizures (<a href="./references#CD011481-bbs2-0075" title="Dell'ossoB , LaderM . Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. European Psychiatry: the Journal of the Association of European Psychiatrists2013;28(1):7‐20. [PUBMED: 22521806] ">Dell'osso 2013</a>). The importance of individual adjustment of withdrawal rate is emphasised in clinical practice guidelines. The individually adjusted withdrawal rate should include consideration of benzodiazepine type and dosage, original reason for prescribing, environmental stressors, and amount of available support (<a href="./references#CD011481-bbs2-0061" title="AshtonH . The diagnosis and management of benzodiazepine dependence. Current Opinion in Psychiatry2005;18(3):249‐55. [PUBMED: 16639148] ">Ashton 2005</a>). The duration of tapering is thus sometimes prolonged for months or years; however, very slow tapering rates do not seem superior to faster tapering regimens (<a href="./references#CD011481-bbs2-0103" title="ParrJM , KavanaghDJ , CahillL , MitchellG , McD YoungR . Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta‐analysis. Addiction2009;104(1):13‐24. ">Parr 2009</a>). Withdrawal symptoms may manifest both physically (e.g. flu‐like complaints, muscle cramps) and psychologically (e.g. irritability, insomnia, perceptual changes, anxiety, depersonalisation, derealisation) (<a href="./references#CD011481-bbs2-0064" title="BaldwinDS , AitchisonK , BatesonA , CurranHV , DaviesS , LeonardB , et al. Benzodiazepines: risks and benefits. A reconsideration. Journal of Psychopharmacology2013;27(11):967‐71. ">Baldwin 2013</a>). Withdrawal symptoms therefore often resemble the symptoms that led to the initial benzodiazepine prescription<b>,</b> erroneously leading patients and caregivers to assume that continued prescription is required. Discontinuation is thus complicated by a mixture of withdrawal symptoms and original symptoms that might reoccur in an exaggerated form (rebound symptoms). Psychological interventions (e.g. relaxation training, psycho‐education) for managing rebound symptoms are superior to gradual dose reduction alone in patients in primary care settings (<a href="./references#CD011481-bbs2-0103" title="ParrJM , KavanaghDJ , CahillL , MitchellG , McD YoungR . Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta‐analysis. Addiction2009;104(1):13‐24. ">Parr 2009</a>). Adverse reactions associated with benzodiazepine treatment include cognitive impairment (<a href="./references#CD011481-bbs2-0066" title="BarkerMJ , GreenwoodKM , JacksonM , CroweSF . Cognitive effects of long‐term benzodiazepine use: a meta‐analysis. CNS Drugs2004;18(1):37‐48. ">Barker 2004</a>; <a href="./references#CD011481-bbs2-0082" title="GlassJ , LanctotKL , HerrmannN , SprouleBA , BustoUE . Sedative hypnotics in older people with insomnia: meta‐analysis of risks and benefits. BMJ (Clinical Research Ed.)2005;331(7526):1169. ">Glass 2005</a>), psychomotor impairments with increased risk of falls, <a href="./references#CD011481-bbs2-0126" title="WoolcottJC , RichardsonKJ , WiensMO , PatelB , MarinJ , KhanKM , et al. Meta‐analysis of the impact of 9 medication classes on falls in elderly persons. Archives of Internal Medicine2009;169(21):1952‐60. ">Woolcott 2009</a>, and accidents (<a href="./references#CD011481-bbs2-0110" title="SminkBE , EgbertsAC , LusthofKJ , UgesDR , deGierJJ . The relationship between benzodiazepine use and traffic accidents: a systematic literature review. CNS Drugs2010;24(8):639‐53. ">Smink 2010</a>), daytime sedation (<a href="./references#CD011481-bbs2-0082" title="GlassJ , LanctotKL , HerrmannN , SprouleBA , BustoUE . Sedative hypnotics in older people with insomnia: meta‐analysis of risks and benefits. BMJ (Clinical Research Ed.)2005;331(7526):1169. ">Glass 2005</a>), and increased risk of dementia (<a href="./references#CD011481-bbs2-0067" title="Billioti de GageS , BegaudB , BazinF , VerdouxH , DartiguesJF , PeresK , et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ2012;345(27):e6231. ">Billioti 2012</a>; <a href="./references#CD011481-bbs2-0080" title="GallacherJ , ElwoodP , PickeringJ , BayerA , FishM , Ben‐ShlomoY . Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). Journal of Epidemiology and Community Health2012;66(10):869‐73. ">Gallacher 2012</a>; <a href="./references#CD011481-bbs2-0127" title="WuCS , WangSC , ChangIS , LinKM . The association between dementia and long‐term use of benzodiazepine in the elderly: nested case‐control study using claims data. American Journal of Geriatric Psychiatry2009;17(7):614‐20. ">Wu 2009</a>). Although benzodiazepines initially improve sleep continuity parameters (e.g. sleep latency, total sleep time) (<a href="./references#CD011481-bbs2-0070" title="BuscemiN , VandermeerB , FriesenC , BialyL , TubmanM , OspinaM , et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta‐analysis of RCTs. Journal of General Internal Medicine2007;22(9):1335‐50. ">Buscemi 2007a</a>), the drugs decrease the amount of deep sleep (<a href="./references#CD011481-bbs2-0104" title="ParrinoL , TerzanoMG . Polysomnographic effects of hypnotic drugs. A review. Psychopharmacology1996;126(1):1‐16. ">Parrino 1996</a>), thereby exerting a negative effect on the overall sleep architecture. Moreover, development of tolerance to the sedative effects implies that the original dose of the drug has progressively less effect, and higher doses are needed to obtain the desired effect (<a href="./references#CD011481-bbs2-0118" title="VinkersCH , OlivierB . Mechanisms underlying tolerance after long‐term benzodiazepine use: a future for subtype‐selective GABA(A) receptor modulators?. Advances in Pharmacological Sciences2012;2012:416864. [PUBMED: 22536226] ">Vinkers 2012</a>). Another concern associated with prolonged benzodiazepine use is the increased mortality reported in a number of observational studies (<a href="./references#CD011481-bbs2-0063" title="BachhuberMA , HennessyS , CunninghamCO , StarrelsJL . Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996‐2013. American Journal of Public Health2016;106(4):686‐8. [PUBMED: 26890165] ">Bachhuber 2016</a>; <a href="./references#CD011481-bbs2-0094" title="KripkeDF , KlauberMR , WingardDL , FellRL , AssmusJD , GarfinkelL . Mortality hazard associated with prescription hypnotics. Biological Psychiatry1998;43(9):687‐93. ">Kripke 1998</a>; <a href="./references#CD011481-bbs2-0095" title="KripkeDF , LangerRD , KlineLE . Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open2012;2(1):e000850. ">Kripke 2012</a>; <a href="./references#CD011481-bbs2-0099" title="MallonL , BromanJE , HettaJ . Is usage of hypnotics associated with mortality?. Sleep Medicine2009;10(3):279‐86. ">Mallon 2009</a>; <a href="./references#CD011481-bbs2-0122" title="WeichS , PearceHL , CroftP , SinghS , CromeI , BashfordJ , et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ (Clinical Research Ed.)2014;348:g1996. ">Weich 2014</a>). However, this issue is controversial because of conflicting results (<a href="./references#CD011481-bbs2-0081" title="GisevN , HartikainenS , ChenTF , KorhonenM , BellJS . Mortality associated with benzodiazepines and benzodiazepine‐related drugs among community‐dwelling older people in Finland: a population‐based retrospective cohort study. Canadian Journal of Psychiatry2011;56(6):377‐81. ">Gisev 2011</a>; <a href="./references#CD011481-bbs2-0084" title="HauskenAM , SkurtveitS , TverdalA . Use of anxiolytic or hypnotic drugs and total mortality in a general middle‐aged population. Pharmacoepidemiology and Drug Safety2007;16(8):913‐8. ">Hausken 2007</a>; <a href="./references#CD011481-bbs2-0092" title="JaussentI , AncelinML , BerrC , PeresK , ScaliJ , BessetA , et al. Hypnotics and mortality in an elderly general population: a 12‐year prospective study. BMC Medicine2013;11:212. ">Jaussent 2013</a>), and the lack of appropriate confounder control in many of the studies showing increased mortality (<a href="./references#CD011481-bbs2-0094" title="KripkeDF , KlauberMR , WingardDL , FellRL , AssmusJD , GarfinkelL . Mortality hazard associated with prescription hypnotics. Biological Psychiatry1998;43(9):687‐93. ">Kripke 1998</a>; <a href="./references#CD011481-bbs2-0095" title="KripkeDF , LangerRD , KlineLE . Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open2012;2(1):e000850. ">Kripke 2012</a>; <a href="./references#CD011481-bbs2-0099" title="MallonL , BromanJE , HettaJ . Is usage of hypnotics associated with mortality?. Sleep Medicine2009;10(3):279‐86. ">Mallon 2009</a>). </p> <p>The majority of benzodiazepine prescriptions occur in general practice, where the following characteristics are associated with increased risk of long‐term use: psychiatric comorbidity, older age, being less educated, being lonely, and using more avoidant coping behaviour (<a href="./references#CD011481-bbs2-0128" title="ZandstraSM , VanRijswijkE , RijndersCA , Van DeLisdonkEH , BorJH , VanWeelC , et al. Long‐term benzodiazepine users in family practice: differences from short‐term users in mental health, coping behaviour and psychological characteristics. Family Practice2004;21(3):266‐9. ">Zandstra 2004</a>). In the elderly, benzodiazepine prescribing rates are especially high, and in this population prescriptions are associated with female sex, low level of education, low income, chronic physical diseases, functional limitations, cognitive impairment, depression, anxiety, and insomnia (<a href="./references#CD011481-bbs2-0111" title="SonnenbergCM , BiermanEJ , DeegDJ , ComijsHC , vanTilburgW , BeekmanAT . Ten‐year trends in benzodiazepine use in the Dutch population. Social Psychiatry and Psychiatric Epidemiology2012;47(2):293‐301. ">Sonnenberg 2012</a>). In opioid users, the additional use of benzodiazepines is associated with increased risk of adverse reactions and overdose due to the depression of the central nervous system exerted by both types of drugs, in particular in combination with alcohol intake (<a href="./references#CD011481-bbs2-0093" title="JonesCM , PaulozziLJ , MackKA . Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse‐related emergency department visits and drug‐related deaths ‐ United States, 2010. MMWR. Morbidity and Mortality Weekly Report2014;63(40):881‐5. [PUBMED: 25299603] ">Jones 2014</a>). Use of opioids is increasing, especially in the US, both as analgesics for people with chronic pain and as illicit drug use (<a href="./references#CD011481-bbs2-0100" title="ManchikantiL , SinghA . Therapeutic opioids: a ten‐year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician2008;11(2 Suppl):S63‐88. [PUBMED: 18443641] ">Manchikanti 2008</a>; <a href="./references#CD011481-bbs2-0101" title="ManchikantiL , HelmSJr , FellowsB , JanataJW , PampatiV , GriderJS , et al. Opioid epidemic in the United States. Pain Physician2012;15(3 Suppl):ES9‐38. [PUBMED: 22786464] ">Manchikanti 2012</a>). The management of benzodiazepine dependence in subpopulations with comorbid substance abuse including opioid use therefore warrants attention. </p> </section> <section id="CD011481-sec-0032"> <h3 class="title" id="CD011481-sec-0032">Description of the intervention</h3> <p>Currently, no drugs are recommended or approved for the management of benzodiazepine dependence or facilitation of withdrawal after long‐term use. Theoretically, a drug can facilitate benzodiazepine discontinuation in several ways: by ameliorating physical withdrawal symptoms (e.g. propranolol to reduce tremor and tachycardia); by reducing psychological craving (i.e. administering non‐benzodiazepine sedating drugs); or by treating underlying insomnia or anxiety symptoms (e.g. melatonin, buspirone, imipramine). Antiepileptics and antidepressants are among the drugs most often evaluated, but with conflicting results (<a href="./references#CD011481-bbs2-0103" title="ParrJM , KavanaghDJ , CahillL , MitchellG , McD YoungR . Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta‐analysis. Addiction2009;104(1):13‐24. ">Parr 2009</a>; <a href="./references#CD011481-bbs2-0119" title="VoshaarRC , CouveeJE , vanBalkomAJ , MulderPG , ZitmanFG . Strategies for discontinuing long‐term benzodiazepine use: meta‐analysis. British Journal of Psychiatry2006;189:213‐20. ">Voshaar 2006</a>). Abrupt cessation of benzodiazepine treatment followed by administration of flumazenil (a benzodiazepine receptor antagonist) has also been investigated (<a href="./references#CD011481-bbs2-0008" title="GerraG , ZaimovicA , GiustiF , MoiG , BrewerC . Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo‐controlled study. Addiction Biology2002;7(4):385‐95. ">Gerra 2002</a>), but the feasibility of this approach is limited by the intravenous administration formulation and the need for continuous medical monitoring. An intervention to facilitate benzodiazepine discontinuation can be administered with the aim of 1) benzodiazepine cessation and thereafter discontinuation of the experimental drug, or 2) substituting the ongoing benzodiazepine treatment, that is replacing the benzodiazepine treatment with another temporary or chronic drug with a more favourable adverse reaction profile. </p> </section> <section id="CD011481-sec-0033"> <h3 class="title" id="CD011481-sec-0033">How the intervention might work</h3> <p>A Cochrane Review covering the literature until October 2004 investigated pharmacological interventions for management of benzodiazepine mono‐dependence in outpatient settings (<a href="./references#CD011481-bbs2-0077" title="DenisC , FatseasM , LavieE , AuriacombeM . Pharmacological interventions for benzodiazepine mono‐dependence management in outpatient settings. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD005194.pub2] ">Denis 2006</a>). The conclusion was that gradual taper was preferable to abrupt discontinuation, and that carbamazepine, but not other investigated compounds, might be an effective intervention for gradual benzodiazepine discontinuation. However, the evidence was not strong enough to guide clinical recommendation. A meta‐analysis including both inpatient and outpatient settings reported that augmentation of guided discontinuation programmes with imipramine was more effective than guided discontinuation alone (<a href="./references#CD011481-bbs2-0119" title="VoshaarRC , CouveeJE , vanBalkomAJ , MulderPG , ZitmanFG . Strategies for discontinuing long‐term benzodiazepine use: meta‐analysis. British Journal of Psychiatry2006;189:213‐20. ">Voshaar 2006</a>). Another systematic review of approaches to benzodiazepine discontinuation in general practice and outpatient settings published in 2009 did not support substitutive pharmacotherapies to assist benzodiazepine discontinuation (<a href="./references#CD011481-bbs2-0103" title="ParrJM , KavanaghDJ , CahillL , MitchellG , McD YoungR . Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta‐analysis. Addiction2009;104(1):13‐24. ">Parr 2009</a>). Psychological interventions have been found to be superior to gradual dose reduction (<a href="./references#CD011481-bbs2-0103" title="ParrJM , KavanaghDJ , CahillL , MitchellG , McD YoungR . Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta‐analysis. Addiction2009;104(1):13‐24. ">Parr 2009</a>; <a href="./references#CD011481-bbs2-0119" title="VoshaarRC , CouveeJE , vanBalkomAJ , MulderPG , ZitmanFG . Strategies for discontinuing long‐term benzodiazepine use: meta‐analysis. British Journal of Psychiatry2006;189:213‐20. ">Voshaar 2006</a>), and are the topic of another recently published Cochrane Review (<a href="./references#CD011481-bbs2-0073" title="DarkerCD , SweeneyBP , BarryJM , FarrellMF , Donnelly‐SwiftE . Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. The Cochrane Database of Systematic Reviews2015, Issue 5. [DOI: 10.1002/14651858.CD009652.pub2] ">Darker 2015</a>). </p> <p>The pharmacological interventions hitherto investigated have tried to address the pharmacology of benzodiazepines and have thereby theoretically tried to counteract the withdrawal symptoms or to treat re‐emerging insomnia and anxiety. In this respect, carbamazepine has been one of the most promising drugs so far (<a href="./references#CD011481-bbs2-0077" title="DenisC , FatseasM , LavieE , AuriacombeM . Pharmacological interventions for benzodiazepine mono‐dependence management in outpatient settings. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD005194.pub2] ">Denis 2006</a>), but other drugs are accessible such as melatonin to counteract insomnia developed as part of the withdrawal syndrome (<a href="./references#CD011481-bbs2-0006" title="GarfinkelD , ZisapelN , WainsteinJ , LaudonM . Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Archives of Internal Medicine1999;159(20):2456‐60. ">Garfinkel 1999</a>), or pregabalin to reduce symptoms of general anxiety emerging or worsening when benzodiazepines are withdrawn (<a href="./references#CD011481-bbs2-0010" title="HadleySJ , MandelFS , SchweizerE . Switching from long‐term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double‐blind, placebo‐controlled trial. Journal of Psychopharmacology2012;26(4):461‐70. [DOI: 10.1177/0269881111405360] SzczypaP , HadleySJ , DonevanS , MandelFS , LeonT . P.4.a.016 Switching from long‐term benzodiazepine therapy to pregabalin in patients with generalised anxiety disorder (GAD). European Neuropsychopharmacology2009;19:S594‐5. [DOI: 10.1016/S0924‐977X(09)70952‐6] ">Hadley 2012</a>). </p> </section> <section id="CD011481-sec-0034"> <h3 class="title" id="CD011481-sec-0034">Why it is important to do this review</h3> <p>Long‐term benzodiazepine use is generally inappropriate due to adverse reactions (e.g. impaired psychomotor and cognitive functioning) and the risks of development of dependence and addiction. Distressing adverse reactions often complicate withdrawal attempts, and therefore it is important to evaluate whether any pharmacological intervention may facilitate the withdrawal or discontinuation of benzodiazepines. This could potentially minimise both individual and societal costs associated with the often extensive and prolonged withdrawal regimens. Since the previous reviews were conducted (<a href="./references#CD011481-bbs2-0077" title="DenisC , FatseasM , LavieE , AuriacombeM . Pharmacological interventions for benzodiazepine mono‐dependence management in outpatient settings. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD005194.pub2] ">Denis 2006</a>; <a href="./references#CD011481-bbs2-0103" title="ParrJM , KavanaghDJ , CahillL , MitchellG , McD YoungR . Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta‐analysis. Addiction2009;104(1):13‐24. ">Parr 2009</a>; <a href="./references#CD011481-bbs2-0119" title="VoshaarRC , CouveeJE , vanBalkomAJ , MulderPG , ZitmanFG . Strategies for discontinuing long‐term benzodiazepine use: meta‐analysis. British Journal of Psychiatry2006;189:213‐20. ">Voshaar 2006</a>), new studies investigating how to facilitate benzodiazepine discontinuation have been published, and a new systematic review was therefore warranted. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011481-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011481-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011481-sec-0143">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011481-sec-0035"></div> <p>To assess the benefits and harms of pharmacological interventions to facilitate discontinuation of chronic benzodiazepine use. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011481-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011481-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011481-sec-0144">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011481-sec-0036"></div> <section id="CD011481-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011481-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included relevant randomised controlled trials irrespective of publication type, publication date, publication language, and publication status. We did not include quasi‐randomised clinical studies and observational studies. In making this decision we are well aware that we achieve more focus on potential benefits and less on potential harms, since rare adverse events that develop only after long‐term exposure are underestimated in randomised controlled trials. </p> </section> <section id="CD011481-sec-0039"> <h4 class="title">Types of participants</h4> <p>Adult (aged 18 years or older) chronic benzodiazepine users defined as daily use of benzodiazepines for a minimum duration of two months; or people diagnosed with benzodiazepine dependence by any diagnostic criteria (e.g. International Classification of Diseases (ICD)‐10: F13.1 or F13.2). We also included participants with psychiatric or somatic comorbidities. Benzodiazepines in this review included the benzodiazepine‐like compounds (sometimes referred to as Z‐drugs, e.g. zolpidem and zopiclone). </p> </section> <section id="CD011481-sec-0040"> <h4 class="title">Types of interventions</h4> <section id="CD011481-sec-0041"> <h5 class="title">Experimental intervention</h5> <p>The experimental intervention could be any drug administered to facilitate benzodiazepine withdrawal or to switch from benzodiazepine treatment to another drug. We included interventions conducted in general practice, outpatient settings, and in hospitalised patients. </p> </section> <section id="CD011481-sec-0042"> <h5 class="title">Control intervention</h5> <p>The control interventions included:</p> <p> <ul id="CD011481-list-0001"> <li> <p>treatment as usual, as defined by the trialists;</p> </li> <li> <p>placebo;</p> </li> <li> <p>any active pharmacological comparator.</p> </li> </ul> </p> </section> <section id="CD011481-sec-0043"> <h5 class="title">Co‐interventions</h5> <p>Co‐interventions of any kind were allowed, as long as they were delivered equally in both intervention groups. </p> </section> </section> <section id="CD011481-sec-0044"> <h4 class="title">Types of outcome measures</h4> <p>We assessed all outcomes at two time points:</p> <p> <ul id="CD011481-list-0002"> <li> <p>end of intervention, as defined by the trialists. This was the primary outcome time point in the review; </p> </li> <li> <p>longest follow‐up, as defined by the trialists.</p> </li> </ul> </p> <section id="CD011481-sec-0045"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD011481-list-0003"> <li> <p>Benzodiazepine discontinuation (defined as cessation) measured by examining the blood or urine concentration of the participant or by self reported use. </p> </li> <li> <p>Benzodiazepine withdrawal symptoms as measured by relevant questionnaires.</p> </li> <li> <p>Serious adverse events, defined as any adverse event that results in death, is life‐threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect (<a href="./references#CD011481-bbs2-0087" title="International Council for Harmonisation (ICH) Topic E 6 (R1) Guideline for Good Clinical Practice. ichgcp.net/pdf/ich‐gcp‐en.pdf (accessed prior to 10 February 2018). ">ICH GCP</a>). </p> </li> </ol> </p> </section> <section id="CD011481-sec-0046"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011481-list-0004"> <li> <p>Benzodiazepine mean dose.</p> </li> <li> <p>Insomnia as measured by any relevant questionnaire.</p> </li> <li> <p>Anxiety as measured by any relevant questionnaire.</p> </li> <li> <p>Comorbid substance abuse as measured by self reported use of other drugs or alcohol.</p> </li> <li> <p>Non‐serious adverse events, defined as any non‐serious undesirable medical event experienced by participants during a clinical trial that does not necessarily have a causal relationship with the intervention (<a href="./references#CD011481-bbs2-0087" title="International Council for Harmonisation (ICH) Topic E 6 (R1) Guideline for Good Clinical Practice. ichgcp.net/pdf/ich‐gcp‐en.pdf (accessed prior to 10 February 2018). ">ICH GCP</a>). </p> </li> <li> <p>Relapse to benzodiazepine use (defined according to the trialists), assessed only at longest follow‐up after end of intervention among the subgroup of participants who discontinued benzodiazepine use at end of intervention. </p> </li> <li> <p>Discontinuation due to adverse events assessed only at the end of intervention.</p> </li> </ol> </p> </section> </section> </section> <section id="CD011481-sec-0047"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant randomised controlled trials regardless of language or publication status (published, unpublished, in press, or in progress). </p> <section id="CD011481-sec-0048"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases:</p> <p> <ul id="CD011481-list-0005"> <li> <p>Cochrane Drugs and Alcohol Group's Specialised Register of Trials (searched on 17 October 2017); </p> </li> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 9);</p> </li> <li> <p>PubMed (January 1966 to 17 October 2017);</p> </li> <li> <p>Embase (Embase.com) (January 1974 to 17 October 2017);</p> </li> <li> <p>CINAHL (Cumulative Index to Nursing and Allied Health Literature) (EbscoHOST) (1982 to 17 October 2017); </p> </li> <li> <p>Web of Knowledge, Web of Science (1990 to 17 October 2017).</p> </li> </ul> </p> <p>We searched the databases using MeSH and free‐text terms relating to substance use disorders. We combined the PubMed search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity‐ and precision‐maximising version (2008 revision) (<a href="./references#CD011481-bbs2-0096" title="LefebvreC , ManheimerE , Glanville . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Lefebvre 2011</a>). Detailed search strategies were developed for each database used, accounting for differences in controlled vocabulary and syntax rules. For details see <a href="./appendices#CD011481-sec-0122">Appendix 1</a>; <a href="./appendices#CD011481-sec-0123">Appendix 2</a>; <a href="./appendices#CD011481-sec-0124">Appendix 3</a>; <a href="./appendices#CD011481-sec-0125">Appendix 4</a>; <a href="./appendices#CD011481-sec-0126">Appendix 5</a>; <a href="./appendices#CD011481-sec-0127">Appendix 6</a>. </p> <p>We searched the following trials registries on 17 October 2017:</p> <p> <ul id="CD011481-list-0006"> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>); </p> </li> <li> <p>the ISRCTN registry (<a href="http://www.isrctn.com/" target="_blank">www.isrctn.com</a>). </p> </li> </ul> </p> </section> <section id="CD011481-sec-0049"> <h4 class="title">Searching other resources</h4> <p>We searched for further relevant trials by screening reference lists of previous review papers and those of all articles selected for inclusion. </p> <p>Where possible, we contacted the first author of each included study to seek information about further relevant published and unpublished trials. </p> </section> </section> <section id="CD011481-sec-0050"> <h3 class="title" id="CD011481-sec-0050">Data collection and analysis</h3> <section id="CD011481-sec-0051"> <h4 class="title">Selection of studies</h4> <p>Two review authors (LB and BE, or LB and JR) independently screened titles of all studies obtained by the search strategy. After excluding all obviously irrelevant articles, we screened the abstracts of all remaining publications. We obtained all potentially relevant studies in full text, and two review authors independently assessed these studies for inclusion in the review (LB and BE, or LB and JR). During this process, we linked multiple reports of the same trial. </p> </section> <section id="CD011481-sec-0052"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (LB and BE, or LB and JR) extracted data from the included studies using a standard extraction form. Any disagreements were resolved by consensus between raters (LB and BE, or LB and JR), and if not possible by judgement of authors JL and CG. </p> <p>We extracted the following data.</p> <p> <ul id="CD011481-list-0007"> <li> <p>General information: publication status, title, authors’ names, source, country, contact address, language of publication, year of publication, duplicate publication. </p> </li> <li> <p>Trial characteristics: design and setting.</p> </li> <li> <p>Interventions: type of pharmacological intervention, dose, duration, type of control intervention. </p> </li> <li> <p>Participants: inclusion and exclusion criteria, number of participants in intervention and control groups, participant demographics such as sex and age, baseline characteristics, and number of participants lost to follow‐up. </p> </li> <li> <p>Outcomes: please see <a href="#CD011481-sec-0044">Types of outcome measures</a> above. </p> </li> <li> <p>Risk of bias: please see <a href="#CD011481-sec-0053">Assessment of risk of bias in included studies</a> below. </p> </li> </ul> </p> </section> <section id="CD011481-sec-0053"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias for randomised controlled trials using the criteria recommended by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011481-bbs2-0085" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). The recommended approach for assessing risk of bias in studies included in a Cochrane Review is a two‐part tool, addressing seven specific domains, namely sequence generation and allocation concealment (selection bias), blinding of participants and providers (performance bias), blinding of outcome assessor (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias), and other sources of bias including industry bias (<a href="./references#CD011481-bbs2-0097" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3; PUBMED: 28207928] ">Lundh 2017</a>). The first part of the tool involves describing what was reported to have happened in the trial. The second part of the tool involves assigning a judgement relating to the risk of bias for that entry, in terms of low, high, or unclear risk. To make these judgements we used the criteria indicated by the <i>Cochrane Handbook</i> adapted to the addiction field. See <a href="./appendices#CD011481-sec-0128">Appendix 7</a> for details. </p> <p>We addressed the domains of sequence generation and allocation concealment (avoidance of selection bias) in the tool by a single entry for each study. </p> <p>Regarding blinding of participants, personnel, and outcome assessor (avoidance of performance bias and detection bias), we planned to consider these items separately for objective outcomes (e.g. urine drug screening) and subjective outcomes (e.g. severity of signs and symptoms of withdrawal, adverse events). However, since all available outcomes were self reported, the dichotomisation into objective and subjective outcomes was not relevant. </p> <p>We considered incomplete outcome data (avoidance of attrition bias) for all outcomes.</p> <section id="CD011481-sec-0054"> <h5 class="title">Overall assessment of risk of bias</h5> <p>We classified a trial as at low risk of bias only if all of the bias components described in the above paragraphs were classified as at low risk of bias. If one or more of the bias domains were classified as at unclear or high risk of bias, we classified the trial as at high risk of bias. If we found no trials at low risk of bias or only a very few trials at low risk of bias, we planned to identify a group of trials with lower risk of bias, defined as those having low risk of bias in the following domains: generation of allocation sequence, allocation concealment, and blinding of participants and treatment providers. However, since we classified only one trial as at low risk of bias, and thus the majority of the trials (k = 37; 97%) as at high risk of bias, it was not possible to apply this classification in the current review. </p> </section> </section> <section id="CD011481-sec-0055"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we calculated a risk ratio (RR) with 95% confidence interval (CI), and in case of a significant result based on trials at low risk of bias, we reported the number needed to treat for an additional beneficial outcome (NNTB) or the number needed to treat for an additional harmful outcome (NNTH) as the inverse of the absolute risk difference. </p> <p>For continuous data, we calculated the mean difference (MD) between groups. We did not calculate effect size measures (standardised mean difference (SMD)) for all outcomes because of the inherent limitations associated with this measure (<a href="./references#CD011481-bbs2-0085" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). However, if scales of very considerable similarity were used, we could presume there was a small difference in the different measurements, and we calculated the effect size and planned to transform the effect back to the units of one or more of the specific instruments. However, due to marked differences in among‐participant variability, we did not find it relevant to re‐express the SMD using one of the specific measurement instruments. </p> </section> <section id="CD011481-sec-0056"> <h4 class="title">Unit of analysis issues</h4> <p>The trial participant was the unit of analysis.</p> <section id="CD011481-sec-0057"> <h5 class="title">1. Cluster trials</h5> <p>No cluster‐randomised trials were included. If one or more cluster‐randomised trials had been included, we would have calculated the ‘design effect’ as described in our protocol (<a href="./references#CD011481-bbs2-0062" title="BaandrupL , EbdrupBH , LindschouJ , GluudC , GlenthøjBY . Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database of Systematic Reviews2015, Issue 1. [DOI: 10.1002/14651858.CD011481] ">Baandrup 2015</a>). </p> </section> <section id="CD011481-sec-0058"> <h5 class="title">2. Cross‐over trials</h5> <p>We used data only from the first phase of cross‐over trials.</p> </section> <section id="CD011481-sec-0059"> <h5 class="title">3. Studies with multiple intervention groups</h5> <p>Where a trial involved more than two intervention groups, we included both when relevant, or included data from the most relevant comparison if it was not appropriate from a clinical point of view to combine the experimental intervention groups into a single group (<a href="./references#CD011481-bbs2-0085" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </section> </section> <section id="CD011481-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>We tried to contact the first authors of studies to supply any missing data with regard to the defined outcomes. However, many of the included studies were old and the reported author contact details were outdated. It was thus impossible to contact many of the authors, and even the authors of newer studies did not reply to our queries for missing data. </p> <section id="CD011481-sec-0061"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous outcomes, we did not impute missing values and analysed data as a complete‐case analysis. </p> </section> <section id="CD011481-sec-0062"> <h5 class="title">Continuous data</h5> <p>If standard deviations (SDs) were not reported, we calculated them, if possible, using other data from the trial. If calculation of the SD was impossible, we imputed SDs from trials with similar characteristics if we considered this to be a valid approach. </p> </section> </section> <section id="CD011481-sec-0063"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity in the trials both by visual inspection of a forest plot and by using a standard Chi<sup>2</sup> value with a significance level of P = 0.10. We assessed heterogeneity by use of the I<sup>2</sup> statistic. We interpreted an I<sup>2</sup> estimate greater than or equal to 50% and a significant Chi<sup>2</sup> statistic as evidence of substantial heterogeneity (<a href="./references#CD011481-bbs2-0085" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). If this was the case, we explored the reasons for heterogeneity. If there was high inconsistency, and a clear reason was found, we planned to present data separately. We only performed a meta‐analysis if a sufficient number of studies were identified and if combining these studies was feasible as judged by clinical and statistical characteristics. </p> </section> <section id="CD011481-sec-0064"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to inspect funnel plot symmetry when at least 10 trials were included in the meta‐analysis (<a href="./references#CD011481-bbs2-0079" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.)1997;315(7109):629‐34. ">Egger 1997</a>; <a href="./references#CD011481-bbs2-0098" title="MacaskillP , WalterSD , IrwigL . A comparison of methods to detect publication bias in meta‐analysis. Statistics in Medicine2001;20(4):641‐54. ">Macaskill 2001</a>), bearing in mind that publication bias does not necessarily cause asymmetry, and that asymmetry may have other causes than publication bias. The inspection by funnel plot was not possible because none of the meta‐analyses included at least 10 trials. </p> <p>For each included study, we investigated whether a study protocol was available. We searched PubMed, other major reference databases, and the Internet for a study protocol if a web address was not specifically stated in the article. This search could reveal abstracts or presentations relating to the study, and a comparison of outcomes with published outcomes was then possible. For newer studies, we searched for information on predefined outcome measures in trial registries. We had planned to construct a matrix containing recorded outcomes in each study, which then could indicate which studies did not report outcomes reported by the majority of included studies. However, during the process of data extraction and quality assessment, it was very evident which trials were associated with reporting bias, since these trials did not report the most evident outcome, namely some measure of benzodiazepine consumption. </p> </section> <section id="CD011481-sec-0065"> <h4 class="title">Data synthesis</h4> <p>We divided the analyses according to type of experimental drug and pooling of drugs where a class effect could be expected (i.e. pooling of data from trials investigating drugs with a similar pharmacological profile, if clinical and statistical heterogeneity allowed). We performed meta‐analyses according to the recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011481-bbs2-0085" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), using the software Review Manager 5 (<a href="./references#CD011481-bbs2-0106" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We further conducted Trial Sequential Analysis using the software available from <a href="./references#CD011481-bbs2-0072" title="Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. ctu.dk/tsa/ (accessed 25 March 2017). ">CTU 2011</a>. </p> <section id="CD011481-sec-0066"> <h5 class="title">Meta‐analysis</h5> <p>We performed meta‐analyses using a random‐effects model based on expectations of substantial heterogeneity among included trials (<a href="./references#CD011481-bbs2-0074" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>; <a href="./references#CD011481-bbs2-0076" title="DeMetsDL . Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine1987;6(3):341‐50. ">DeMets 1987</a>; <a href="./references#CD011481-bbs2-0078" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>). However, in case we found that one or two trials dominated the reported evidence (i.e. constituted more than 75% of the evidence), and there was substantial heterogeneity, we planned to synthesise data when appropriate and to emphasise results from the fixed‐effect model. However, due to the nature of the extracted data this scenario was not relevant. </p> </section> <section id="CD011481-sec-0067"> <h5 class="title">Trial Sequential Analysis</h5> <p>We applied Trial Sequential Analysis, <a href="./references#CD011481-bbs2-0072" title="Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. ctu.dk/tsa/ (accessed 25 March 2017). ">CTU 2011</a>; <a href="./references#CD011481-bbs2-0115" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf (accessed 19 March 2014). ">Thorlund 2011b</a>, because cumulative meta‐analyses are at risk of producing random errors due to sparse data and repetitive testing of the accumulating data (<a href="./references#CD011481-bbs2-0068" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology2008;61(8):763‐9. ">Brok 2008</a>; <a href="./references#CD011481-bbs2-0069" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. ">Brok 2009</a>; <a href="./references#CD011481-bbs2-0112" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology2009;38(1):276‐86. ">Thorlund 2009</a>; <a href="./references#CD011481-bbs2-0113" title="ThorlundK , AnemaA , MillsE . Interpreting meta‐analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV‐infected individuals. Clinical Epidemiology2010;2:57‐66. ">Thorlund 2010</a>; <a href="./references#CD011481-bbs2-0123" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>; <a href="./references#CD011481-bbs2-0124" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>). To minimise random errors, we calculated the required information size (i.e. the number of participants needed in a meta‐analysis to detect or reject a certain intervention effect) (<a href="./references#CD011481-bbs2-0114" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis ‐ a simulation study. PLoS ONE2011;6(10):e25491. ">Thorlund 2011a</a>; <a href="./references#CD011481-bbs2-0123" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>; <a href="./references#CD011481-bbs2-0125" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta‐analysis. BMC Medical Research Methodology2017;17(1):39. [PUBMED: 28264661] ">Wetterslev 2017</a>). The required information size for a meta‐analysis corresponds to the sample size for a single trial (<a href="./references#CD011481-bbs2-0125" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta‐analysis. BMC Medical Research Methodology2017;17(1):39. [PUBMED: 28264661] ">Wetterslev 2017</a>). The required information size takes into account: the event proportion in the control group; the assumption of a plausible risk ratio (RR) reduction, or the RR reduction observed in the included trials with low risk of bias; and the assumed heterogeneity, <a href="./references#CD011481-bbs2-0117" title="TurnerRM , JacksonD , WeiY , ThompsonSG , HigginsJP . Predictive distributions for between‐study heterogeneity and simple methods for their application in Bayesian meta‐analysis. Statistics in Medicine2014;34(6):984‐98. [PUBMED: 25475839] ">Turner 2014</a>, or diversity of the meta‐analysis (<a href="./references#CD011481-bbs2-0123" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>; <a href="./references#CD011481-bbs2-0124" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>; <a href="./references#CD011481-bbs2-0125" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta‐analysis. BMC Medical Research Methodology2017;17(1):39. [PUBMED: 28264661] ">Wetterslev 2017</a>). </p> <p>Trial Sequential Analysis enables testing for significance each time a new trial is added to the meta‐analysis (<a href="./references#CD011481-bbs2-0115" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf (accessed 19 March 2014). ">Thorlund 2011b</a>; <a href="./references#CD011481-bbs2-0123" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>; <a href="./references#CD011481-bbs2-0125" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta‐analysis. BMC Medical Research Methodology2017;17(1):39. [PUBMED: 28264661] ">Wetterslev 2017</a>). We added the trials according to the year of publication, and if more than one trial had been published in a year, we added trials alphabetically according to the last name of the first author. On the basis of the required information size and risk of type I and type II errors, we further constructed trial sequential monitoring boundaries. These boundaries determine the statistical inference one may draw from a meta‐analysis that has not reached the required information size. If the trial sequential boundary is crossed before the required information size is reached, firm evidence may perhaps be established and further trials may turn out to be superfluous. On the other hand, it is probably necessary to continue doing trials in order to detect or reject a certain intervention effect, if the trial sequential boundaries are not crossed. </p> <p>As default, we originally planned to use a type I error of 5%, and a type II error of 20%. However, to account for multiplicity, we decreased the risk of type I error for the three primary outcomes to 2.5%, and to 1.25% for the seven secondary outcomes (<a href="./references#CD011481-bbs2-0091" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. [PUBMED: 25416419] ">Jakobsen 2014</a>). Furthermore, we decreased the risk of type II error to 10%. For dichotomous outcomes, we had planned to estimate the required information size based on the proportion of participants with an outcome in the control group, a risk ratio of 20% or as suggested by the trials with low risk of bias, a diversity of 30% and 60%, or as suggested by the trials in the meta‐analysis. Specifically, for the primary dichotomised outcome 'benzodiazepine discontinuation', we used a control event proportion of 48% for all analyses, as this was the observed mean for trials assessing this outcome. For continuous outcomes, we estimated the required information size based on the SD observed in the control group of trials with low risk of bias and a minimal relevant difference of 50% of this SD, a diversity of 30% and 60%, or as suggested by the trials in the meta‐analysis. Specifically, for the secondary continuous outcome 'anxiety', assessed with the Hamilton Anxiety Rating Scale (HAM‐A), we used a variance of 103 (corresponding to an SD of 10 points), and a minimal relevant difference of 5 points for all analyses, as this was the highest observed variance in the trials assessing this outcome. Likewise, we used a variance of 20 points (corresponding to an SD of 4.5 points), and a minimal relevant difference of 2.25 points for all analyses of benzodiazepine withdrawal symptoms assessed with the Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ), as this was the highest observed variance in the trials assessing this outcome. </p> <p>It was only possible to conduct Trial Sequential Analysis for eight outcomes, because fewer than two trials reported the same outcome, using the same instrument. In such situations the accrued information is such a small proportion of the required information size that Trial Sequential Analysis figures become uninterpretable. </p> </section> </section> <section id="CD011481-sec-0068"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We had planned to group the results from included studies according to the following methodological or clinical issues. </p> <p> <ol id="CD011481-list-0008"> <li> <p>Trials at low risk of bias compared to trials at high risk of bias, or if we found no trials with low risk of bias, we would compare trials at lower risk of bias to trials at high risk of bias. </p> </li> <li> <p>Type of benzodiazepine or benzodiazepine‐related drug.</p> </li> <li> <p>Trials with different types of treatment setting (e.g. general practice compared to outpatient setting compared to inpatient setting). </p> </li> <li> <p>Trials with different modes of benzodiazepine tapering (e.g. prescheduled or symptom‐guided).</p> </li> <li> <p>Participants with concurrent psychiatric illness compared to participants without concurrent psychiatric illness. </p> </li> <li> <p>Trials with different duration of the intervention: short (0 to 2 months), medium (3 to 6 months), and long (&gt; 6 months). </p> </li> <li> <p>Trials including inpatients compared to trials including outpatients.</p> </li> <li> <p>Participants with other substance dependence versus participants with only benzodiazepine dependence/chronic use. </p> </li> </ol> </p> <p>However, due to the high number of different pharmacological add‐on agents with few trials per agent, we chose not to perform any of our planned subgroup analyses. </p> </section> <section id="CD011481-sec-0069"> <h4 class="title">Sensitivity analysis</h4> <p>We had planned to perform a sensitivity analysis to examine the impact of our assumptions regarding missing data. Furthermore, we had planned a sensitivity analysis to investigate the influence of trials with low compliance with study medication compared to trials with high compliance with study medication (compliance as defined by the trialists). </p> <section id="CD011481-sec-0070"> <h5 class="title">Assumption for lost dichotomous data</h5> <p>We had planned to perform two sensitivity analyses:</p> <p> <ul id="CD011481-list-0009"> <li> <p>’Best‐worst‐case’ scenario: It will be assumed that all participants lost to follow‐up in the experimental group had no outcome, and that all participants lost to follow‐up in the control group had the outcome. </p> </li> <li> <p>’Worst‐best‐case’ scenario: It will be assumed that all participants lost to follow‐up in the experimental group had the outcome, and that all participants lost to follow‐up in the control group had no outcome. </p> </li> </ul> </p> </section> <section id="CD011481-sec-0071"> <h5 class="title">Assumptions for lost continuous data</h5> <p>Where assumptions had to be made regarding missing SDs (see: <a href="#CD011481-sec-0060">Dealing with missing data</a>), we had planned sensitivity analysis to test how prone results were to change when 'completer' data only were compared to the imputed data using the above assumption. If there was a substantial difference, we had planned to report results and discuss them but continue to employ our assumption. Imputation of data turned out to be relevant for only one comparison: alpidem versus placebo (anxiety; <a href="./references#CD011481-fig-0056" title="">Analysis 8.3</a>). </p> <p>However, due to the high number of different pharmacological add‐on agents with few trials per agent, we chose not to perform any of our planned sensitivity analyses. </p> </section> <section id="CD011481-sec-0072"> <h5 class="title">'Summary of findings'</h5> <p>We used the GRADE system to assess the quality of the body of evidence and constructed 'Summary of findings' tables for the two primary outcomes on benzodiazepine consumption, employing GRADEpro software (<a href="./references#CD011481-bbs2-0083" title="ims.cochrane.org/revman/gradepro. ">GRADE</a>). We assessed five factors of the study design and implementation of available trials that may downgrade the quality of the evidence, namely: risk of bias; indirectness of evidence (population, intervention, control, outcomes); unexplained heterogeneity or inconsistency of results (including problems with subgroup analyses); imprecision of results; and high probability of publication bias. </p> <p>Based on this, we defined the levels of evidence as follows (<a href="./references#CD011481-bbs2-0065" title="BalshemH , HelfandM , SchunemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401‐6. ">Balshem 2011</a>). </p> <p> <ul id="CD011481-list-0010"> <li> <p>High‐quality evidence when "we are very confident that the true effect lies close to that of the estimate of the effect". </p> </li> <li> <p>Moderate‐quality evidence when "we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different". </p> </li> <li> <p>Low‐quality evidence when the following statement applies: "Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect". </p> </li> <li> <p>Very low‐quality evidence when the following statement applies: "We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect". </p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011481-sec-0073" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011481-sec-0073"></div> <section id="CD011481-sec-0074"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD011481-sec-0136" title="">Characteristics of included studies</a> section. </p> <section id="CD011481-sec-0075"> <h4 class="title">Results of the search</h4> <p>Our search strategy identified 3280 unique records. After removal of duplicates and irrelevant records, the number was reduced to 1239. Of these, we excluded 1174 after screening, and a further 22 after reviewing the full texts (<a href="#CD011481-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011481-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011481-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011481-sec-0076"> <h4 class="title">Included studies</h4> <p>We included 43 publications reporting on 38 trials. Due to general poor reporting of the trials, we were not able to extract relevant data from all of the trials, even after attempting to contact the authors where possible. For this reason, we have not extracted data from <a href="./references#CD011481-bbs2-0027" title="RomachMK , KaplanHL , BustoUE , SomerG , SellersEM . A controlled trial of ondansetron, a 5‐HT3 antagonist, in benzodiazepine discontinuation. Journal of Clinical Psychopharmacology1998;18(2):121‐31. ">Romach 1998</a> (experimental drug: ondansetron), <a href="./references#CD011481-bbs2-0029" title="SaulPA , KorliparaK , PresleyP . A randomised, multicentre, double‐blind, comparison of atenolol and placebo in the control of benzodiazepine withdrawal symptoms. Acta Therapeutica1989;15(2):117‐23. ">Saul 1989</a> (experimental drug: atenolol), and <a href="./references#CD011481-bbs2-0019" title="MarianiJJ , MalcolmRJ , MamczurAK , ChoiJC , BradyR , NunesE , et al. Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients. American Journal of Drug and Alcohol Abuse2016;42(3):333‐40. [PUBMED: 26962719] ">Mariani 2016</a> (experimental drug: gabapentin). As a result, we included 35 trials involving 2295 participants with data in the quantitative meta‐analyses. See <a href="./references#CD011481-sec-0136" title="">Characteristics of included studies</a>. </p> <p>Most of the trials (n = 35) involved a comparison between an active medication versus placebo or no intervention, while three trials investigated the experimental drug against another active comparator. The experimental drugs investigated were diverse, which limited the pooled analyses that were possible. If clinically relevant, we grouped investigational drugs with a similar mechanism, for example tricyclic antidepressants. To retain the clinical relevance of the meta‐analyses, we did not group medications with dissimilar pharmacological action even though they may belong to the same Anatomical Therapeutic Chemical‐group, for example valproate and carbamazepine trials were not pooled. The interventions investigated and included in the quantitative meta‐analyses were as follows. </p> <p> <ul id="CD011481-list-0011"> <li> <p>Valproate versus placebo, <a href="./references#CD011481-bbs2-0025" title="RickelsK , SchweizerE , Garcia EspanaF , Case , G , DeMartinisN , GreenblattD . Trazodone and valproate in patients discontinuing long‐term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology1999;141(1):1‐5. ">Rickels 1999</a>, or no intervention (<a href="./references#CD011481-bbs2-0036" title="VormaH , KatilaH . Effect of valproate on benzodiazepine withdrawal severity in opioid‐dependent subjects: a pilot study. Heroin Addiction and Related Clinical Problems2011;13(1):15‐20. ">Vorma 2011</a>). </p> </li> <li> <p>Carbamazepine versus placebo (<a href="./references#CD011481-bbs2-0005" title="DiCostanzoE , RoveaA . The prophylaxis of benzodiazepine withdrawal syndrome in the elderly: the effectiveness of carbamazepine. A double‐blind study vs. placebo. Minerva Psichiatrica1992;33:301‐4. ">Di Costanzo 1992</a>; <a href="./references#CD011481-bbs2-0013" title="KleinE , ColinV , StolkJ , LenoxRH . Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. American Journal of Psychiatry1994;151(12):1760‐6. ">Klein 1994</a>; <a href="./references#CD011481-bbs2-0030" title="SchweizerE , Rickels , K , CaseWG , GreenblattDJ . Carbamazepine treatment in patients discontinuing long‐term benzodiazepine therapy. Effects on withdrawal severity and outcome. Archives of General Psychiatry1991;48(5):448‐52. ">Schweizer 1991</a>). </p> </li> <li> <p>Lithium versus placebo (<a href="./references#CD011481-bbs2-0017" title="LecrubierY , FessardN . Benzodiazepine discontinuation in chronic users: a double‐blind trial of lithium gluconate vs placebo [Arrêt des benzodiazépines chez des consommateurs chronique: un essai en double insu du gluconate de lithium vs placebo]. Annales Médico Phychologiques2005;163:24‐9. ">Lecrubier 2005</a>). </p> </li> <li> <p>Pregabalin versus placebo (<a href="./references#CD011481-bbs2-0010" title="HadleySJ , MandelFS , SchweizerE . Switching from long‐term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double‐blind, placebo‐controlled trial. Journal of Psychopharmacology2012;26(4):461‐70. [DOI: 10.1177/0269881111405360] SzczypaP , HadleySJ , DonevanS , MandelFS , LeonT . P.4.a.016 Switching from long‐term benzodiazepine therapy to pregabalin in patients with generalised anxiety disorder (GAD). European Neuropsychopharmacology2009;19:S594‐5. [DOI: 10.1016/S0924‐977X(09)70952‐6] ">Hadley 2012</a>). </p> </li> <li> <p>Captodiame versus placebo (<a href="./references#CD011481-bbs2-0020" title="Mercier‐GuyonC , ChabannesJP , SaviucP . The role of captodiamine in the withdrawal from long‐term benzodiazepine treatment. Current Medical Research and Opinion2004;20(9):1347‐55. [DOI: 10.1185/030079904125004457] ">Mercier‐Guyon 2004</a>). </p> </li> <li> <p>Paroxetine versus placebo, <a href="./references#CD011481-bbs2-0009" title="GlaxoSmithKline . Clinical comparison of paroxetine and placebo on the symptoms emerging during the taper phase of a chronic benzodiazepine treatment, in patients suffering from a variety of anxiety disorders. GSK ‐ Clinical Study Register (www.gsk‐clinicalstudyregister.com)2002. ">GlaxoSmithKline 2002</a>; <a href="./references#CD011481-bbs2-0038" title="ZitmanFG , CouveeJE . Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper‐off: report on behalf of the Dutch Chronic Benzodiazepine Working Group. British Journal of Psychiatry2001;178:317‐24. ">Zitman 2001</a>, or no intervention (<a href="./references#CD011481-bbs2-0022" title="NakaoM , TakeuchiT , NomuraK , TeramotoT , YanoE . Clinical application of paroxetine for chronic benzodiazepine users at an internal medicine clinic. Therapeutic Research2006;27(5):859‐67. NakaoM , TakeuchiT , NomuraK , TeramotoT , YanoE . Clinical application of paroxetine for tapering benzodiazepine use in non‐major‐depressive outpatients visiting an internal medicine clinic. Psychiatry and Clinical Neurosciences2006;60(5):605‐10. ">Nakao 2006</a>). </p> </li> <li> <p>Tricyclic antidepressants (dosulepin (<a href="./references#CD011481-bbs2-0033" title="TyrerP , FergusonB , HallstromC , MichieM , TyrerS , CooperS , et al. A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms. British Journal of Psychiatry1996;168(4):457‐61. ">Tyrer 1996</a>), imipramine (<a href="./references#CD011481-bbs2-0026" title="RickelsK , DeMartinisN , Garcia‐EspanaF , GreenblattDJ , MandosLA , RynnM . Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long‐term benzodiazepine therapy. American Journal of Psychiatry2000;157(12):1973‐9. ">Rickels 2000</a>; <a href="./references#CD011481-bbs2-0028" title="RynnM , Garcia‐EspanaF , GreenblattDJ , MandosLA , SchweizerE , RickelsK . Imipramine and buspirone in patients with panic disorder who are discontinuing long‐term benzodiazepine therapy. Journal of Clinical Psychopharmacology2003;23(5):505‐8. ">Rynn 2003</a>), or trazodone (<a href="./references#CD011481-bbs2-0037" title="ZhangH , JiangX , MaM , ZhangJ . A control study on treatment for benzodiazepine dependence with trazodone. Chinese Journal of Contemporary Neurology and Neurosurgery2013;13(5):411‐5. ">Zhang 2013</a>)) versus placebo. </p> </li> <li> <p>Alpidem versus placebo (<a href="./references#CD011481-bbs2-0003" title="CassanoGB , PetraccaA , BorghiC , ChiroliS , DidoniG , GarreauM . A randomized, double‐blind study of alpidem vs placebo in the prevention and treatment of benzodiazepine withdrawal syndrome. European Psychiatry1996;11(2):93‐9. ">Cassano 1996</a>; <a href="./references#CD011481-bbs2-0016" title="LaderM , FarrI , MortonS . A comparison of alpidem and placebo in relieving benzodiazepine withdrawal symptoms. International Clinical Psychopharmacology1993;8(1):31‐6. ">Lader 1993</a>). </p> </li> <li> <p>Buspirone versus placebo (<a href="./references#CD011481-bbs2-0001" title="AshtonCH , RawlinsMD , TyrerSP . A double‐blind placebo‐controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. British Journal of Psychiatry1990;157:232‐8. ">Ashton 1990</a>; <a href="./references#CD011481-bbs2-0015" title="LaderM , OlajideD . A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. Journal of Clinical Psychopharmacology1987;7(1):11‐5. ">Lader 1987</a>; <a href="./references#CD011481-bbs2-0021" title="MortonS , LaderM . Buspirone treatment as an aid to benzodiazepine withdrawal. Journal of Psychopharmacology1995;9(4):331‐5. ">Morton 1995</a>; <a href="./references#CD011481-bbs2-0034" title="UdelmanHD , UdelmanDL . Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy. Journal of Clinical Psychiatry1990;51 Suppl:46‐50. ">Udelman 1990</a>). </p> </li> <li> <p>Melatonin (short‐acting, <a href="./references#CD011481-bbs2-0024" title="PelesE , HetzroniT , Bar‐HamburgerR , AdelsonM , SchreiberS . Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double‐blind randomized clinical trial. Addiction2007;102(12):1947‐53. ">Peles 2007</a>; <a href="./references#CD011481-bbs2-0035" title="VissersFH , KnipschildPG , CrebolderHF . Is melatonin helpful in stopping the long‐term use of hypnotics? A discontinuation trial. Pharmacy World &amp; Science2007;29(6):641‐6. [DOI: 10.1007/s11096‐007‐9118‐y] ">Vissers 2007</a>, and prolonged‐release, <a href="./references#CD011481-bbs2-0002" title="BaandrupL , FagerlundB , GlenthojB . Neurocognitive performance, subjective well‐being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add‐on melatonin versus placebo. European Archives of Psychiatry and Clinical Neuroscience2017;267(2):163‐71. [PUBMED: 27400927] BaandrupL , GlenthojBY , JennumPJ . Objective and subjective sleep quality: melatonin versus placebo add‐on treatment in patients with schizophrenia or bipolar disorder withdrawing from long‐term benzodiazepine use. Psychiatry Research2016;240:163‐9. [PUBMED: 27107670] BaandrupL , LindschouJ , WinkelP , GluudC , GlenthojBY . Prolonged‐release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: a randomised, placebo‐controlled, blinded trial. World Journal of Biological Psychiatry2016;17(7):514‐24. [PUBMED: 26086792] ">Baandrup 2016</a>; <a href="./references#CD011481-bbs2-0006" title="GarfinkelD , ZisapelN , WainsteinJ , LaudonM . Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Archives of Internal Medicine1999;159(20):2456‐60. ">Garfinkel 1999</a>) versus placebo. </p> </li> <li> <p>Flumazenil versus placebo (<a href="./references#CD011481-bbs2-0007" title="GerraG , MarcatoA , CaccavariR , Fertonani‐AffiniG , FontanesiB , ZaimovicA , et al. Effectiveness of flumazenil (Ro 15‐1788) in the treatment of benzodiazepine withdrawal. Current Therapeutic Research ‐ Clinical and Experimental1993;54(5):580‐7. ">Gerra 1993</a>; <a href="./references#CD011481-bbs2-0008" title="GerraG , ZaimovicA , GiustiF , MoiG , BrewerC . Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo‐controlled study. Addiction Biology2002;7(4):385‐95. ">Gerra 2002</a>; <a href="./references#CD011481-bbs2-0012" title="Harrison‐ReadPE , TyrerP , LawsonC , LackS , FernandesC , FileSE . Flumazenil‐precipitated panic and dysphoria in patients dependent on benzodiazepines: a possible aid to abstinence. Journal of Psychopharmacology1996;10(2):89‐97. ">Harrison‐Read 1996</a>). </p> </li> <li> <p>Propranolol versus placebo (<a href="./references#CD011481-bbs2-0032" title="TyrerP , RutherfordD , HuggettT . Benzodiazepine withdrawal symptoms and propranolol. Lancet1981;1(8219):520‐2. ">Tyrer 1981</a>). </p> </li> <li> <p>Progesterone versus placebo (<a href="./references#CD011481-bbs2-0031" title="SchweizerE , CaseWG , Garcia‐EspanaF , GreenblattDJ , RickelsK . Progesterone co‐administration in patients discontinuing long‐term benzodiazepine therapy: effects on withdrawal severity and taper outcome. Psychopharmacology1995;117(4):424‐9. ">Schweizer 1995</a>). </p> </li> <li> <p>Magnesium aspartate versus placebo (<a href="./references#CD011481-bbs2-0011" title="HantoucheEG , GuelfiJD , CometD . Discontinuation of long‐term benzodiazepine use: double‐blind controlled study of α‐β L‐aspartate magnesium versus placebo in 144 chronic users of benzodiazepines [α‐β L‐aspartate de magnésium dans l'arrêt de la consommation chronique des benzodiazépines: étude contrôlée en double aveugle versus placebo]. L'encéphale1998;XXIV:469‐79. HantoucheEG , JacobL , CometD , GuelfiJD . Discontinuation of long‐term benzodiazepine use: predictive model of success in a double‐blind, controlled‐study. 150th Annual Meeting of the American Psychiatric Association, 1997 May 17‐22; San Diego, (CA). 1997. ">Hantouche 1998</a>). </p> </li> <li> <p>Homeopathic drugs versus placebo (<a href="./references#CD011481-bbs2-0004" title="CialdellaP , BoisselJP , BelonP , the ASTRHO group. Homeopathic specialties as a substitute for benzodiazepines: a double‐blind vs. placebo study. Thérapie2001;56:397‐402. ">Cialdella 2001</a>). </p> </li> <li> <p>Carbamazepine versus tricyclic antidepressant (tianeptine) (<a href="./references#CD011481-bbs2-0014" title="KornowskiJ . The comparison between tianeptine and carbamazepine in benzodiazepines withdrawal syndrome. Psychiatria Polska2002;6(Suppl):311‐8. ">Kornowski 2002</a>). </p> </li> <li> <p>Bromazepam versus cyamemazine (<a href="./references#CD011481-bbs2-0018" title="LemoineP , KermadiI , Garcia‐AcostaS , GarayRP , DibM . Double‐blind, comparative study of cyamemazine vs. bromazepam in the benzodiazepine withdrawal syndrome. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2006;30(1):131‐7. ">Lemoine 2006</a>). </p> </li> <li> <p>Zopiclone versus flunitrazepam (<a href="./references#CD011481-bbs2-0023" title="Pat‐HorenczykR , HacohenD , HererP , LavieP . The effects of substituting zopiclone in withdrawal from chronic use of benzodiazepine hypnotics. Psychopharmacology1998;140(4):450‐7. [DOI: 10.1007/s002130050789] ">Pat‐Horenczyk 1998</a>). </p> </li> </ul> </p> <p>Out of the 38 trials, 24 were single‐centre (<a href="./references#CD011481-bbs2-0001" title="AshtonCH , RawlinsMD , TyrerSP . A double‐blind placebo‐controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. British Journal of Psychiatry1990;157:232‐8. ">Ashton 1990</a>; <a href="./references#CD011481-bbs2-0002" title="BaandrupL , FagerlundB , GlenthojB . Neurocognitive performance, subjective well‐being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add‐on melatonin versus placebo. European Archives of Psychiatry and Clinical Neuroscience2017;267(2):163‐71. [PUBMED: 27400927] BaandrupL , GlenthojBY , JennumPJ . Objective and subjective sleep quality: melatonin versus placebo add‐on treatment in patients with schizophrenia or bipolar disorder withdrawing from long‐term benzodiazepine use. Psychiatry Research2016;240:163‐9. [PUBMED: 27107670] BaandrupL , LindschouJ , WinkelP , GluudC , GlenthojBY . Prolonged‐release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: a randomised, placebo‐controlled, blinded trial. World Journal of Biological Psychiatry2016;17(7):514‐24. [PUBMED: 26086792] ">Baandrup 2016</a>; <a href="./references#CD011481-bbs2-0004" title="CialdellaP , BoisselJP , BelonP , the ASTRHO group. Homeopathic specialties as a substitute for benzodiazepines: a double‐blind vs. placebo study. Thérapie2001;56:397‐402. ">Cialdella 2001</a>; <a href="./references#CD011481-bbs2-0005" title="DiCostanzoE , RoveaA . The prophylaxis of benzodiazepine withdrawal syndrome in the elderly: the effectiveness of carbamazepine. A double‐blind study vs. placebo. Minerva Psichiatrica1992;33:301‐4. ">Di Costanzo 1992</a>; <a href="./references#CD011481-bbs2-0006" title="GarfinkelD , ZisapelN , WainsteinJ , LaudonM . Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Archives of Internal Medicine1999;159(20):2456‐60. ">Garfinkel 1999</a>; <a href="./references#CD011481-bbs2-0007" title="GerraG , MarcatoA , CaccavariR , Fertonani‐AffiniG , FontanesiB , ZaimovicA , et al. Effectiveness of flumazenil (Ro 15‐1788) in the treatment of benzodiazepine withdrawal. Current Therapeutic Research ‐ Clinical and Experimental1993;54(5):580‐7. ">Gerra 1993</a>; <a href="./references#CD011481-bbs2-0008" title="GerraG , ZaimovicA , GiustiF , MoiG , BrewerC . Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo‐controlled study. Addiction Biology2002;7(4):385‐95. ">Gerra 2002</a>; <a href="./references#CD011481-bbs2-0012" title="Harrison‐ReadPE , TyrerP , LawsonC , LackS , FernandesC , FileSE . Flumazenil‐precipitated panic and dysphoria in patients dependent on benzodiazepines: a possible aid to abstinence. Journal of Psychopharmacology1996;10(2):89‐97. ">Harrison‐Read 1996</a>; <a href="./references#CD011481-bbs2-0013" title="KleinE , ColinV , StolkJ , LenoxRH . Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. American Journal of Psychiatry1994;151(12):1760‐6. ">Klein 1994</a>; <a href="./references#CD011481-bbs2-0014" title="KornowskiJ . The comparison between tianeptine and carbamazepine in benzodiazepines withdrawal syndrome. Psychiatria Polska2002;6(Suppl):311‐8. ">Kornowski 2002</a>; <a href="./references#CD011481-bbs2-0019" title="MarianiJJ , MalcolmRJ , MamczurAK , ChoiJC , BradyR , NunesE , et al. Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients. American Journal of Drug and Alcohol Abuse2016;42(3):333‐40. [PUBMED: 26962719] ">Mariani 2016</a>; <a href="./references#CD011481-bbs2-0021" title="MortonS , LaderM . Buspirone treatment as an aid to benzodiazepine withdrawal. Journal of Psychopharmacology1995;9(4):331‐5. ">Morton 1995</a>; <a href="./references#CD011481-bbs2-0022" title="NakaoM , TakeuchiT , NomuraK , TeramotoT , YanoE . Clinical application of paroxetine for chronic benzodiazepine users at an internal medicine clinic. Therapeutic Research2006;27(5):859‐67. NakaoM , TakeuchiT , NomuraK , TeramotoT , YanoE . Clinical application of paroxetine for tapering benzodiazepine use in non‐major‐depressive outpatients visiting an internal medicine clinic. Psychiatry and Clinical Neurosciences2006;60(5):605‐10. ">Nakao 2006</a>; <a href="./references#CD011481-bbs2-0023" title="Pat‐HorenczykR , HacohenD , HererP , LavieP . The effects of substituting zopiclone in withdrawal from chronic use of benzodiazepine hypnotics. Psychopharmacology1998;140(4):450‐7. [DOI: 10.1007/s002130050789] ">Pat‐Horenczyk 1998</a>; <a href="./references#CD011481-bbs2-0024" title="PelesE , HetzroniT , Bar‐HamburgerR , AdelsonM , SchreiberS . Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double‐blind randomized clinical trial. Addiction2007;102(12):1947‐53. ">Peles 2007</a>; <a href="./references#CD011481-bbs2-0025" title="RickelsK , SchweizerE , Garcia EspanaF , Case , G , DeMartinisN , GreenblattD . Trazodone and valproate in patients discontinuing long‐term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology1999;141(1):1‐5. ">Rickels 1999</a>; <a href="./references#CD011481-bbs2-0026" title="RickelsK , DeMartinisN , Garcia‐EspanaF , GreenblattDJ , MandosLA , RynnM . Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long‐term benzodiazepine therapy. American Journal of Psychiatry2000;157(12):1973‐9. ">Rickels 2000</a>; <a href="./references#CD011481-bbs2-0027" title="RomachMK , KaplanHL , BustoUE , SomerG , SellersEM . A controlled trial of ondansetron, a 5‐HT3 antagonist, in benzodiazepine discontinuation. Journal of Clinical Psychopharmacology1998;18(2):121‐31. ">Romach 1998</a>; <a href="./references#CD011481-bbs2-0028" title="RynnM , Garcia‐EspanaF , GreenblattDJ , MandosLA , SchweizerE , RickelsK . Imipramine and buspirone in patients with panic disorder who are discontinuing long‐term benzodiazepine therapy. Journal of Clinical Psychopharmacology2003;23(5):505‐8. ">Rynn 2003</a>; <a href="./references#CD011481-bbs2-0030" title="SchweizerE , Rickels , K , CaseWG , GreenblattDJ . Carbamazepine treatment in patients discontinuing long‐term benzodiazepine therapy. Effects on withdrawal severity and outcome. Archives of General Psychiatry1991;48(5):448‐52. ">Schweizer 1991</a>; <a href="./references#CD011481-bbs2-0031" title="SchweizerE , CaseWG , Garcia‐EspanaF , GreenblattDJ , RickelsK . Progesterone co‐administration in patients discontinuing long‐term benzodiazepine therapy: effects on withdrawal severity and taper outcome. Psychopharmacology1995;117(4):424‐9. ">Schweizer 1995</a>; <a href="./references#CD011481-bbs2-0033" title="TyrerP , FergusonB , HallstromC , MichieM , TyrerS , CooperS , et al. A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms. British Journal of Psychiatry1996;168(4):457‐61. ">Tyrer 1996</a>; <a href="./references#CD011481-bbs2-0036" title="VormaH , KatilaH . Effect of valproate on benzodiazepine withdrawal severity in opioid‐dependent subjects: a pilot study. Heroin Addiction and Related Clinical Problems2011;13(1):15‐20. ">Vorma 2011</a>; <a href="./references#CD011481-bbs2-0037" title="ZhangH , JiangX , MaM , ZhangJ . A control study on treatment for benzodiazepine dependence with trazodone. Chinese Journal of Contemporary Neurology and Neurosurgery2013;13(5):411‐5. ">Zhang 2013</a>), and 14 were multicentre (<a href="./references#CD011481-bbs2-0003" title="CassanoGB , PetraccaA , BorghiC , ChiroliS , DidoniG , GarreauM . A randomized, double‐blind study of alpidem vs placebo in the prevention and treatment of benzodiazepine withdrawal syndrome. European Psychiatry1996;11(2):93‐9. ">Cassano 1996</a>; <a href="./references#CD011481-bbs2-0009" title="GlaxoSmithKline . Clinical comparison of paroxetine and placebo on the symptoms emerging during the taper phase of a chronic benzodiazepine treatment, in patients suffering from a variety of anxiety disorders. GSK ‐ Clinical Study Register (www.gsk‐clinicalstudyregister.com)2002. ">GlaxoSmithKline 2002</a>; <a href="./references#CD011481-bbs2-0010" title="HadleySJ , MandelFS , SchweizerE . Switching from long‐term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double‐blind, placebo‐controlled trial. Journal of Psychopharmacology2012;26(4):461‐70. [DOI: 10.1177/0269881111405360] SzczypaP , HadleySJ , DonevanS , MandelFS , LeonT . P.4.a.016 Switching from long‐term benzodiazepine therapy to pregabalin in patients with generalised anxiety disorder (GAD). European Neuropsychopharmacology2009;19:S594‐5. [DOI: 10.1016/S0924‐977X(09)70952‐6] ">Hadley 2012</a>; <a href="./references#CD011481-bbs2-0011" title="HantoucheEG , GuelfiJD , CometD . Discontinuation of long‐term benzodiazepine use: double‐blind controlled study of α‐β L‐aspartate magnesium versus placebo in 144 chronic users of benzodiazepines [α‐β L‐aspartate de magnésium dans l'arrêt de la consommation chronique des benzodiazépines: étude contrôlée en double aveugle versus placebo]. L'encéphale1998;XXIV:469‐79. HantoucheEG , JacobL , CometD , GuelfiJD . Discontinuation of long‐term benzodiazepine use: predictive model of success in a double‐blind, controlled‐study. 150th Annual Meeting of the American Psychiatric Association, 1997 May 17‐22; San Diego, (CA). 1997. ">Hantouche 1998</a>; <a href="./references#CD011481-bbs2-0015" title="LaderM , OlajideD . A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. Journal of Clinical Psychopharmacology1987;7(1):11‐5. ">Lader 1987</a>; <a href="./references#CD011481-bbs2-0016" title="LaderM , FarrI , MortonS . A comparison of alpidem and placebo in relieving benzodiazepine withdrawal symptoms. International Clinical Psychopharmacology1993;8(1):31‐6. ">Lader 1993</a>; <a href="./references#CD011481-bbs2-0017" title="LecrubierY , FessardN . Benzodiazepine discontinuation in chronic users: a double‐blind trial of lithium gluconate vs placebo [Arrêt des benzodiazépines chez des consommateurs chronique: un essai en double insu du gluconate de lithium vs placebo]. Annales Médico Phychologiques2005;163:24‐9. ">Lecrubier 2005</a>; <a href="./references#CD011481-bbs2-0018" title="LemoineP , KermadiI , Garcia‐AcostaS , GarayRP , DibM . Double‐blind, comparative study of cyamemazine vs. bromazepam in the benzodiazepine withdrawal syndrome. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2006;30(1):131‐7. ">Lemoine 2006</a>; <a href="./references#CD011481-bbs2-0020" title="Mercier‐GuyonC , ChabannesJP , SaviucP . The role of captodiamine in the withdrawal from long‐term benzodiazepine treatment. Current Medical Research and Opinion2004;20(9):1347‐55. [DOI: 10.1185/030079904125004457] ">Mercier‐Guyon 2004</a>; <a href="./references#CD011481-bbs2-0029" title="SaulPA , KorliparaK , PresleyP . A randomised, multicentre, double‐blind, comparison of atenolol and placebo in the control of benzodiazepine withdrawal symptoms. Acta Therapeutica1989;15(2):117‐23. ">Saul 1989</a>; <a href="./references#CD011481-bbs2-0032" title="TyrerP , RutherfordD , HuggettT . Benzodiazepine withdrawal symptoms and propranolol. Lancet1981;1(8219):520‐2. ">Tyrer 1981</a>; <a href="./references#CD011481-bbs2-0034" title="UdelmanHD , UdelmanDL . Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy. Journal of Clinical Psychiatry1990;51 Suppl:46‐50. ">Udelman 1990</a>; <a href="./references#CD011481-bbs2-0035" title="VissersFH , KnipschildPG , CrebolderHF . Is melatonin helpful in stopping the long‐term use of hypnotics? A discontinuation trial. Pharmacy World &amp; Science2007;29(6):641‐6. [DOI: 10.1007/s11096‐007‐9118‐y] ">Vissers 2007</a>; <a href="./references#CD011481-bbs2-0038" title="ZitmanFG , CouveeJE . Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper‐off: report on behalf of the Dutch Chronic Benzodiazepine Working Group. British Journal of Psychiatry2001;178:317‐24. ">Zitman 2001</a>). </p> <p>The majority of the trials were performed in outpatient settings. The three trials investigating intravenous injection of flumazenil were conducted in inpatient settings (<a href="./references#CD011481-bbs2-0007" title="GerraG , MarcatoA , CaccavariR , Fertonani‐AffiniG , FontanesiB , ZaimovicA , et al. Effectiveness of flumazenil (Ro 15‐1788) in the treatment of benzodiazepine withdrawal. Current Therapeutic Research ‐ Clinical and Experimental1993;54(5):580‐7. ">Gerra 1993</a>; <a href="./references#CD011481-bbs2-0008" title="GerraG , ZaimovicA , GiustiF , MoiG , BrewerC . Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo‐controlled study. Addiction Biology2002;7(4):385‐95. ">Gerra 2002</a>; <a href="./references#CD011481-bbs2-0012" title="Harrison‐ReadPE , TyrerP , LawsonC , LackS , FernandesC , FileSE . Flumazenil‐precipitated panic and dysphoria in patients dependent on benzodiazepines: a possible aid to abstinence. Journal of Psychopharmacology1996;10(2):89‐97. ">Harrison‐Read 1996</a>), as was a trial with rapid benzodiazepine dose reduction in opioid maintenance patients (<a href="./references#CD011481-bbs2-0036" title="VormaH , KatilaH . Effect of valproate on benzodiazepine withdrawal severity in opioid‐dependent subjects: a pilot study. Heroin Addiction and Related Clinical Problems2011;13(1):15‐20. ">Vorma 2011</a>). In <a href="./references#CD011481-bbs2-0007" title="GerraG , MarcatoA , CaccavariR , Fertonani‐AffiniG , FontanesiB , ZaimovicA , et al. Effectiveness of flumazenil (Ro 15‐1788) in the treatment of benzodiazepine withdrawal. Current Therapeutic Research ‐ Clinical and Experimental1993;54(5):580‐7. ">Gerra 1993</a> and <a href="./references#CD011481-bbs2-0008" title="GerraG , ZaimovicA , GiustiF , MoiG , BrewerC . Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo‐controlled study. Addiction Biology2002;7(4):385‐95. ">Gerra 2002</a>, participants were hospitalised for the duration of the trial (seven and eight days, respectively) whereas participants in <a href="./references#CD011481-bbs2-0012" title="Harrison‐ReadPE , TyrerP , LawsonC , LackS , FernandesC , FileSE . Flumazenil‐precipitated panic and dysphoria in patients dependent on benzodiazepines: a possible aid to abstinence. Journal of Psychopharmacology1996;10(2):89‐97. ">Harrison‐Read 1996</a> were hospitalised as they received a challenge with flumazenil and were thereafter treated as outpatients. Twenty‐four trials were conducted in Europe; eight trials in the US or Canada; and six trials in Asia. </p> <p>Nine trials reported the source of funding as research grants (<a href="./references#CD011481-bbs2-0002" title="BaandrupL , FagerlundB , GlenthojB . Neurocognitive performance, subjective well‐being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add‐on melatonin versus placebo. European Archives of Psychiatry and Clinical Neuroscience2017;267(2):163‐71. [PUBMED: 27400927] BaandrupL , GlenthojBY , JennumPJ . Objective and subjective sleep quality: melatonin versus placebo add‐on treatment in patients with schizophrenia or bipolar disorder withdrawing from long‐term benzodiazepine use. Psychiatry Research2016;240:163‐9. [PUBMED: 27107670] BaandrupL , LindschouJ , WinkelP , GluudC , GlenthojBY . Prolonged‐release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: a randomised, placebo‐controlled, blinded trial. World Journal of Biological Psychiatry2016;17(7):514‐24. [PUBMED: 26086792] ">Baandrup 2016</a>; <a href="./references#CD011481-bbs2-0004" title="CialdellaP , BoisselJP , BelonP , the ASTRHO group. Homeopathic specialties as a substitute for benzodiazepines: a double‐blind vs. placebo study. Thérapie2001;56:397‐402. ">Cialdella 2001</a>; <a href="./references#CD011481-bbs2-0019" title="MarianiJJ , MalcolmRJ , MamczurAK , ChoiJC , BradyR , NunesE , et al. Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients. American Journal of Drug and Alcohol Abuse2016;42(3):333‐40. [PUBMED: 26962719] ">Mariani 2016</a>; <a href="./references#CD011481-bbs2-0024" title="PelesE , HetzroniT , Bar‐HamburgerR , AdelsonM , SchreiberS . Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double‐blind randomized clinical trial. Addiction2007;102(12):1947‐53. ">Peles 2007</a>; <a href="./references#CD011481-bbs2-0025" title="RickelsK , SchweizerE , Garcia EspanaF , Case , G , DeMartinisN , GreenblattD . Trazodone and valproate in patients discontinuing long‐term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology1999;141(1):1‐5. ">Rickels 1999</a>; <a href="./references#CD011481-bbs2-0026" title="RickelsK , DeMartinisN , Garcia‐EspanaF , GreenblattDJ , MandosLA , RynnM . Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long‐term benzodiazepine therapy. American Journal of Psychiatry2000;157(12):1973‐9. ">Rickels 2000</a>; <a href="./references#CD011481-bbs2-0030" title="SchweizerE , Rickels , K , CaseWG , GreenblattDJ . Carbamazepine treatment in patients discontinuing long‐term benzodiazepine therapy. Effects on withdrawal severity and outcome. Archives of General Psychiatry1991;48(5):448‐52. ">Schweizer 1991</a>; <a href="./references#CD011481-bbs2-0031" title="SchweizerE , CaseWG , Garcia‐EspanaF , GreenblattDJ , RickelsK . Progesterone co‐administration in patients discontinuing long‐term benzodiazepine therapy: effects on withdrawal severity and taper outcome. Psychopharmacology1995;117(4):424‐9. ">Schweizer 1995</a>; <a href="./references#CD011481-bbs2-0036" title="VormaH , KatilaH . Effect of valproate on benzodiazepine withdrawal severity in opioid‐dependent subjects: a pilot study. Heroin Addiction and Related Clinical Problems2011;13(1):15‐20. ">Vorma 2011</a>), and the funding was unclear for 15 trials (<a href="./references#CD011481-bbs2-0003" title="CassanoGB , PetraccaA , BorghiC , ChiroliS , DidoniG , GarreauM . A randomized, double‐blind study of alpidem vs placebo in the prevention and treatment of benzodiazepine withdrawal syndrome. European Psychiatry1996;11(2):93‐9. ">Cassano 1996</a>; <a href="./references#CD011481-bbs2-0005" title="DiCostanzoE , RoveaA . The prophylaxis of benzodiazepine withdrawal syndrome in the elderly: the effectiveness of carbamazepine. A double‐blind study vs. placebo. Minerva Psichiatrica1992;33:301‐4. ">Di Costanzo 1992</a>; <a href="./references#CD011481-bbs2-0007" title="GerraG , MarcatoA , CaccavariR , Fertonani‐AffiniG , FontanesiB , ZaimovicA , et al. Effectiveness of flumazenil (Ro 15‐1788) in the treatment of benzodiazepine withdrawal. Current Therapeutic Research ‐ Clinical and Experimental1993;54(5):580‐7. ">Gerra 1993</a>; <a href="./references#CD011481-bbs2-0008" title="GerraG , ZaimovicA , GiustiF , MoiG , BrewerC . Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo‐controlled study. Addiction Biology2002;7(4):385‐95. ">Gerra 2002</a>; <a href="./references#CD011481-bbs2-0011" title="HantoucheEG , GuelfiJD , CometD . Discontinuation of long‐term benzodiazepine use: double‐blind controlled study of α‐β L‐aspartate magnesium versus placebo in 144 chronic users of benzodiazepines [α‐β L‐aspartate de magnésium dans l'arrêt de la consommation chronique des benzodiazépines: étude contrôlée en double aveugle versus placebo]. L'encéphale1998;XXIV:469‐79. HantoucheEG , JacobL , CometD , GuelfiJD . Discontinuation of long‐term benzodiazepine use: predictive model of success in a double‐blind, controlled‐study. 150th Annual Meeting of the American Psychiatric Association, 1997 May 17‐22; San Diego, (CA). 1997. ">Hantouche 1998</a>; <a href="./references#CD011481-bbs2-0014" title="KornowskiJ . The comparison between tianeptine and carbamazepine in benzodiazepines withdrawal syndrome. Psychiatria Polska2002;6(Suppl):311‐8. ">Kornowski 2002</a>; <a href="./references#CD011481-bbs2-0015" title="LaderM , OlajideD . A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. Journal of Clinical Psychopharmacology1987;7(1):11‐5. ">Lader 1987</a>; <a href="./references#CD011481-bbs2-0016" title="LaderM , FarrI , MortonS . A comparison of alpidem and placebo in relieving benzodiazepine withdrawal symptoms. International Clinical Psychopharmacology1993;8(1):31‐6. ">Lader 1993</a>; <a href="./references#CD011481-bbs2-0017" title="LecrubierY , FessardN . Benzodiazepine discontinuation in chronic users: a double‐blind trial of lithium gluconate vs placebo [Arrêt des benzodiazépines chez des consommateurs chronique: un essai en double insu du gluconate de lithium vs placebo]. Annales Médico Phychologiques2005;163:24‐9. ">Lecrubier 2005</a>; <a href="./references#CD011481-bbs2-0022" title="NakaoM , TakeuchiT , NomuraK , TeramotoT , YanoE . Clinical application of paroxetine for chronic benzodiazepine users at an internal medicine clinic. Therapeutic Research2006;27(5):859‐67. NakaoM , TakeuchiT , NomuraK , TeramotoT , YanoE . Clinical application of paroxetine for tapering benzodiazepine use in non‐major‐depressive outpatients visiting an internal medicine clinic. Psychiatry and Clinical Neurosciences2006;60(5):605‐10. ">Nakao 2006</a>; <a href="./references#CD011481-bbs2-0029" title="SaulPA , KorliparaK , PresleyP . A randomised, multicentre, double‐blind, comparison of atenolol and placebo in the control of benzodiazepine withdrawal symptoms. Acta Therapeutica1989;15(2):117‐23. ">Saul 1989</a>; <a href="./references#CD011481-bbs2-0032" title="TyrerP , RutherfordD , HuggettT . Benzodiazepine withdrawal symptoms and propranolol. Lancet1981;1(8219):520‐2. ">Tyrer 1981</a>; <a href="./references#CD011481-bbs2-0033" title="TyrerP , FergusonB , HallstromC , MichieM , TyrerS , CooperS , et al. A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms. British Journal of Psychiatry1996;168(4):457‐61. ">Tyrer 1996</a>; <a href="./references#CD011481-bbs2-0035" title="VissersFH , KnipschildPG , CrebolderHF . Is melatonin helpful in stopping the long‐term use of hypnotics? A discontinuation trial. Pharmacy World &amp; Science2007;29(6):641‐6. [DOI: 10.1007/s11096‐007‐9118‐y] ">Vissers 2007</a>; <a href="./references#CD011481-bbs2-0037" title="ZhangH , JiangX , MaM , ZhangJ . A control study on treatment for benzodiazepine dependence with trazodone. Chinese Journal of Contemporary Neurology and Neurosurgery2013;13(5):411‐5. ">Zhang 2013</a>). Fourteen trials used medications provided by the manufacturing company (<a href="./references#CD011481-bbs2-0001" title="AshtonCH , RawlinsMD , TyrerSP . A double‐blind placebo‐controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. British Journal of Psychiatry1990;157:232‐8. ">Ashton 1990</a>; <a href="./references#CD011481-bbs2-0006" title="GarfinkelD , ZisapelN , WainsteinJ , LaudonM . Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Archives of Internal Medicine1999;159(20):2456‐60. ">Garfinkel 1999</a>; <a href="./references#CD011481-bbs2-0009" title="GlaxoSmithKline . Clinical comparison of paroxetine and placebo on the symptoms emerging during the taper phase of a chronic benzodiazepine treatment, in patients suffering from a variety of anxiety disorders. GSK ‐ Clinical Study Register (www.gsk‐clinicalstudyregister.com)2002. ">GlaxoSmithKline 2002</a>; <a href="./references#CD011481-bbs2-0011" title="HantoucheEG , GuelfiJD , CometD . Discontinuation of long‐term benzodiazepine use: double‐blind controlled study of α‐β L‐aspartate magnesium versus placebo in 144 chronic users of benzodiazepines [α‐β L‐aspartate de magnésium dans l'arrêt de la consommation chronique des benzodiazépines: étude contrôlée en double aveugle versus placebo]. L'encéphale1998;XXIV:469‐79. HantoucheEG , JacobL , CometD , GuelfiJD . Discontinuation of long‐term benzodiazepine use: predictive model of success in a double‐blind, controlled‐study. 150th Annual Meeting of the American Psychiatric Association, 1997 May 17‐22; San Diego, (CA). 1997. ">Hantouche 1998</a>; <a href="./references#CD011481-bbs2-0012" title="Harrison‐ReadPE , TyrerP , LawsonC , LackS , FernandesC , FileSE . Flumazenil‐precipitated panic and dysphoria in patients dependent on benzodiazepines: a possible aid to abstinence. Journal of Psychopharmacology1996;10(2):89‐97. ">Harrison‐Read 1996</a>; <a href="./references#CD011481-bbs2-0013" title="KleinE , ColinV , StolkJ , LenoxRH . Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. American Journal of Psychiatry1994;151(12):1760‐6. ">Klein 1994</a>; <a href="./references#CD011481-bbs2-0018" title="LemoineP , KermadiI , Garcia‐AcostaS , GarayRP , DibM . Double‐blind, comparative study of cyamemazine vs. bromazepam in the benzodiazepine withdrawal syndrome. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2006;30(1):131‐7. ">Lemoine 2006</a>; <a href="./references#CD011481-bbs2-0020" title="Mercier‐GuyonC , ChabannesJP , SaviucP . The role of captodiamine in the withdrawal from long‐term benzodiazepine treatment. Current Medical Research and Opinion2004;20(9):1347‐55. [DOI: 10.1185/030079904125004457] ">Mercier‐Guyon 2004</a>; <a href="./references#CD011481-bbs2-0021" title="MortonS , LaderM . Buspirone treatment as an aid to benzodiazepine withdrawal. Journal of Psychopharmacology1995;9(4):331‐5. ">Morton 1995</a>; <a href="./references#CD011481-bbs2-0023" title="Pat‐HorenczykR , HacohenD , HererP , LavieP . The effects of substituting zopiclone in withdrawal from chronic use of benzodiazepine hypnotics. Psychopharmacology1998;140(4):450‐7. [DOI: 10.1007/s002130050789] ">Pat‐Horenczyk 1998</a>; <a href="./references#CD011481-bbs2-0027" title="RomachMK , KaplanHL , BustoUE , SomerG , SellersEM . A controlled trial of ondansetron, a 5‐HT3 antagonist, in benzodiazepine discontinuation. Journal of Clinical Psychopharmacology1998;18(2):121‐31. ">Romach 1998</a>; <a href="./references#CD011481-bbs2-0028" title="RynnM , Garcia‐EspanaF , GreenblattDJ , MandosLA , SchweizerE , RickelsK . Imipramine and buspirone in patients with panic disorder who are discontinuing long‐term benzodiazepine therapy. Journal of Clinical Psychopharmacology2003;23(5):505‐8. ">Rynn 2003</a>; <a href="./references#CD011481-bbs2-0034" title="UdelmanHD , UdelmanDL . Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy. Journal of Clinical Psychiatry1990;51 Suppl:46‐50. ">Udelman 1990</a>; <a href="./references#CD011481-bbs2-0038" title="ZitmanFG , CouveeJE . Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper‐off: report on behalf of the Dutch Chronic Benzodiazepine Working Group. British Journal of Psychiatry2001;178:317‐24. ">Zitman 2001</a>), and in all but one of these studies information regarding the degree of involvement of the pharmaceutical company was insufficient. </p> <p>The trials investigated participants with a varying clinical picture dominated by anxiety. Three trials specifically investigated participants in opioid maintenance treatment (<a href="./references#CD011481-bbs2-0019" title="MarianiJJ , MalcolmRJ , MamczurAK , ChoiJC , BradyR , NunesE , et al. Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients. American Journal of Drug and Alcohol Abuse2016;42(3):333‐40. [PUBMED: 26962719] ">Mariani 2016</a>; <a href="./references#CD011481-bbs2-0024" title="PelesE , HetzroniT , Bar‐HamburgerR , AdelsonM , SchreiberS . Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double‐blind randomized clinical trial. Addiction2007;102(12):1947‐53. ">Peles 2007</a>; <a href="./references#CD011481-bbs2-0036" title="VormaH , KatilaH . Effect of valproate on benzodiazepine withdrawal severity in opioid‐dependent subjects: a pilot study. Heroin Addiction and Related Clinical Problems2011;13(1):15‐20. ">Vorma 2011</a>). In most trials, the majority of participants were women. The mean age was around 50 years (+/‐ 10 years) in most trials, and mean duration of benzodiazepine use was between 5 and 10 years in most trials. In eight trials there was no information at all on baseline characteristics. Eight trials applied abrupt discontinuation of benzodiazepine treatment with follow‐up periods between 1 and 8 weeks, whereas the remainder of the trials applied a gradual benzodiazepine dosage reduction regimen lasting between 2 and 24 weeks. </p> <p>Trial duration ranged between 1 and 24 weeks, and mean trial duration was 9.4 weeks.</p> </section> <section id="CD011481-sec-0077"> <h4 class="title">Excluded studies</h4> <p>We excluded 22 studies that were considered potentially relevant and assessed in detail (<a href="#CD011481-fig-0001">Figure 1</a>). The reasons for exclusion were: 17 studies had a study design not fulfilling our inclusion criteria; 3 studies had a patient population not fulfilling our inclusion criteria; and 2 studies had interventions not fulfilling our inclusion criteria. For further details see <a href="./references#CD011481-sec-0137" title="">Characteristics of excluded studies</a> section. </p> </section> </section> <section id="CD011481-sec-0078"> <h3 class="title">Risk of bias in included studies</h3> <p>The overall risk of bias associated with the included studies is summarised in <a href="#CD011481-fig-0002">Figure 2</a> and <a href="#CD011481-fig-0003">Figure 3</a>. Please also see <a href="./references#CD011481-sec-0136" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD011481-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011481-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD011481-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011481-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD011481-sec-0079"> <h4 class="title">Allocation</h4> <section id="CD011481-sec-0080"> <h5 class="title">Sequence generation</h5> <p>We judged only two trials as at low risk of bias because the random sequence was described as computer‐generated (<a href="./references#CD011481-bbs2-0002" title="BaandrupL , FagerlundB , GlenthojB . Neurocognitive performance, subjective well‐being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add‐on melatonin versus placebo. European Archives of Psychiatry and Clinical Neuroscience2017;267(2):163‐71. [PUBMED: 27400927] BaandrupL , GlenthojBY , JennumPJ . Objective and subjective sleep quality: melatonin versus placebo add‐on treatment in patients with schizophrenia or bipolar disorder withdrawing from long‐term benzodiazepine use. Psychiatry Research2016;240:163‐9. [PUBMED: 27107670] BaandrupL , LindschouJ , WinkelP , GluudC , GlenthojBY . Prolonged‐release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: a randomised, placebo‐controlled, blinded trial. World Journal of Biological Psychiatry2016;17(7):514‐24. [PUBMED: 26086792] ">Baandrup 2016</a>; <a href="./references#CD011481-bbs2-0038" title="ZitmanFG , CouveeJE . Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper‐off: report on behalf of the Dutch Chronic Benzodiazepine Working Group. British Journal of Psychiatry2001;178:317‐24. ">Zitman 2001</a>). For all other trials (n = 36; 95%), information on random sequence generation was not provided and they were therefore judged as at unclear risk of selection bias. </p> </section> <section id="CD011481-sec-0081"> <h5 class="title">Allocation concealment</h5> <p>We judged five trials as at low risk of bias because they sufficiently described how the randomisation was administered in a way that staff and trial participants could not anticipate to which group the next participant would be randomised. In two trials, randomisation was administered by a third party who paced and distributed the trial medication using numbered medication containers (<a href="./references#CD011481-bbs2-0002" title="BaandrupL , FagerlundB , GlenthojB . Neurocognitive performance, subjective well‐being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add‐on melatonin versus placebo. European Archives of Psychiatry and Clinical Neuroscience2017;267(2):163‐71. [PUBMED: 27400927] BaandrupL , GlenthojBY , JennumPJ . Objective and subjective sleep quality: melatonin versus placebo add‐on treatment in patients with schizophrenia or bipolar disorder withdrawing from long‐term benzodiazepine use. Psychiatry Research2016;240:163‐9. [PUBMED: 27107670] BaandrupL , LindschouJ , WinkelP , GluudC , GlenthojBY . Prolonged‐release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: a randomised, placebo‐controlled, blinded trial. World Journal of Biological Psychiatry2016;17(7):514‐24. [PUBMED: 26086792] ">Baandrup 2016</a>; <a href="./references#CD011481-bbs2-0038" title="ZitmanFG , CouveeJE . Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper‐off: report on behalf of the Dutch Chronic Benzodiazepine Working Group. British Journal of Psychiatry2001;178:317‐24. ">Zitman 2001</a>); in one trial consecutive container numbers were used (<a href="./references#CD011481-bbs2-0024" title="PelesE , HetzroniT , Bar‐HamburgerR , AdelsonM , SchreiberS . Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double‐blind randomized clinical trial. Addiction2007;102(12):1947‐53. ">Peles 2007</a>); in one trial allocation was performed by an independent pharmacist (<a href="./references#CD011481-bbs2-0012" title="Harrison‐ReadPE , TyrerP , LawsonC , LackS , FernandesC , FileSE . Flumazenil‐precipitated panic and dysphoria in patients dependent on benzodiazepines: a possible aid to abstinence. Journal of Psychopharmacology1996;10(2):89‐97. ">Harrison‐Read 1996</a>); and one trial used sealed envelopes (<a href="./references#CD011481-bbs2-0036" title="VormaH , KatilaH . Effect of valproate on benzodiazepine withdrawal severity in opioid‐dependent subjects: a pilot study. Heroin Addiction and Related Clinical Problems2011;13(1):15‐20. ">Vorma 2011</a>). We judged all other studies (n = 33; 87%) as at unclear risk of selection bias due to lack of information on allocation concealment. </p> </section> </section> <section id="CD011481-sec-0082"> <h4 class="title">Blinding</h4> <section id="CD011481-sec-0083"> <h5 class="title">Performance bias</h5> <p>We evaluated 13 trials as at unclear risk of performance bias due to insufficient description of blinding procedures for participants and personnel (<a href="./references#CD011481-bbs2-0003" title="CassanoGB , PetraccaA , BorghiC , ChiroliS , DidoniG , GarreauM . A randomized, double‐blind study of alpidem vs placebo in the prevention and treatment of benzodiazepine withdrawal syndrome. European Psychiatry1996;11(2):93‐9. ">Cassano 1996</a>; <a href="./references#CD011481-bbs2-0004" title="CialdellaP , BoisselJP , BelonP , the ASTRHO group. Homeopathic specialties as a substitute for benzodiazepines: a double‐blind vs. placebo study. Thérapie2001;56:397‐402. ">Cialdella 2001</a>; <a href="./references#CD011481-bbs2-0005" title="DiCostanzoE , RoveaA . The prophylaxis of benzodiazepine withdrawal syndrome in the elderly: the effectiveness of carbamazepine. A double‐blind study vs. placebo. Minerva Psichiatrica1992;33:301‐4. ">Di Costanzo 1992</a>; <a href="./references#CD011481-bbs2-0010" title="HadleySJ , MandelFS , SchweizerE . Switching from long‐term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double‐blind, placebo‐controlled trial. Journal of Psychopharmacology2012;26(4):461‐70. [DOI: 10.1177/0269881111405360] SzczypaP , HadleySJ , DonevanS , MandelFS , LeonT . P.4.a.016 Switching from long‐term benzodiazepine therapy to pregabalin in patients with generalised anxiety disorder (GAD). European Neuropsychopharmacology2009;19:S594‐5. [DOI: 10.1016/S0924‐977X(09)70952‐6] ">Hadley 2012</a>; <a href="./references#CD011481-bbs2-0011" title="HantoucheEG , GuelfiJD , CometD . Discontinuation of long‐term benzodiazepine use: double‐blind controlled study of α‐β L‐aspartate magnesium versus placebo in 144 chronic users of benzodiazepines [α‐β L‐aspartate de magnésium dans l'arrêt de la consommation chronique des benzodiazépines: étude contrôlée en double aveugle versus placebo]. L'encéphale1998;XXIV:469‐79. HantoucheEG , JacobL , CometD , GuelfiJD . Discontinuation of long‐term benzodiazepine use: predictive model of success in a double‐blind, controlled‐study. 150th Annual Meeting of the American Psychiatric Association, 1997 May 17‐22; San Diego, (CA). 1997. ">Hantouche 1998</a>; <a href="./references#CD011481-bbs2-0014" title="KornowskiJ . The comparison between tianeptine and carbamazepine in benzodiazepines withdrawal syndrome. Psychiatria Polska2002;6(Suppl):311‐8. ">Kornowski 2002</a>; <a href="./references#CD011481-bbs2-0020" title="Mercier‐GuyonC , ChabannesJP , SaviucP . The role of captodiamine in the withdrawal from long‐term benzodiazepine treatment. Current Medical Research and Opinion2004;20(9):1347‐55. [DOI: 10.1185/030079904125004457] ">Mercier‐Guyon 2004</a>; <a href="./references#CD011481-bbs2-0024" title="PelesE , HetzroniT , Bar‐HamburgerR , AdelsonM , SchreiberS . Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double‐blind randomized clinical trial. Addiction2007;102(12):1947‐53. ">Peles 2007</a>; <a href="./references#CD011481-bbs2-0025" title="RickelsK , SchweizerE , Garcia EspanaF , Case , G , DeMartinisN , GreenblattD . Trazodone and valproate in patients discontinuing long‐term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology1999;141(1):1‐5. ">Rickels 1999</a>; <a href="./references#CD011481-bbs2-0033" title="TyrerP , FergusonB , HallstromC , MichieM , TyrerS , CooperS , et al. A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms. British Journal of Psychiatry1996;168(4):457‐61. ">Tyrer 1996</a>; <a href="./references#CD011481-bbs2-0035" title="VissersFH , KnipschildPG , CrebolderHF . Is melatonin helpful in stopping the long‐term use of hypnotics? A discontinuation trial. Pharmacy World &amp; Science2007;29(6):641‐6. [DOI: 10.1007/s11096‐007‐9118‐y] ">Vissers 2007</a>; <a href="./references#CD011481-bbs2-0037" title="ZhangH , JiangX , MaM , ZhangJ . A control study on treatment for benzodiazepine dependence with trazodone. Chinese Journal of Contemporary Neurology and Neurosurgery2013;13(5):411‐5. ">Zhang 2013</a>; <a href="./references#CD011481-bbs2-0038" title="ZitmanFG , CouveeJE . Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper‐off: report on behalf of the Dutch Chronic Benzodiazepine Working Group. British Journal of Psychiatry2001;178:317‐24. ">Zitman 2001</a>). We considered more than half of the trials (n = 21; 55%) as at low risk of performance bias due to sufficient blinding procedures of participants and personnel. Four of the included trials were not blinded for participants and personnel and were therefore judged as at high risk of performance bias (<a href="./references#CD011481-bbs2-0007" title="GerraG , MarcatoA , CaccavariR , Fertonani‐AffiniG , FontanesiB , ZaimovicA , et al. Effectiveness of flumazenil (Ro 15‐1788) in the treatment of benzodiazepine withdrawal. Current Therapeutic Research ‐ Clinical and Experimental1993;54(5):580‐7. ">Gerra 1993</a>; <a href="./references#CD011481-bbs2-0008" title="GerraG , ZaimovicA , GiustiF , MoiG , BrewerC . Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo‐controlled study. Addiction Biology2002;7(4):385‐95. ">Gerra 2002</a>; <a href="./references#CD011481-bbs2-0022" title="NakaoM , TakeuchiT , NomuraK , TeramotoT , YanoE . Clinical application of paroxetine for chronic benzodiazepine users at an internal medicine clinic. Therapeutic Research2006;27(5):859‐67. NakaoM , TakeuchiT , NomuraK , TeramotoT , YanoE . Clinical application of paroxetine for tapering benzodiazepine use in non‐major‐depressive outpatients visiting an internal medicine clinic. Psychiatry and Clinical Neurosciences2006;60(5):605‐10. ">Nakao 2006</a>; <a href="./references#CD011481-bbs2-0036" title="VormaH , KatilaH . Effect of valproate on benzodiazepine withdrawal severity in opioid‐dependent subjects: a pilot study. Heroin Addiction and Related Clinical Problems2011;13(1):15‐20. ">Vorma 2011</a>). </p> </section> <section id="CD011481-sec-0084"> <h5 class="title">Detection bias</h5> <p>The majority of included trials (n = 25; 66%) were associated with unclear risk of detection bias due to insufficient descriptions of what was done to ensure blinding of outcome assessors. Three of the included trials were not blinded for outcome assessors and were therefore judged as at high risk of detection bias (<a href="./references#CD011481-bbs2-0007" title="GerraG , MarcatoA , CaccavariR , Fertonani‐AffiniG , FontanesiB , ZaimovicA , et al. Effectiveness of flumazenil (Ro 15‐1788) in the treatment of benzodiazepine withdrawal. Current Therapeutic Research ‐ Clinical and Experimental1993;54(5):580‐7. ">Gerra 1993</a>; <a href="./references#CD011481-bbs2-0008" title="GerraG , ZaimovicA , GiustiF , MoiG , BrewerC . Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo‐controlled study. Addiction Biology2002;7(4):385‐95. ">Gerra 2002</a>; <a href="./references#CD011481-bbs2-0022" title="NakaoM , TakeuchiT , NomuraK , TeramotoT , YanoE . Clinical application of paroxetine for chronic benzodiazepine users at an internal medicine clinic. Therapeutic Research2006;27(5):859‐67. NakaoM , TakeuchiT , NomuraK , TeramotoT , YanoE . Clinical application of paroxetine for tapering benzodiazepine use in non‐major‐depressive outpatients visiting an internal medicine clinic. Psychiatry and Clinical Neurosciences2006;60(5):605‐10. ">Nakao 2006</a>). We judged 10 trials as at low risk of detection bias because they provided sufficient information on blinding of outcome assessors (<a href="./references#CD011481-bbs2-0002" title="BaandrupL , FagerlundB , GlenthojB . Neurocognitive performance, subjective well‐being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add‐on melatonin versus placebo. European Archives of Psychiatry and Clinical Neuroscience2017;267(2):163‐71. [PUBMED: 27400927] BaandrupL , GlenthojBY , JennumPJ . Objective and subjective sleep quality: melatonin versus placebo add‐on treatment in patients with schizophrenia or bipolar disorder withdrawing from long‐term benzodiazepine use. Psychiatry Research2016;240:163‐9. [PUBMED: 27107670] BaandrupL , LindschouJ , WinkelP , GluudC , GlenthojBY . Prolonged‐release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: a randomised, placebo‐controlled, blinded trial. World Journal of Biological Psychiatry2016;17(7):514‐24. [PUBMED: 26086792] ">Baandrup 2016</a>; <a href="./references#CD011481-bbs2-0003" title="CassanoGB , PetraccaA , BorghiC , ChiroliS , DidoniG , GarreauM . A randomized, double‐blind study of alpidem vs placebo in the prevention and treatment of benzodiazepine withdrawal syndrome. European Psychiatry1996;11(2):93‐9. ">Cassano 1996</a>; <a href="./references#CD011481-bbs2-0006" title="GarfinkelD , ZisapelN , WainsteinJ , LaudonM . Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Archives of Internal Medicine1999;159(20):2456‐60. ">Garfinkel 1999</a>; <a href="./references#CD011481-bbs2-0015" title="LaderM , OlajideD . A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. Journal of Clinical Psychopharmacology1987;7(1):11‐5. ">Lader 1987</a>; <a href="./references#CD011481-bbs2-0016" title="LaderM , FarrI , MortonS . A comparison of alpidem and placebo in relieving benzodiazepine withdrawal symptoms. International Clinical Psychopharmacology1993;8(1):31‐6. ">Lader 1993</a>; <a href="./references#CD011481-bbs2-0024" title="PelesE , HetzroniT , Bar‐HamburgerR , AdelsonM , SchreiberS . Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double‐blind randomized clinical trial. Addiction2007;102(12):1947‐53. ">Peles 2007</a>; <a href="./references#CD011481-bbs2-0030" title="SchweizerE , Rickels , K , CaseWG , GreenblattDJ . Carbamazepine treatment in patients discontinuing long‐term benzodiazepine therapy. Effects on withdrawal severity and outcome. Archives of General Psychiatry1991;48(5):448‐52. ">Schweizer 1991</a>; <a href="./references#CD011481-bbs2-0032" title="TyrerP , RutherfordD , HuggettT . Benzodiazepine withdrawal symptoms and propranolol. Lancet1981;1(8219):520‐2. ">Tyrer 1981</a>; <a href="./references#CD011481-bbs2-0036" title="VormaH , KatilaH . Effect of valproate on benzodiazepine withdrawal severity in opioid‐dependent subjects: a pilot study. Heroin Addiction and Related Clinical Problems2011;13(1):15‐20. ">Vorma 2011</a>; <a href="./references#CD011481-bbs2-0038" title="ZitmanFG , CouveeJE . Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper‐off: report on behalf of the Dutch Chronic Benzodiazepine Working Group. British Journal of Psychiatry2001;178:317‐24. ">Zitman 2001</a>). </p> </section> </section> <section id="CD011481-sec-0085"> <h4 class="title">Incomplete outcome data</h4> <p>We judged 14 studies (37%) as at high risk of attrition bias due to unacceptably high dropout rates, that is close to 50% (<a href="./references#CD011481-bbs2-0001" title="AshtonCH , RawlinsMD , TyrerSP . A double‐blind placebo‐controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. British Journal of Psychiatry1990;157:232‐8. ">Ashton 1990</a>; <a href="./references#CD011481-bbs2-0003" title="CassanoGB , PetraccaA , BorghiC , ChiroliS , DidoniG , GarreauM . A randomized, double‐blind study of alpidem vs placebo in the prevention and treatment of benzodiazepine withdrawal syndrome. European Psychiatry1996;11(2):93‐9. ">Cassano 1996</a>; <a href="./references#CD011481-bbs2-0010" title="HadleySJ , MandelFS , SchweizerE . Switching from long‐term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double‐blind, placebo‐controlled trial. Journal of Psychopharmacology2012;26(4):461‐70. [DOI: 10.1177/0269881111405360] SzczypaP , HadleySJ , DonevanS , MandelFS , LeonT . P.4.a.016 Switching from long‐term benzodiazepine therapy to pregabalin in patients with generalised anxiety disorder (GAD). European Neuropsychopharmacology2009;19:S594‐5. [DOI: 10.1016/S0924‐977X(09)70952‐6] ">Hadley 2012</a>; <a href="./references#CD011481-bbs2-0013" title="KleinE , ColinV , StolkJ , LenoxRH . Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. American Journal of Psychiatry1994;151(12):1760‐6. ">Klein 1994</a>; <a href="./references#CD011481-bbs2-0015" title="LaderM , OlajideD . A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. Journal of Clinical Psychopharmacology1987;7(1):11‐5. ">Lader 1987</a>; <a href="./references#CD011481-bbs2-0019" title="MarianiJJ , MalcolmRJ , MamczurAK , ChoiJC , BradyR , NunesE , et al. Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients. American Journal of Drug and Alcohol Abuse2016;42(3):333‐40. [PUBMED: 26962719] ">Mariani 2016</a>; <a href="./references#CD011481-bbs2-0023" title="Pat‐HorenczykR , HacohenD , HererP , LavieP . The effects of substituting zopiclone in withdrawal from chronic use of benzodiazepine hypnotics. Psychopharmacology1998;140(4):450‐7. [DOI: 10.1007/s002130050789] ">Pat‐Horenczyk 1998</a>; <a href="./references#CD011481-bbs2-0029" title="SaulPA , KorliparaK , PresleyP . A randomised, multicentre, double‐blind, comparison of atenolol and placebo in the control of benzodiazepine withdrawal symptoms. Acta Therapeutica1989;15(2):117‐23. ">Saul 1989</a>; <a href="./references#CD011481-bbs2-0030" title="SchweizerE , Rickels , K , CaseWG , GreenblattDJ . Carbamazepine treatment in patients discontinuing long‐term benzodiazepine therapy. Effects on withdrawal severity and outcome. Archives of General Psychiatry1991;48(5):448‐52. ">Schweizer 1991</a>; <a href="./references#CD011481-bbs2-0031" title="SchweizerE , CaseWG , Garcia‐EspanaF , GreenblattDJ , RickelsK . Progesterone co‐administration in patients discontinuing long‐term benzodiazepine therapy: effects on withdrawal severity and taper outcome. Psychopharmacology1995;117(4):424‐9. ">Schweizer 1995</a>; <a href="./references#CD011481-bbs2-0032" title="TyrerP , RutherfordD , HuggettT . Benzodiazepine withdrawal symptoms and propranolol. Lancet1981;1(8219):520‐2. ">Tyrer 1981</a>; <a href="./references#CD011481-bbs2-0033" title="TyrerP , FergusonB , HallstromC , MichieM , TyrerS , CooperS , et al. A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms. British Journal of Psychiatry1996;168(4):457‐61. ">Tyrer 1996</a>; <a href="./references#CD011481-bbs2-0034" title="UdelmanHD , UdelmanDL . Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy. Journal of Clinical Psychiatry1990;51 Suppl:46‐50. ">Udelman 1990</a>; <a href="./references#CD011481-bbs2-0038" title="ZitmanFG , CouveeJE . Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper‐off: report on behalf of the Dutch Chronic Benzodiazepine Working Group. British Journal of Psychiatry2001;178:317‐24. ">Zitman 2001</a>). We judged six studies (16%) as at unclear risk of attrition bias due to missing information on flow of participants through the trials (<a href="./references#CD011481-bbs2-0004" title="CialdellaP , BoisselJP , BelonP , the ASTRHO group. Homeopathic specialties as a substitute for benzodiazepines: a double‐blind vs. placebo study. Thérapie2001;56:397‐402. ">Cialdella 2001</a>; <a href="./references#CD011481-bbs2-0011" title="HantoucheEG , GuelfiJD , CometD . Discontinuation of long‐term benzodiazepine use: double‐blind controlled study of α‐β L‐aspartate magnesium versus placebo in 144 chronic users of benzodiazepines [α‐β L‐aspartate de magnésium dans l'arrêt de la consommation chronique des benzodiazépines: étude contrôlée en double aveugle versus placebo]. L'encéphale1998;XXIV:469‐79. HantoucheEG , JacobL , CometD , GuelfiJD . Discontinuation of long‐term benzodiazepine use: predictive model of success in a double‐blind, controlled‐study. 150th Annual Meeting of the American Psychiatric Association, 1997 May 17‐22; San Diego, (CA). 1997. ">Hantouche 1998</a>; <a href="./references#CD011481-bbs2-0024" title="PelesE , HetzroniT , Bar‐HamburgerR , AdelsonM , SchreiberS . Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double‐blind randomized clinical trial. Addiction2007;102(12):1947‐53. ">Peles 2007</a>; <a href="./references#CD011481-bbs2-0026" title="RickelsK , DeMartinisN , Garcia‐EspanaF , GreenblattDJ , MandosLA , RynnM . Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long‐term benzodiazepine therapy. American Journal of Psychiatry2000;157(12):1973‐9. ">Rickels 2000</a>; <a href="./references#CD011481-bbs2-0027" title="RomachMK , KaplanHL , BustoUE , SomerG , SellersEM . A controlled trial of ondansetron, a 5‐HT3 antagonist, in benzodiazepine discontinuation. Journal of Clinical Psychopharmacology1998;18(2):121‐31. ">Romach 1998</a>; <a href="./references#CD011481-bbs2-0036" title="VormaH , KatilaH . Effect of valproate on benzodiazepine withdrawal severity in opioid‐dependent subjects: a pilot study. Heroin Addiction and Related Clinical Problems2011;13(1):15‐20. ">Vorma 2011</a>). We judged the remaining studies (n = 18; 47%) as at low risk of attrition bias. </p> </section> <section id="CD011481-sec-0086"> <h4 class="title">Selective reporting</h4> <p>We judged four studies (11%) as at high risk of reporting bias because important outcome measures were not reported, that is benzodiazepine dosage at follow‐up (<a href="./references#CD011481-bbs2-0009" title="GlaxoSmithKline . Clinical comparison of paroxetine and placebo on the symptoms emerging during the taper phase of a chronic benzodiazepine treatment, in patients suffering from a variety of anxiety disorders. GSK ‐ Clinical Study Register (www.gsk‐clinicalstudyregister.com)2002. ">GlaxoSmithKline 2002</a>; <a href="./references#CD011481-bbs2-0013" title="KleinE , ColinV , StolkJ , LenoxRH . Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. American Journal of Psychiatry1994;151(12):1760‐6. ">Klein 1994</a>; <a href="./references#CD011481-bbs2-0037" title="ZhangH , JiangX , MaM , ZhangJ . A control study on treatment for benzodiazepine dependence with trazodone. Chinese Journal of Contemporary Neurology and Neurosurgery2013;13(5):411‐5. ">Zhang 2013</a>), or reporting of an unusual primary outcome (<a href="./references#CD011481-bbs2-0018" title="LemoineP , KermadiI , Garcia‐AcostaS , GarayRP , DibM . Double‐blind, comparative study of cyamemazine vs. bromazepam in the benzodiazepine withdrawal syndrome. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2006;30(1):131‐7. ">Lemoine 2006</a>). We judged seven studies (18%) as at unclear risk of reporting bias due to insufficient information regarding whether selective reporting was present (<a href="./references#CD011481-bbs2-0015" title="LaderM , OlajideD . A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. Journal of Clinical Psychopharmacology1987;7(1):11‐5. ">Lader 1987</a>; <a href="./references#CD011481-bbs2-0017" title="LecrubierY , FessardN . Benzodiazepine discontinuation in chronic users: a double‐blind trial of lithium gluconate vs placebo [Arrêt des benzodiazépines chez des consommateurs chronique: un essai en double insu du gluconate de lithium vs placebo]. Annales Médico Phychologiques2005;163:24‐9. ">Lecrubier 2005</a>; <a href="./references#CD011481-bbs2-0020" title="Mercier‐GuyonC , ChabannesJP , SaviucP . The role of captodiamine in the withdrawal from long‐term benzodiazepine treatment. Current Medical Research and Opinion2004;20(9):1347‐55. [DOI: 10.1185/030079904125004457] ">Mercier‐Guyon 2004</a>; <a href="./references#CD011481-bbs2-0024" title="PelesE , HetzroniT , Bar‐HamburgerR , AdelsonM , SchreiberS . Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double‐blind randomized clinical trial. Addiction2007;102(12):1947‐53. ">Peles 2007</a>; <a href="./references#CD011481-bbs2-0035" title="VissersFH , KnipschildPG , CrebolderHF . Is melatonin helpful in stopping the long‐term use of hypnotics? A discontinuation trial. Pharmacy World &amp; Science2007;29(6):641‐6. [DOI: 10.1007/s11096‐007‐9118‐y] ">Vissers 2007</a>; <a href="./references#CD011481-bbs2-0036" title="VormaH , KatilaH . Effect of valproate on benzodiazepine withdrawal severity in opioid‐dependent subjects: a pilot study. Heroin Addiction and Related Clinical Problems2011;13(1):15‐20. ">Vorma 2011</a>; <a href="./references#CD011481-bbs2-0038" title="ZitmanFG , CouveeJE . Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper‐off: report on behalf of the Dutch Chronic Benzodiazepine Working Group. British Journal of Psychiatry2001;178:317‐24. ">Zitman 2001</a>). We judged the remaining studies (n = 27; 71%) as at low risk of reporting bias. </p> </section> <section id="CD011481-sec-0087"> <h4 class="title">Other potential sources of bias</h4> <p>We judged nine trials (24%) as at unclear risk of other bias mostly due to unclear or lacking description of funding. We rated 14 (37%) of the included trials as at high risk of other bias due to missing information on how the funding pharmaceutical company was involved in designing the trial as well as in analysing and interpreting the results. </p> <section id="CD011481-sec-0088"> <h5 class="title"><i>Overall risk of bias</i> </h5> <p>According to criteria described above, we could classify only one trial as at low risk of bias (<a href="./references#CD011481-bbs2-0002" title="BaandrupL , FagerlundB , GlenthojB . Neurocognitive performance, subjective well‐being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add‐on melatonin versus placebo. European Archives of Psychiatry and Clinical Neuroscience2017;267(2):163‐71. [PUBMED: 27400927] BaandrupL , GlenthojBY , JennumPJ . Objective and subjective sleep quality: melatonin versus placebo add‐on treatment in patients with schizophrenia or bipolar disorder withdrawing from long‐term benzodiazepine use. Psychiatry Research2016;240:163‐9. [PUBMED: 27107670] BaandrupL , LindschouJ , WinkelP , GluudC , GlenthojBY . Prolonged‐release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: a randomised, placebo‐controlled, blinded trial. World Journal of Biological Psychiatry2016;17(7):514‐24. [PUBMED: 26086792] ">Baandrup 2016</a>), and no other trial qualified as at lower risk of bias. The large majority of the trials were thus at high risk of bias. </p> </section> </section> </section> <section id="CD011481-sec-0089"> <h3 class="title" id="CD011481-sec-0089">Effects of interventions</h3> <p>See: <a href="./full#CD011481-tbl-0001"><b>Summary of findings for the main comparison</b> Valproate compared with placebo or no intervention for benzodiazepine discontinuation in chronic benzodiazepine users</a>; <a href="./full#CD011481-tbl-0002"><b>Summary of findings 2</b> Carbamazepine compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</a>; <a href="./full#CD011481-tbl-0003"><b>Summary of findings 3</b> Lithium compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</a>; <a href="./full#CD011481-tbl-0004"><b>Summary of findings 4</b> Pregabalin compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</a>; <a href="./full#CD011481-tbl-0005"><b>Summary of findings 5</b> Captodiame compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</a>; <a href="./full#CD011481-tbl-0006"><b>Summary of findings 6</b> Paroxetine compared with placebo or no intervention for benzodiazepine discontinuation in chronic benzodiazepine users</a>; <a href="./full#CD011481-tbl-0007"><b>Summary of findings 7</b> Tricyclic antidepressants compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</a>; <a href="./full#CD011481-tbl-0008"><b>Summary of findings 8</b> Alpidem compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</a>; <a href="./full#CD011481-tbl-0009"><b>Summary of findings 9</b> Buspirone compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</a>; <a href="./full#CD011481-tbl-0010"><b>Summary of findings 10</b> Melatonin compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</a>; <a href="./full#CD011481-tbl-0011"><b>Summary of findings 11</b> Flumazenil compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</a>; <a href="./full#CD011481-tbl-0012"><b>Summary of findings 12</b> Progesterone compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</a>; <a href="./full#CD011481-tbl-0013"><b>Summary of findings 13</b> Magnesium aspartate compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</a>; <a href="./full#CD011481-tbl-0014"><b>Summary of findings 14</b> Homéogène 46/Sedatif PC (homeopathic drugs) compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</a>; <a href="./full#CD011481-tbl-0015"><b>Summary of findings 15</b> Carbamazepine compared with tricyclic antidepressant for benzodiazepine discontinuation in chronic benzodiazepine users</a> </p> <section id="CD011481-sec-0090"> <h4 class="title">Valproate versus placebo or no intervention</h4> <p>Results for this comparison were mainly from a small trial comparing valproate versus placebo (<a href="./references#CD011481-bbs2-0025" title="RickelsK , SchweizerE , Garcia EspanaF , Case , G , DeMartinisN , GreenblattD . Trazodone and valproate in patients discontinuing long‐term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology1999;141(1):1‐5. ">Rickels 1999</a>). Results showed a beneficial effect of valproate on benzodiazepine discontinuation at end of intervention (<a href="./references#CD011481-fig-0012" title="">Analysis 1.1</a>: 1 study, 27 participants; RR 2.55, 95% CI 1.08 to 6.03; GRADE: very low‐quality evidence) and on benzodiazepine relapse at end of intervention (<a href="./references#CD011481-fig-0013" title="">Analysis 1.2</a>: 1 study, 27 participants; RR 0.31, 95% CI 0.11 to 0.90; GRADE: very low‐quality evidence). However, there was no effect on benzodiazepine discontinuation at longest follow‐up (<a href="./references#CD011481-fig-0014" title="">Analysis 1.3</a>: 1 study, 24 participants; RR 1.57, 95% CI 0.80 to 3.09; GRADE: very low‐quality evidence), benzodiazepine relapse at longest follow‐up (<a href="./references#CD011481-fig-0015" title="">Analysis 1.4</a>: 1 study, 24 participants; RR 0.43, 95% CI 0.13 to 1.39; GRADE: very low‐quality evidence), or symptoms of anxiety at end of intervention (<a href="./references#CD011481-fig-0016" title="">Analysis 1.5</a>: 1 study, 27 participants; MD ‐0.40 points, 95% CI ‐6.47 to 5.67; GRADE: very low‐quality evidence). </p> <p>For benzodiazepine discontinuation, we calculated the required information size to be 1918 participants, using a control event proportion of 48%, a relative risk reduction of 20%, type I error of 2.5%, power of 90%, and a diversity of 30%. We could not perform Trial Sequential Analysis as there was only one trial. </p> <p>For benzodiazepine withdrawal symptoms, it was possible to perform a meta‐analysis using data from <a href="./references#CD011481-bbs2-0025" title="RickelsK , SchweizerE , Garcia EspanaF , Case , G , DeMartinisN , GreenblattD . Trazodone and valproate in patients discontinuing long‐term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology1999;141(1):1‐5. ">Rickels 1999</a> and data from another small trial investigating benzodiazepine withdrawal in methadone maintenance users, <a href="./references#CD011481-bbs2-0036" title="VormaH , KatilaH . Effect of valproate on benzodiazepine withdrawal severity in opioid‐dependent subjects: a pilot study. Heroin Addiction and Related Clinical Problems2011;13(1):15‐20. ">Vorma 2011</a>, comparing valproate versus no intervention. This meta‐analysis indicated no difference between intervention groups (<a href="./references#CD011481-fig-0017" title="">Analysis 1.6</a>: 2 studies, 56 participants; SMD ‐0.15, 95% CI ‐0.68 to 0.37; GRADE: very low‐quality evidence). Due to marked differences in among‐participant variability, we did not re‐express the SMD using one of the specific measurement instruments. Results were similar if analysing placebo or no intervention separately as control group. </p> <p>Please see <a href="./full#CD011481-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD011481-sec-0091"> <h4 class="title">Carbamazepine versus placebo</h4> <p>Results for this comparison stem from three smaller trials (<a href="./references#CD011481-bbs2-0005" title="DiCostanzoE , RoveaA . The prophylaxis of benzodiazepine withdrawal syndrome in the elderly: the effectiveness of carbamazepine. A double‐blind study vs. placebo. Minerva Psichiatrica1992;33:301‐4. ">Di Costanzo 1992</a>; <a href="./references#CD011481-bbs2-0013" title="KleinE , ColinV , StolkJ , LenoxRH . Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. American Journal of Psychiatry1994;151(12):1760‐6. ">Klein 1994</a>; <a href="./references#CD011481-bbs2-0030" title="SchweizerE , Rickels , K , CaseWG , GreenblattDJ . Carbamazepine treatment in patients discontinuing long‐term benzodiazepine therapy. Effects on withdrawal severity and outcome. Archives of General Psychiatry1991;48(5):448‐52. ">Schweizer 1991</a>), not all of which contribute data to all outcomes. It was possible to perform a meta‐analysis for benzodiazepine discontinuation at end of intervention, where no significant differences between groups were detected (<a href="./references#CD011481-fig-0020" title="">Analysis 2.1</a>: 3 studies, 147 participants; RR 1.33, 95% CI 0.99 to 1.80; GRADE: low quality‐evidence). Trial Sequential Analysis showed that the diversity‐adjusted required information size of 2109 participants was not reached, as the accrued number of participants was only 147 (7.0%), showing that insufficient information has been accrued (<a href="#CD011481-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD011481-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of comparison: 2 Carbamazepine versus placebo, outcome: 2.1 Benzodiazepine discontinuation. Trial Sequential Analysis on benzodiazepine discontinuation in three trials was performed based on the proportion with benzodiazepine discontinuation in the control group set at 48%, a relative risk reduction (RRR) of 20%, a type I error of 2.5%, a type II error of 10% (90% power), and diversity of 36% as observed in the trials. The diversity‐adjusted required information size (DARIS) was 2109 participants, and the Trial Sequential Analysis‐adjusted confidence interval is 0.24 to 2.38. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 5%. The cumulative Z‐curve (blue line) touches the conventional statistical boundaries, but does not cross the trial sequential monitoring boundaries, and the diversity‐adjusted required information size is not met, showing that insufficient information has been accrued." data-id="CD011481-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of comparison: 2 Carbamazepine versus placebo, outcome: 2.1 Benzodiazepine discontinuation. Trial Sequential Analysis on benzodiazepine discontinuation in three trials was performed based on the proportion with benzodiazepine discontinuation in the control group set at 48%, a relative risk reduction (RRR) of 20%, a type I error of 2.5%, a type II error of 10% (90% power), and diversity of 36% as observed in the trials. The diversity‐adjusted required information size (DARIS) was 2109 participants, and the Trial Sequential Analysis‐adjusted confidence interval is 0.24 to 2.38. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 5%. The cumulative Z‐curve (blue line) touches the conventional statistical boundaries, but does not cross the trial sequential monitoring boundaries, and the diversity‐adjusted required information size is not met, showing that insufficient information has been accrued. </p> </div> </div> </div> <p>For benzodiazepine withdrawal symptoms, results did not favour carbamazepine (<a href="./references#CD011481-fig-0021" title="">Analysis 2.2</a>: 2 studies, 76 participants; SMD ‐1.14, 95% CI ‐2.43 to 0.16; GRADE: very low quality‐evidence). Due to marked differences in among‐participant variability, we did not re‐express the SMD using one of the specific measurement instruments. </p> <p>For the following outcomes, only data from single trials were available, finding no differences between groups regarding benzodiazepine discontinuation at longest follow‐up (<a href="./references#CD011481-fig-0022" title="">Analysis 2.3</a>: 1 study, 40 participants; RR 1.41, 95% CI 0.86 to 2.29; GRADE: very low‐quality evidence), relapse to benzodiazepine use (<a href="./references#CD011481-fig-0023" title="">Analysis 2.4</a>: 1 study, 36 participants; RR 0.33, 95% CI 0.08 to 1.44; GRADE: very low‐quality evidence), and non‐serious adverse events (<a href="./references#CD011481-fig-0025" title="">Analysis 2.6</a>: 1 study, 36 participants; RR 7.00, 95% CI 0.39 to 126.48; GRADE: very low‐quality evidence). Data from a single trial found carbamazepine superior to placebo regarding symptoms of anxiety (<a href="./references#CD011481-fig-0026" title="">Analysis 2.7</a>: 1 study, 36 participants; MD ‐6.00 points, 95% CI ‐9.58 to ‐2.42; GRADE: very low‐quality evidence). </p> <p>When evaluating benzodiazepine withdrawal symptoms, the results were associated with significant heterogeneity. We could identify no obvious reason for this heterogeneity. </p> <p>Please see <a href="./full#CD011481-tbl-0002">summary of findings Table 2</a>. </p> </section> <section id="CD011481-sec-0092"> <h4 class="title">Lithium versus placebo</h4> <p>One trial of moderate size investigated lithium versus placebo for benzodiazepine discontinuation and found no difference between groups regarding benzodiazepine discontinuation (<a href="./references#CD011481-fig-0028" title="">Analysis 3.1</a>: 1 study, 230 participants; RR 1.05, 95% CI 0.86 to 1.28; GRADE: low‐quality evidence), non‐serious adverse events (<a href="./references#CD011481-fig-0030" title="">Analysis 3.3</a>: 1 study, 230 participants; RR 1.06, 95% CI 0.75 to 1.49; GRADE: very low‐quality evidence), and discontinuation due to adverse events (<a href="./references#CD011481-fig-0031" title="">Analysis 3.4</a>: 1 study, 230 participants; RR 1.38, 95% CI 0.13 to 15.03; GRADE: very low‐quality evidence) (<a href="./references#CD011481-bbs2-0017" title="LecrubierY , FessardN . Benzodiazepine discontinuation in chronic users: a double‐blind trial of lithium gluconate vs placebo [Arrêt des benzodiazépines chez des consommateurs chronique: un essai en double insu du gluconate de lithium vs placebo]. Annales Médico Phychologiques2005;163:24‐9. ">Lecrubier 2005</a>). Data on other outcomes specified in this review were not available. </p> <p>For benzodiazepine discontinuation, we calculated the required information size to be 1918 participants, using a control event proportion of 48%, a relative risk reduction of 20%, type I error of 2.5%, power of 90%, and a diversity of 30%. We could not perform Trial Sequential Analysis as there was only one trial. </p> <p>Please see <a href="./full#CD011481-tbl-0003">summary of findings Table 3</a>. </p> </section> <section id="CD011481-sec-0093"> <h4 class="title">Pregabalin versus placebo</h4> <p>One smaller trial investigated this comparison (<a href="./references#CD011481-bbs2-0010" title="HadleySJ , MandelFS , SchweizerE . Switching from long‐term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double‐blind, placebo‐controlled trial. Journal of Psychopharmacology2012;26(4):461‐70. [DOI: 10.1177/0269881111405360] SzczypaP , HadleySJ , DonevanS , MandelFS , LeonT . P.4.a.016 Switching from long‐term benzodiazepine therapy to pregabalin in patients with generalised anxiety disorder (GAD). European Neuropsychopharmacology2009;19:S594‐5. [DOI: 10.1016/S0924‐977X(09)70952‐6] ">Hadley 2012</a>), finding no significant difference between groups regarding benzodiazepine discontinuation (<a href="./references#CD011481-fig-0032" title="">Analysis 4.1</a>: 1 study, 106 participants; RR 1.44, 95% CI 0.92 to 2.25; GRADE: very low‐quality evidence), but finding superior effect of pregabalin regarding benzodiazepine withdrawal symptoms (<a href="./references#CD011481-fig-0033" title="">Analysis 4.2</a>; 1 study, 106 participants; MD ‐3.10 points, 95% CI ‐3.51 to ‐2.69; GRADE: very low‐quality evidence) and symptoms of anxiety (<a href="./references#CD011481-fig-0034" title="">Analysis 4.3</a>: 1 study, 106 participants; MD ‐4.80 points, 95% CI ‐5.28 to ‐4.32; GRADE: very low‐quality evidence). There were no differences between groups for serious and non‐serious adverse events as well as for discontinuation due to side effects (<a href="./references#CD011481-fig-0035" title="">Analysis 4.4</a>; <a href="./references#CD011481-fig-0036" title="">Analysis 4.5</a>; <a href="./references#CD011481-fig-0037" title="">Analysis 4.6</a>). </p> <p>For benzodiazepine discontinuation, we calculated the required information size to be 1918 participants, using a control event proportion of 48%, a relative risk reduction of 20%, type I error of 2.5%, power of 90%, and a diversity of 30%. We could not perform Trial Sequential Analysis as there was only one trial. </p> <p>Please see <a href="./full#CD011481-tbl-0004">summary of findings Table 4</a>. </p> </section> <section id="CD011481-sec-0094"> <h4 class="title">Captodiame versus placebo</h4> <p>One smaller trial compared captodiame (an antihistamine used as a sedative and anxiolytic) with placebo and found that captodiame had a beneficial effect in terms of benzodiazepine withdrawal symptoms (<a href="./references#CD011481-fig-0038" title="">Analysis 5.1</a>: 1 study, 81 participants; MD ‐1.00 points, 95% CI ‐1.13 to ‐0.87; GRADE: very low‐quality evidence) and symptoms of anxiety (<a href="./references#CD011481-fig-0039" title="">Analysis 5.2</a>: 1 study, 81 participants; MD ‐5.70 points, 95% CI ‐6.05 to ‐5.35) (<a href="./references#CD011481-bbs2-0020" title="Mercier‐GuyonC , ChabannesJP , SaviucP . The role of captodiamine in the withdrawal from long‐term benzodiazepine treatment. Current Medical Research and Opinion2004;20(9):1347‐55. [DOI: 10.1185/030079904125004457] ">Mercier‐Guyon 2004</a>). Data on other outcomes specified in this review were not available. </p> <p>For benzodiazepine withdrawal symptoms assessed with the Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ), we calculated the required information size to be 229 participants, using a variance of 20 points, a minimal relative difference of 2.25 points, type I error of 2.5%, power of 90%, and a diversity of 30%. We could not perform Trial Sequential Analysis as there was only one trial. </p> <p>Please see <a href="./full#CD011481-tbl-0005">summary of findings Table 5</a>. </p> </section> <section id="CD011481-sec-0095"> <h4 class="title">Paroxetine versus placebo or no intervention</h4> <p>Three smaller trials evaluated paroxetine to facilitate benzodiazepine discontinuation: two versus placebo, <a href="./references#CD011481-bbs2-0009" title="GlaxoSmithKline . Clinical comparison of paroxetine and placebo on the symptoms emerging during the taper phase of a chronic benzodiazepine treatment, in patients suffering from a variety of anxiety disorders. GSK ‐ Clinical Study Register (www.gsk‐clinicalstudyregister.com)2002. ">GlaxoSmithKline 2002</a>; <a href="./references#CD011481-bbs2-0038" title="ZitmanFG , CouveeJE . Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper‐off: report on behalf of the Dutch Chronic Benzodiazepine Working Group. British Journal of Psychiatry2001;178:317‐24. ">Zitman 2001</a>, and one versus no intervention (<a href="./references#CD011481-bbs2-0022" title="NakaoM , TakeuchiT , NomuraK , TeramotoT , YanoE . Clinical application of paroxetine for chronic benzodiazepine users at an internal medicine clinic. Therapeutic Research2006;27(5):859‐67. NakaoM , TakeuchiT , NomuraK , TeramotoT , YanoE . Clinical application of paroxetine for tapering benzodiazepine use in non‐major‐depressive outpatients visiting an internal medicine clinic. Psychiatry and Clinical Neurosciences2006;60(5):605‐10. ">Nakao 2006</a>). It was possible to perform a meta‐analysis for the following outcomes, where placebo and no intervention were pooled as control group. </p> <p> <ul id="CD011481-list-0012"> <li> <p>Benzodiazepine discontinuation at end of intervention, where no intervention effect could be found (<a href="./references#CD011481-fig-0042" title="">Analysis 6.1</a>: 3 studies, 221 participants; RR 1.45, 95% CI 0.88 to 2.39; GRADE: very low‐quality evidence). Trial Sequential Analysis showed that the diversity‐adjusted required information size of 9448 participants was not reached, as the accrued number of participants was only 210 (2.34%), showing that insufficient information has been obtained (<a href="#CD011481-fig-0005">Figure 5</a>). Results for benzodiazepine discontinuation were associated with significant heterogeneity (<a href="./references#CD011481-fig-0042" title="">Analysis 6.1</a>), for which we could not identify any obvious reason. </p> </li> <li> <p>Benzodiazepine withdrawal symptoms at end of intervention, assessed with BWSQ, indicated a difference in favour of paroxetine (<a href="./references#CD011481-fig-0043" title="">Analysis 6.2</a>: 2 studies, 99 participants; MD ‐3.57 points, 95% CI ‐5.34 to ‐1.80; GRADE: very low‐quality evidence). Trial Sequential Analysis based on a minimal relevant clinical difference of 2.25 points, variance of 20 (empirical data), a type I error of 1.25%, a type II error of 10% (90% power), and diversity of 0% showed that the diversity‐adjusted required information size of 229 participants was not met (<a href="#CD011481-fig-0006">Figure 6</a>). However, the cumulative Z‐curve touched the trial sequential monitoring boundaries for benefit, indicating that sufficient information had been obtained, and that the result was not due to random error. </p> </li> <li> <p>Symptoms of anxiety, assessed with Hamilton Anxiety Rating Scale (HAM‐A), indicated a difference in favour of paroxetine (<a href="./references#CD011481-fig-0044" title="">Analysis 6.3</a>: 2 studies, 99 participants; MD ‐6.75 points, 95% CI ‐9.64 to ‐3.86; GRADE: very low‐quality evidence). We performed Trial Sequential Analysis on anxiety, assessed with HAM‐A, with a minimal relevant clinical difference of 5 points, variance of 103 points, based on a type I error of 1.25%, a type II error of 10% (90% power), and diversity of 0% (<a href="#CD011481-fig-0007">Figure 7</a>). The diversity‐adjusted required information size of 236 participants was not met. However, the cumulative Z‐curve crossed the trial sequential monitoring boundaries for benefit, indicating that sufficient information had been obtained, and that the result was not due to random error. </p> </li> </ul> </p> <div class="figure" id="CD011481-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of comparison: 6 Paroxetine versus placebo, outcome: 6.1 Benzodiazepine discontinuation. Trial Sequential Analysis on benzodiazepine discontinuation in three trials was performed based on the proportion with benzodiazepine discontinuation in the control group set at 48%, a relative risk reduction of 20%, a type I error of 2.5%, a type II error of 10% (90% power), and diversity of 86% as observed in the trials. The diversity‐adjusted required information size was 9448 participants, and the Trial Sequential Analysis‐adjusted confidence interval could not be estimated due to lack of information. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 5%. The cumulative Z‐curve (blue line) does not cross the conventional statistical boundaries. The trial sequential monitoring boundaries and the diversity‐adjusted required information size are not shown as the accrued number of participants only amounted to 221/9448 (2.34%), showing that insufficient information has been accrued." data-id="CD011481-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of comparison: 6 Paroxetine versus placebo, outcome: 6.1 Benzodiazepine discontinuation. Trial Sequential Analysis on benzodiazepine discontinuation in three trials was performed based on the proportion with benzodiazepine discontinuation in the control group set at 48%, a relative risk reduction of 20%, a type I error of 2.5%, a type II error of 10% (90% power), and diversity of 86% as observed in the trials. The diversity‐adjusted required information size was 9448 participants, and the Trial Sequential Analysis‐adjusted confidence interval could not be estimated due to lack of information. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 5%. The cumulative Z‐curve (blue line) does not cross the conventional statistical boundaries. The trial sequential monitoring boundaries and the diversity‐adjusted required information size are not shown as the accrued number of participants only amounted to 221/9448 (2.34%), showing that insufficient information has been accrued. </p> </div> </div> </div> <div class="figure" id="CD011481-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of comparison: 6 Paroxetine versus placebo, outcome: 6.2 Benzodiazepine withdrawal symptoms Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ). Trial Sequential Analysis on benzodiazepine withdrawal symptoms assessed with BWSQ assessing a minimal relevant clinical difference (MIREDIF) of 2.25 points, and a variance of 20 points (empirical data), was performed based on a type I error of 1.25%, a type II error of 10% (90% power), and diversity of 0%. The diversity‐adjusted required information size (DARIS) was 229 participants, and the Trial Sequential Analysis‐adjusted confidence interval is ‐7.18 to 0.05. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 0.05. The red inward‐sloping lines represent the trial sequential monitoring boundaries. The cumulative Z‐curve touches the trial sequential monitoring boundaries, indicating that sufficient information was provided." data-id="CD011481-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of comparison: 6 Paroxetine versus placebo, outcome: 6.2 Benzodiazepine withdrawal symptoms Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ). Trial Sequential Analysis on benzodiazepine withdrawal symptoms assessed with BWSQ assessing a minimal relevant clinical difference (MIREDIF) of 2.25 points, and a variance of 20 points (empirical data), was performed based on a type I error of 1.25%, a type II error of 10% (90% power), and diversity of 0%. The diversity‐adjusted required information size (DARIS) was 229 participants, and the Trial Sequential Analysis‐adjusted confidence interval is ‐7.18 to 0.05. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 0.05. The red inward‐sloping lines represent the trial sequential monitoring boundaries. The cumulative Z‐curve touches the trial sequential monitoring boundaries, indicating that sufficient information was provided. </p> </div> </div> </div> <div class="figure" id="CD011481-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of comparison: 6 Paroxetine versus placebo, outcome: 6.3 Anxiety, Hamilton Anxiety Rating Scale (HAM‐A). Trial Sequential Analysis on anxiety evaluated with HAM‐A assessing a minimal relevant clinical difference (MIREDIF) of 5 points, and a variance of 103 points, was performed based on a type I error of 1.25%, a type II error of 10% (90% power), and diversity of 0%. The diversity‐adjusted required information size (DARIS) was 236 participants, and the Trial Sequential Analysis‐adjusted confidence interval is ‐12.72 to ‐0.80. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 0.05. The red inward‐sloping lines represent the trial sequential monitoring boundaries. The cumulative Z‐curve crosses the trial sequential monitoring boundaries, indicating that sufficient information was provided." data-id="CD011481-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of comparison: 6 Paroxetine versus placebo, outcome: 6.3 Anxiety, Hamilton Anxiety Rating Scale (HAM‐A). Trial Sequential Analysis on anxiety evaluated with HAM‐A assessing a minimal relevant clinical difference (MIREDIF) of 5 points, and a variance of 103 points, was performed based on a type I error of 1.25%, a type II error of 10% (90% power), and diversity of 0%. The diversity‐adjusted required information size (DARIS) was 236 participants, and the Trial Sequential Analysis‐adjusted confidence interval is ‐12.72 to ‐0.80. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 0.05. The red inward‐sloping lines represent the trial sequential monitoring boundaries. The cumulative Z‐curve crosses the trial sequential monitoring boundaries, indicating that sufficient information was provided. </p> </div> </div> </div> <p>Results were similar if analysing placebo or no intervention separately as control group. </p> <p>One trial evaluated benzodiazepine withdrawal symptoms at longest follow‐up, where no effect of paroxetine could be found (<a href="./references#CD011481-fig-0045" title="">Analysis 6.4</a>: 1 study, 54 participants; MD ‐0.13 points, 95% CI ‐4.03 to 3.77; GRADE: very low‐quality evidence). For non‐serious adverse events, no differences between intervention groups were found (<a href="./references#CD011481-fig-0047" title="">Analysis 6.6</a>). </p> <p>Please see <a href="./full#CD011481-tbl-0006">summary of findings Table 6</a>. </p> </section> <section id="CD011481-sec-0096"> <h4 class="title">Tricyclic antidepressants (dosulepin, imipramine, or trazodone) versus placebo</h4> <p>Four trials, each with a small sample size, investigated tricyclic antidepressants versus placebo (<a href="./references#CD011481-bbs2-0026" title="RickelsK , DeMartinisN , Garcia‐EspanaF , GreenblattDJ , MandosLA , RynnM . Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long‐term benzodiazepine therapy. American Journal of Psychiatry2000;157(12):1973‐9. ">Rickels 2000</a>; <a href="./references#CD011481-bbs2-0028" title="RynnM , Garcia‐EspanaF , GreenblattDJ , MandosLA , SchweizerE , RickelsK . Imipramine and buspirone in patients with panic disorder who are discontinuing long‐term benzodiazepine therapy. Journal of Clinical Psychopharmacology2003;23(5):505‐8. ">Rynn 2003</a>; <a href="./references#CD011481-bbs2-0033" title="TyrerP , FergusonB , HallstromC , MichieM , TyrerS , CooperS , et al. A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms. British Journal of Psychiatry1996;168(4):457‐61. ">Tyrer 1996</a>; <a href="./references#CD011481-bbs2-0037" title="ZhangH , JiangX , MaM , ZhangJ . A control study on treatment for benzodiazepine dependence with trazodone. Chinese Journal of Contemporary Neurology and Neurosurgery2013;13(5):411‐5. ">Zhang 2013</a>). It was possible to perform a meta‐analysis for benzodiazepine discontinuation at end of intervention, where results showed no difference between intervention groups (<a href="./references#CD011481-fig-0048" title="">Analysis 7.1</a>: 2 studies, 105 participants; RR 0.82, 95% CI 0.52 to 1.28; GRADE: very low‐quality evidence). Trial Sequential Analysis showed that the diversity‐adjusted required information size of 1343 participants was not reached, as the accrued number of participants was only 105 (7.81%), indicating that insufficient information has been obtained (<a href="#CD011481-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD011481-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of comparison: 7 Tricyclic antidepressants versus placebo, outcome: 7.1 Benzodiazepine discontinuation. Trial Sequential Analysis on benzodiazepine discontinuation in two trials was performed based on the proportion with benzodiazepine discontinuation in the control group set at 48%, a relative risk reduction (RRR) of 20%, a type I error of 2.5%, a type II error of 10% (90% power), and diversity of 0% as observed in the trials. The diversity‐adjusted required information size (DARIS) was 1343 participants, and the Trial Sequential Analysis‐adjusted confidence interval is 0.20 to 7.55. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 5%. The cumulative Z‐curve (blue line) does not cross the conventional statistical boundaries or the trial sequential monitoring boundaries (red dotted lines), and the diversity‐adjusted required information size is not met, showing that insufficient information has been accrued." data-id="CD011481-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of comparison: 7 Tricyclic antidepressants versus placebo, outcome: 7.1 Benzodiazepine discontinuation. Trial Sequential Analysis on benzodiazepine discontinuation in two trials was performed based on the proportion with benzodiazepine discontinuation in the control group set at 48%, a relative risk reduction (RRR) of 20%, a type I error of 2.5%, a type II error of 10% (90% power), and diversity of 0% as observed in the trials. The diversity‐adjusted required information size (DARIS) was 1343 participants, and the Trial Sequential Analysis‐adjusted confidence interval is 0.20 to 7.55. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 5%. The cumulative Z‐curve (blue line) does not cross the conventional statistical boundaries or the trial sequential monitoring boundaries (red dotted lines), and the diversity‐adjusted required information size is not met, showing that insufficient information has been accrued. </p> </div> </div> </div> <p>Two trials reported symptoms of anxiety (<a href="./references#CD011481-bbs2-0028" title="RynnM , Garcia‐EspanaF , GreenblattDJ , MandosLA , SchweizerE , RickelsK . Imipramine and buspirone in patients with panic disorder who are discontinuing long‐term benzodiazepine therapy. Journal of Clinical Psychopharmacology2003;23(5):505‐8. ">Rynn 2003</a>; <a href="./references#CD011481-bbs2-0037" title="ZhangH , JiangX , MaM , ZhangJ . A control study on treatment for benzodiazepine dependence with trazodone. Chinese Journal of Contemporary Neurology and Neurosurgery2013;13(5):411‐5. ">Zhang 2013</a>), with no difference between intervention groups (<a href="./references#CD011481-fig-0049" title="">Analysis 7.2</a>: 2 studies, 66 participants; MD ‐10.38 points, 95% CI ‐25.96 to 5.20; GRADE: very low‐quality evidence). These data were associated with significant heterogeneity, the reason for which was that the Chinese study, <a href="./references#CD011481-bbs2-0037" title="ZhangH , JiangX , MaM , ZhangJ . A control study on treatment for benzodiazepine dependence with trazodone. Chinese Journal of Contemporary Neurology and Neurosurgery2013;13(5):411‐5. ">Zhang 2013</a>, reported results that were far more positive in favour of the experimental drug than the remainder of the included trials. </p> <p>The following outcomes were reported in one trial each: benzodiazepine discontinuation at longest follow‐up, showing a beneficial effect of tricyclic antidepressants (<a href="./references#CD011481-fig-0050" title="">Analysis 7.3</a>: 1 study, 47 participants; RR 2.20, 95% CI 1.27 to 3.82; GRADE: low‐quality evidence); benzodiazepine withdrawal symptoms (<a href="./references#CD011481-fig-0051" title="">Analysis 7.4</a>: 1 study, 38 participants; MD ‐19.78 points, 95% CI ‐20.25 to ‐19.31; GRADE: very low‐quality evidence) with a significant difference between groups in favour of tricyclic antidepressants; relapse to benzodiazepine use, showing no intervention effect (<a href="./references#CD011481-fig-0052" title="">Analysis 7.5</a>: 1 study, 36 participants; RR 2.00, 95% CI 0.73 to 5.47); and discontinuation due to adverse events, also showing no intervention effect (<a href="./references#CD011481-fig-0053" title="">Analysis 7.6</a>: 2 studies, 134 participants; RR 1.16, 95% CI 0.42 to 3.21; GRADE: very low‐quality evidence). </p> <p>Please see <a href="./full#CD011481-tbl-0007">summary of findings Table 7</a>. </p> </section> <section id="CD011481-sec-0097"> <h4 class="title">Alpidem versus placebo</h4> <p>Two smaller trials compared alpidem (an anxiolytic drug from the imidazopyridine family) with placebo for benzodiazepine discontinuation (<a href="./references#CD011481-bbs2-0003" title="CassanoGB , PetraccaA , BorghiC , ChiroliS , DidoniG , GarreauM . A randomized, double‐blind study of alpidem vs placebo in the prevention and treatment of benzodiazepine withdrawal syndrome. European Psychiatry1996;11(2):93‐9. ">Cassano 1996</a>; <a href="./references#CD011481-bbs2-0016" title="LaderM , FarrI , MortonS . A comparison of alpidem and placebo in relieving benzodiazepine withdrawal symptoms. International Clinical Psychopharmacology1993;8(1):31‐6. ">Lader 1993</a>), showing a disadvantage of alpidem for this outcome at end of intervention (<a href="./references#CD011481-fig-0054" title="">Analysis 8.1</a>: 1 study, 25 participants; RR 0.41, 95% CI 0.17 to 0.99; NNTH 2.3 participants; GRADE: low‐quality evidence). We calculated the required information size to be 1918 participants, using a control event proportion of 48%, a relative risk reduction of 20%, type I error of 2.5%, power of 90%, and a diversity of 30%. Withdrawal syndrome was also analysed, suggesting a disadvantage of alpidem (<a href="./references#CD011481-fig-0055" title="">Analysis 8.2</a>: 1 study, 145 participants; RR 4.86, 95% CI 1.12 to 21.14; NNTH 5.9 participants; GRADE: low‐quality evidence). We calculated the required information size to be 9202 participants, using a control event proportion of 15%, a relative risk reduction of 20%, type I error of 2.5%, power of 90%, and a diversity of 30%. We could not perform Trial Sequential Analysis for either of these outcomes because they were only reported in one trial. </p> <p>It was possible to perform a meta‐analysis for symptoms of anxiety, as assessed by HAM‐A, where no intervention effect was found (<a href="./references#CD011481-fig-0056" title="">Analysis 8.3</a>: 2 studies, 170 participants; MD ‐1.60 points, 95% CI ‐4.64 to 1.45; GRADE: low‐quality evidence). In Trial Sequential Analysis using a minimal relevant clinical difference of 5 points, variance of 103 points, type I error of 1.25%, type II error of 10% (90% power), and diversity of 0% (<a href="#CD011481-fig-0009">Figure 9</a>), we found that the diversity‐adjusted required information size of 235 participants was not met. However, the cumulative Z‐curve crossed the beta‐spending (futility) boundaries, indicating that an intervention effect, if any, was less than 5 points. </p> <div class="figure" id="CD011481-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of comparison: 8 Alpidem versus placebo, outcome: 8.3 Anxiety, Hamilton Anxiety Rating Scale (HAM‐A). Trial Sequential Analysis on anxiety evaluated with HAM‐A assessing a minimal relevant clinical difference (MIREDIF) of 5 points, and a variance of 103 points (empirical data), was performed based on a type I error of 1.25%, a type II error of 10% (90% power), and diversity of 0%. The diversity‐adjusted required information size (DARIS) was 235 participants, and the Trial Sequential Analysis‐adjusted confidence interval is ‐6.28 to 3.08. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 0.05. The red inward‐sloping lines represent the trial sequential alpha‐spending monitoring boundaries, while the red outward‐sloping lines represent the beta‐spending (futility) boundaries. The cumulative Z‐curve crosses the beta‐spending (futility) boundaries, showing that an intervention effect, if any, is less than 5 points." data-id="CD011481-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of comparison: 8 Alpidem versus placebo, outcome: 8.3 Anxiety, Hamilton Anxiety Rating Scale (HAM‐A). Trial Sequential Analysis on anxiety evaluated with HAM‐A assessing a minimal relevant clinical difference (MIREDIF) of 5 points, and a variance of 103 points (empirical data), was performed based on a type I error of 1.25%, a type II error of 10% (90% power), and diversity of 0%. The diversity‐adjusted required information size (DARIS) was 235 participants, and the Trial Sequential Analysis‐adjusted confidence interval is ‐6.28 to 3.08. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 0.05. The red inward‐sloping lines represent the trial sequential alpha‐spending monitoring boundaries, while the red outward‐sloping lines represent the beta‐spending (futility) boundaries. The cumulative Z‐curve crosses the beta‐spending (futility) boundaries, showing that an intervention effect, if any, is less than 5 points. </p> </div> </div> </div> <p>One trial reported relapse to benzodiazepine use, suggesting no intervention effect (<a href="./references#CD011481-fig-0057" title="">Analysis 8.4</a>: 1 study, 145 participants; RR 0.33, 95% CI 0.09 to 1.20; GRADE: very low‐quality evidence). </p> <p>Please see <a href="./full#CD011481-tbl-0008">summary of findings Table 8</a>. </p> </section> <section id="CD011481-sec-0098"> <h4 class="title">Buspirone versus placebo</h4> <p>Four trials examined use of buspirone compared with placebo (<a href="./references#CD011481-bbs2-0001" title="AshtonCH , RawlinsMD , TyrerSP . A double‐blind placebo‐controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. British Journal of Psychiatry1990;157:232‐8. ">Ashton 1990</a>; <a href="./references#CD011481-bbs2-0015" title="LaderM , OlajideD . A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. Journal of Clinical Psychopharmacology1987;7(1):11‐5. ">Lader 1987</a>; <a href="./references#CD011481-bbs2-0021" title="MortonS , LaderM . Buspirone treatment as an aid to benzodiazepine withdrawal. Journal of Psychopharmacology1995;9(4):331‐5. ">Morton 1995</a>; <a href="./references#CD011481-bbs2-0034" title="UdelmanHD , UdelmanDL . Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy. Journal of Clinical Psychiatry1990;51 Suppl:46‐50. ">Udelman 1990</a>), each with a small sample size. It was possible to perform a meta‐analysis with regard to benzodiazepine discontinuation at end of intervention, finding no difference between intervention groups (<a href="./references#CD011481-fig-0060" title="">Analysis 9.1</a>: 4 studies, 143 participants; RR 0.82, 95% CI 0.49 to 1.37; GRADE: low‐quality evidence). Trial Sequential Analysis showed that the diversity‐adjusted required information size of 3381 participants was not reached, as the accrued number of participants was only 143 (4.23%), showing that insufficient information has been accrued (<a href="#CD011481-fig-0010">Figure 10</a>). </p> <div class="figure" id="CD011481-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of comparison: 9 Buspirone versus placebo, outcome: 9.1 Benzodiazepine discontinuation. Trial Sequential Analysis on benzodiazepine discontinuation in four trials was performed based on the proportion with benzodiazepine discontinuation in the control group set at 48%, a relative risk reduction of 20%, a type I error of 2.5%, a type II error of 10% (90% power), and diversity of 60% as observed in the trials. The diversity‐adjusted required information size was 3381 participants, and the Trial Sequential Analysis‐adjusted confidence interval could not be estimated due to lack of information. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 5%. The cumulative Z‐curve (blue line) does not cross the conventional statistical boundaries. The trial sequential monitoring boundaries and the diversity‐adjusted required information size are not shown, as the accrued number of participants only amounted to 143/3381 (4.23%), showing that insufficient information has been accrued." data-id="CD011481-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of comparison: 9 Buspirone versus placebo, outcome: 9.1 Benzodiazepine discontinuation. Trial Sequential Analysis on benzodiazepine discontinuation in four trials was performed based on the proportion with benzodiazepine discontinuation in the control group set at 48%, a relative risk reduction of 20%, a type I error of 2.5%, a type II error of 10% (90% power), and diversity of 60% as observed in the trials. The diversity‐adjusted required information size was 3381 participants, and the Trial Sequential Analysis‐adjusted confidence interval could not be estimated due to lack of information. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 5%. The cumulative Z‐curve (blue line) does not cross the conventional statistical boundaries. The trial sequential monitoring boundaries and the diversity‐adjusted required information size are not shown, as the accrued number of participants only amounted to 143/3381 (4.23%), showing that insufficient information has been accrued. </p> </div> </div> </div> <p>There was also no intervention effect for anxiety symptoms at end of intervention (<a href="./references#CD011481-fig-0061" title="">Analysis 9.2</a>: 2 studies, 41 participants; SMD 0.18, 95% CI ‐0.50 to 0.86; GRADE: very low‐quality evidence). </p> <p>The following outcomes were reported in only one trial each and with no sign of intervention effect: benzodiazepine withdrawal symptoms at end of intervention (<a href="./references#CD011481-fig-0062" title="">Analysis 9.3</a>: 1 study, 17 participants; MD 4.69 points, 95% CI ‐14.47 to 23.85; GRADE: very low‐quality evidence), benzodiazepine discontinuation at longest follow‐up (<a href="./references#CD011481-fig-0063" title="">Analysis 9.4</a>: 1 study, 23 participants; RR 0.60, 95% CI 0.34 to 1.05; GRADE: low‐quality evidence), benzodiazepine withdrawal symptoms at longest follow‐up (<a href="./references#CD011481-fig-0064" title="">Analysis 9.5</a>: 1 study, 15 participants; MD ‐1.34 points, 95% CI ‐14.31 to 11.63; GRADE: very low‐quality evidence), and symptoms of anxiety at longest follow‐up (<a href="./references#CD011481-fig-0065" title="">Analysis 9.6</a>: 1 study, 12 participants; MD 2.75 points, 95% CI ‐2.83 to 8.33; GRADE: very low‐quality evidence). Due to marked differences in among‐participant variability, we did not re‐express the SMD using one of the specific measurement instruments. </p> <p>Results for benzodiazepine discontinuation (<a href="./references#CD011481-fig-0060" title="">Analysis 9.1</a>) were associated with significant heterogeneity, with the most marked differences between <a href="./references#CD011481-bbs2-0001" title="AshtonCH , RawlinsMD , TyrerSP . A double‐blind placebo‐controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. British Journal of Psychiatry1990;157:232‐8. ">Ashton 1990</a> (more in favour of placebo or no difference between groups) and <a href="./references#CD011481-bbs2-0034" title="UdelmanHD , UdelmanDL . Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy. Journal of Clinical Psychiatry1990;51 Suppl:46‐50. ">Udelman 1990</a> (more in favour of buspirone). We could not identify any obvious reasons for the observed heterogeneity. </p> <p>Please see <a href="./full#CD011481-tbl-0009">summary of findings Table 9</a>. </p> </section> <section id="CD011481-sec-0099"> <h4 class="title">Melatonin versus placebo</h4> <p>Four trials of small to moderate sample size investigated melatonin (both short‐acting and prolonged release formulation) versus placebo for benzodiazepine discontinuation at end of intervention (<a href="./references#CD011481-bbs2-0002" title="BaandrupL , FagerlundB , GlenthojB . Neurocognitive performance, subjective well‐being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add‐on melatonin versus placebo. European Archives of Psychiatry and Clinical Neuroscience2017;267(2):163‐71. [PUBMED: 27400927] BaandrupL , GlenthojBY , JennumPJ . Objective and subjective sleep quality: melatonin versus placebo add‐on treatment in patients with schizophrenia or bipolar disorder withdrawing from long‐term benzodiazepine use. Psychiatry Research2016;240:163‐9. [PUBMED: 27107670] BaandrupL , LindschouJ , WinkelP , GluudC , GlenthojBY . Prolonged‐release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: a randomised, placebo‐controlled, blinded trial. World Journal of Biological Psychiatry2016;17(7):514‐24. [PUBMED: 26086792] ">Baandrup 2016</a>; <a href="./references#CD011481-bbs2-0006" title="GarfinkelD , ZisapelN , WainsteinJ , LaudonM . Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Archives of Internal Medicine1999;159(20):2456‐60. ">Garfinkel 1999</a>; <a href="./references#CD011481-bbs2-0024" title="PelesE , HetzroniT , Bar‐HamburgerR , AdelsonM , SchreiberS . Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double‐blind randomized clinical trial. Addiction2007;102(12):1947‐53. ">Peles 2007</a>; <a href="./references#CD011481-bbs2-0035" title="VissersFH , KnipschildPG , CrebolderHF . Is melatonin helpful in stopping the long‐term use of hypnotics? A discontinuation trial. Pharmacy World &amp; Science2007;29(6):641‐6. [DOI: 10.1007/s11096‐007‐9118‐y] ">Vissers 2007</a>). It was possible to perform a meta‐analysis for benzodiazepine discontinuation at end of intervention, which showed no difference between intervention groups (<a href="./references#CD011481-fig-0067" title="">Analysis 10.1</a>: 4 studies, 219 participants; RR 1.20, 95% CI 0.73 to 1.96; GRADE: very low‐quality evidence). Trial Sequential Analysis showed that the diversity‐adjusted required information size of 3438 participants was not reached, as the accrued number of participants was only 219 (6.37%), showing that insufficient information has been accrued (<a href="#CD011481-fig-0011">Figure 11</a>). </p> <div class="figure" id="CD011481-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of comparison: 10 Melatonin versus placebo, outcome: 10.1 Benzodiazepine discontinuation. Trial Sequential Analysis on benzodiazepine discontinuation in four trials was performed based on the proportion with benzodiazepine discontinuation in the control group set at 48%, a relative risk reduction (RRR) of 20%, a type I error of 2.5%, a type II error of 10% (90% power), and diversity of 61% as observed in the trials. The diversity‐adjusted required information size (DARIS) was 3438 participants, and the Trial Sequential Analysis‐adjusted confidence interval is 0.11 to 6.25. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 5%. The cumulative Z‐curve (blue line) does not cross the conventional statistical boundaries or the trial sequential monitoring boundaries (red dotted lines), and the diversity‐adjusted required information size is not met, showing that insufficient information has been accrued." data-id="CD011481-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of comparison: 10 Melatonin versus placebo, outcome: 10.1 Benzodiazepine discontinuation. Trial Sequential Analysis on benzodiazepine discontinuation in four trials was performed based on the proportion with benzodiazepine discontinuation in the control group set at 48%, a relative risk reduction (RRR) of 20%, a type I error of 2.5%, a type II error of 10% (90% power), and diversity of 61% as observed in the trials. The diversity‐adjusted required information size (DARIS) was 3438 participants, and the Trial Sequential Analysis‐adjusted confidence interval is 0.11 to 6.25. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 5%. The cumulative Z‐curve (blue line) does not cross the conventional statistical boundaries or the trial sequential monitoring boundaries (red dotted lines), and the diversity‐adjusted required information size is not met, showing that insufficient information has been accrued. </p> </div> </div> </div> <p>We found no intervention effect likewise for insomnia (<a href="./references#CD011481-fig-0068" title="">Analysis 10.2</a>: 3 studies, 150 participants; SMD ‐1.23, 95% CI ‐2.70 to 0.23; GRADE: very low‐quality evidence) or discontinuation due to adverse events (<a href="./references#CD011481-fig-0069" title="">Analysis 10.3</a>: 2 studies, 120 participants; RR 2.10, 95% CI 0.20 to 22.26; GRADE: very low‐quality of evidence). The following outcomes were reported in one trial each: benzodiazepine discontinuation at longest follow‐up, showing no intervention effect (<a href="./references#CD011481-fig-0070" title="">Analysis 10.4</a>: 1 study, 38 participants; RR 1.03, 95% CI 0.47 to 2.27; GRADE: very low‐quality evidence), adverse events, with no intervention effect (<a href="./references#CD011481-fig-0071" title="">Analysis 10.5</a>: 1 study, 86 participants; RR 0.97, 95% CI 0.52 to 1.82; GRADE: very low‐quality evidence), and relapse to benzodiazepine use, also with no indication of intervention effect (<a href="./references#CD011481-fig-0072" title="">Analysis 10.6</a>: 1 study, 38 participants; RR 1.80, 95% CI 0.37 to 8.68; GRADE: very low‐quality evidence). </p> <p>When evaluating insomnia, the results were associated with significant heterogeneity; this was explained by <a href="./references#CD011481-bbs2-0006" title="GarfinkelD , ZisapelN , WainsteinJ , LaudonM . Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Archives of Internal Medicine1999;159(20):2456‐60. ">Garfinkel 1999</a>, which showed a markedly significant result in favour of melatonin, whereas the two other the trials included in this meta‐analysis showed no or a much smaller difference between intervention groups (<a href="./references#CD011481-bbs2-0002" title="BaandrupL , FagerlundB , GlenthojB . Neurocognitive performance, subjective well‐being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add‐on melatonin versus placebo. European Archives of Psychiatry and Clinical Neuroscience2017;267(2):163‐71. [PUBMED: 27400927] BaandrupL , GlenthojBY , JennumPJ . Objective and subjective sleep quality: melatonin versus placebo add‐on treatment in patients with schizophrenia or bipolar disorder withdrawing from long‐term benzodiazepine use. Psychiatry Research2016;240:163‐9. [PUBMED: 27107670] BaandrupL , LindschouJ , WinkelP , GluudC , GlenthojBY . Prolonged‐release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: a randomised, placebo‐controlled, blinded trial. World Journal of Biological Psychiatry2016;17(7):514‐24. [PUBMED: 26086792] ">Baandrup 2016</a>; <a href="./references#CD011481-bbs2-0024" title="PelesE , HetzroniT , Bar‐HamburgerR , AdelsonM , SchreiberS . Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double‐blind randomized clinical trial. Addiction2007;102(12):1947‐53. ">Peles 2007</a>). We could not identify any obvious reason for this observed heterogeneity, other than <a href="./references#CD011481-bbs2-0006" title="GarfinkelD , ZisapelN , WainsteinJ , LaudonM . Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Archives of Internal Medicine1999;159(20):2456‐60. ">Garfinkel 1999</a> being the only one of these studies involved with a pharmaceutical company. </p> <p>Please see <a href="./full#CD011481-tbl-0010">summary of findings Table 10</a>. </p> </section> <section id="CD011481-sec-0100"> <h4 class="title">Flumazenil versus placebo</h4> <p>Three small trials examined whether flumazenil can aid in benzodiazepine discontinuation (<a href="./references#CD011481-bbs2-0007" title="GerraG , MarcatoA , CaccavariR , Fertonani‐AffiniG , FontanesiB , ZaimovicA , et al. Effectiveness of flumazenil (Ro 15‐1788) in the treatment of benzodiazepine withdrawal. Current Therapeutic Research ‐ Clinical and Experimental1993;54(5):580‐7. ">Gerra 1993</a>; <a href="./references#CD011481-bbs2-0008" title="GerraG , ZaimovicA , GiustiF , MoiG , BrewerC . Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo‐controlled study. Addiction Biology2002;7(4):385‐95. ">Gerra 2002</a>; <a href="./references#CD011481-bbs2-0012" title="Harrison‐ReadPE , TyrerP , LawsonC , LackS , FernandesC , FileSE . Flumazenil‐precipitated panic and dysphoria in patients dependent on benzodiazepines: a possible aid to abstinence. Journal of Psychopharmacology1996;10(2):89‐97. ">Harrison‐Read 1996</a>). It was possible to perform a meta‐analysis for benzodiazepine withdrawal symptoms at end of intervention, which showed a beneficial effect of flumazenil (<a href="./references#CD011481-fig-0073" title="">Analysis 11.1</a>: 3 studies, 58 participants; SMD ‐0.95, 95% CI ‐1.71 to ‐0.19; GRADE: very low‐quality evidence). Due to marked differences in among‐participant variability, we did not re‐express the SMD using one of the specific measurement instruments. We could not calculate the required information size because the trials did not use the same instrument, and results were reported using SMD. </p> <p>The following outcomes were reported in one trial each: symptoms of anxiety, with results in favour of flumazenil (<a href="./references#CD011481-fig-0074" title="">Analysis 11.2</a>: 1 study, 18 participants; MD ‐1.30 points, 95% CI ‐2.28 to ‐0.32; GRADE: very low‐quality evidence) and benzodiazepine mean dose at end of intervention, with no difference between groups (<a href="./references#CD011481-fig-0075" title="">Analysis 11.3</a>: 1 study, 10 participants; MD ‐3.70 points, 95% CI ‐22.06 to 14.66; GRADE: very low‐quality evidence). As previously noted, one of the flumazenil studies was ended prematurely due to severe withdrawal symptoms elicited during the trial procedure (<a href="./references#CD011481-bbs2-0012" title="Harrison‐ReadPE , TyrerP , LawsonC , LackS , FernandesC , FileSE . Flumazenil‐precipitated panic and dysphoria in patients dependent on benzodiazepines: a possible aid to abstinence. Journal of Psychopharmacology1996;10(2):89‐97. ">Harrison‐Read 1996</a>). </p> <p>When evaluating benzodiazepine withdrawal symptoms, the results were associated with significant heterogeneity for which no obvious reason could be identified. </p> <p>Please see <a href="./full#CD011481-tbl-0011">summary of findings Table 11</a>. </p> </section> <section id="CD011481-sec-0101"> <h4 class="title">Propranolol versus placebo</h4> <p>One small trial evaluated propranolol versus placebo (<a href="./references#CD011481-bbs2-0032" title="TyrerP , RutherfordD , HuggettT . Benzodiazepine withdrawal symptoms and propranolol. Lancet1981;1(8219):520‐2. ">Tyrer 1981</a>). Only data on relapse to benzodiazepine use at end of intervention were available, showing no effect of the study intervention (<a href="./references#CD011481-fig-0076" title="">Analysis 12.1</a>: 1 study, 40 participants; RR 0.64, 95% CI 0.31 to 1.30; GRADE: very low‐quality evidence). </p> </section> <section id="CD011481-sec-0102"> <h4 class="title">Progesterone versus placebo</h4> <p>One small trial evaluated this comparison (<a href="./references#CD011481-bbs2-0031" title="SchweizerE , CaseWG , Garcia‐EspanaF , GreenblattDJ , RickelsK . Progesterone co‐administration in patients discontinuing long‐term benzodiazepine therapy: effects on withdrawal severity and taper outcome. Psychopharmacology1995;117(4):424‐9. ">Schweizer 1995</a>), reporting no intervention effect on benzodiazepine discontinuation at end of intervention (<a href="./references#CD011481-fig-0077" title="">Analysis 13.1</a>: 1 study, 35 participants; RR 1.15, 95% CI 0.52 to 2.54; GRADE: very low‐quality evidence), and a difference between groups in favour of placebo for non‐serious adverse events (<a href="./references#CD011481-fig-0078" title="">Analysis 13.2</a>: 1 study, 35 participants; RR 3.13, 95% CI 1.15 to 8.54; GRADE: very low‐quality evidence). </p> <p>For benzodiazepine discontinuation, we calculated the required information size to be 1918 participants, using a control event proportion of 48%, a relative risk reduction of 20%, type I error of 2.5%, power of 90%, and a diversity of 30%. We could not perform Trial Sequential Analysis as there was only one trial. </p> <p>Please see <a href="./full#CD011481-tbl-0012">summary of findings Table 12</a>. </p> </section> <section id="CD011481-sec-0103"> <h4 class="title">Magnesium aspartate versus placebo</h4> <p>One moderately sized trial compared magnesium aspartate (a mineral supplement) with placebo (<a href="./references#CD011481-bbs2-0011" title="HantoucheEG , GuelfiJD , CometD . Discontinuation of long‐term benzodiazepine use: double‐blind controlled study of α‐β L‐aspartate magnesium versus placebo in 144 chronic users of benzodiazepines [α‐β L‐aspartate de magnésium dans l'arrêt de la consommation chronique des benzodiazépines: étude contrôlée en double aveugle versus placebo]. L'encéphale1998;XXIV:469‐79. HantoucheEG , JacobL , CometD , GuelfiJD . Discontinuation of long‐term benzodiazepine use: predictive model of success in a double‐blind, controlled‐study. 150th Annual Meeting of the American Psychiatric Association, 1997 May 17‐22; San Diego, (CA). 1997. ">Hantouche 1998</a>), and found a beneficial effect of placebo for benzodiazepine discontinuation (<a href="./references#CD011481-fig-0079" title="">Analysis 14.1</a>: 1 study, 144 participants; RR 0.80, 95% CI 0.66 to 0.96; NNTH 5.8; GRADE: very low‐quality evidence), but no difference between groups for symptoms of anxiety (<a href="./references#CD011481-fig-0080" title="">Analysis 14.2</a>: 1 study, 144 participants; MD ‐0.80 points, 95% CI ‐2.73 to 1.13; GRADE: very low‐quality evidence), benzodiazepine relapse (<a href="./references#CD011481-fig-0081" title="">Analysis 14.3</a>: 1 study, 144 participants; RR 0.93, 95% CI 0.46 to 1.87; GRADE: very low‐quality evidence), non‐serious adverse events (<a href="./references#CD011481-fig-0082" title="">Analysis 14.4</a>: 1 study, 144 participants; RR 0.49, 95% CI 0.18 to 1.35; GRADE: very low‐quality evidence), and discontinuation due to adverse events (<a href="./references#CD011481-fig-0083" title="">Analysis 14.5</a>: 1 study, 144 participants; RR 0.40, 95% CI 0.13 to 1.18; GRADE: very low‐quality evidence). </p> <p>For benzodiazepine discontinuation, we calculated the required information size to be 1918 participants, using a control event proportion of 48%, a relative risk reduction of 20%, type I error of 2.5%, power of 90%, and a diversity of 30%. We could not perform Trial Sequential Analysis because there was only one trial. </p> <p>Please see <a href="./full#CD011481-tbl-0013">summary of findings Table 13</a>. </p> </section> <section id="CD011481-sec-0104"> <h4 class="title">Homeopathic drugs versus placebo</h4> <p>One small trial compared two homeopathic drugs ("Homéogène 46" and "Sédatif PC") versus placebo (<a href="./references#CD011481-bbs2-0004" title="CialdellaP , BoisselJP , BelonP , the ASTRHO group. Homeopathic specialties as a substitute for benzodiazepines: a double‐blind vs. placebo study. Thérapie2001;56:397‐402. ">Cialdella 2001</a>), from which it was only possible to extract data on benzodiazepine discontinuation. When combining the homeopathic drugs as one experimental group versus placebo, the results showed no intervention effect (<a href="./references#CD011481-fig-0084" title="">Analysis 15.1</a>: 1 study, 51 participants; RR 0.79, 95% CI 0.36 to 1.70; GRADE: very low‐quality evidence). </p> <p>For benzodiazepine discontinuation, we calculated the required information size to be 1918 participants, using a control event proportion of 48%, a relative risk reduction of 20%, type I error of 2.5%, power of 90%, and a diversity of 30%. We could not perform Trial Sequential Analysis as there was only one trial. </p> <p>Please see <a href="./full#CD011481-tbl-0014">summary of findings Table 14</a>. </p> </section> <section id="CD011481-sec-0105"> <h4 class="title">Carbamazepine versus tricyclic antidepressant (tianeptine)</h4> <p>Only one trial examined this comparison (<a href="./references#CD011481-bbs2-0014" title="KornowskiJ . The comparison between tianeptine and carbamazepine in benzodiazepines withdrawal syndrome. Psychiatria Polska2002;6(Suppl):311‐8. ">Kornowski 2002</a>), finding no additional effect of carbamazepine compared with tricyclic antidepressant for benzodiazepine discontinuation at end of intervention (<a href="./references#CD011481-fig-0085" title="">Analysis 16.1</a>: 1 study, 48 participants; RR 1.00, 95% CI 0.78 to 1.29; GRADE: low‐quality evidence) and relapse to benzodiazepine use (<a href="./references#CD011481-fig-0086" title="">Analysis 16.2</a>: 1 study, 48 participants; RR 1.00, 95% CI 0.28 to 3.54; GRADE: low‐quality evidence). Data on other outcomes specified in this review were not available. </p> <p>Please see <a href="./full#CD011481-tbl-0015">summary of findings Table 15</a>. </p> </section> <section id="CD011481-sec-0106"> <h4 class="title">Bromazepam versus cyamemazine</h4> <p>One moderately sized trial examined bromazepam versus cyamemazine (a first‐generation antipsychotic drug of the phenothiazine class with anxiolytic efficacy) (<a href="./references#CD011481-bbs2-0018" title="LemoineP , KermadiI , Garcia‐AcostaS , GarayRP , DibM . Double‐blind, comparative study of cyamemazine vs. bromazepam in the benzodiazepine withdrawal syndrome. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2006;30(1):131‐7. ">Lemoine 2006</a>), reporting a difference in favour of cyamemazine for relapse to benzodiazepine use (<a href="./references#CD011481-fig-0088" title="">Analysis 17.1</a>: 1 study, 124 participants; RR 0.33, 95% CI 0.14 to 0.78; GRADE: very low‐quality evidence), but no difference between groups for symptoms of anxiety (<a href="./references#CD011481-fig-0089" title="">Analysis 17.2</a>: 1 study, 160 participants; MD 0.50 points, 95% CI ‐1.23 to 2.23) or discontinuation due to adverse events (<a href="./references#CD011481-fig-0090" title="">Analysis 17.3</a>: 1 study, 160 participants; RR 2.87, 95% CI 0.79 to 10.44; GRADE: very low‐quality evidence). We identified a difference in favour of bromazepam for non‐serious adverse events (<a href="./references#CD011481-fig-0091" title="">Analysis 17.4</a>: 1 study, 160 participants; RR 1.68, 95% CI 1.01 to 2.78; GRADE: very low‐quality evidence). </p> </section> <section id="CD011481-sec-0107"> <h4 class="title">Zopiclone versus flunitrazepam</h4> <p>One small trial examined zopiclone (a short‐acting benzodiazepine‐like drug) versus flunitrazepam (a potent intermediate‐acting benzodiazepine, which in many countries is no longer in use due to severe side effects) (<a href="./references#CD011481-bbs2-0023" title="Pat‐HorenczykR , HacohenD , HererP , LavieP . The effects of substituting zopiclone in withdrawal from chronic use of benzodiazepine hypnotics. Psychopharmacology1998;140(4):450‐7. [DOI: 10.1007/s002130050789] ">Pat‐Horenczyk 1998</a>), finding no indication of intervention effect for relapse to benzodiazepine use (<a href="./references#CD011481-fig-0092" title="">Analysis 18.1</a>: 1 study, 18 participants; RR 1.05, 95% CI 0.23 to 4.78; GRADE: very low‐quality evidence). Data on other outcomes specified in this review were not available. </p> </section> <section id="CD011481-sec-0108"> <h4 class="title">Ondansetron, atenolol, and gabapentin</h4> <p>As described above, we were not able to extract data from three trials: <a href="./references#CD011481-bbs2-0027" title="RomachMK , KaplanHL , BustoUE , SomerG , SellersEM . A controlled trial of ondansetron, a 5‐HT3 antagonist, in benzodiazepine discontinuation. Journal of Clinical Psychopharmacology1998;18(2):121‐31. ">Romach 1998</a> (ondansetron versus placebo), <a href="./references#CD011481-bbs2-0029" title="SaulPA , KorliparaK , PresleyP . A randomised, multicentre, double‐blind, comparison of atenolol and placebo in the control of benzodiazepine withdrawal symptoms. Acta Therapeutica1989;15(2):117‐23. ">Saul 1989</a> (atenolol versus placebo), and <a href="./references#CD011481-bbs2-0019" title="MarianiJJ , MalcolmRJ , MamczurAK , ChoiJC , BradyR , NunesE , et al. Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients. American Journal of Drug and Alcohol Abuse2016;42(3):333‐40. [PUBMED: 26962719] ">Mariani 2016</a> (gabapentin versus placebo). None of these trials reported any effect on applied outcome measures of the respective experimental drug. </p> </section> <section id="CD011481-sec-0109"> <h4 class="title">Adverse events</h4> <p>In general, adverse events were insufficiently reported, making it difficult to reliably assess the tolerability and safety of the investigated compounds. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011481-sec-0110" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011481-sec-0110">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011481-sec-0181">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011481-sec-0110"></div> <section id="CD011481-sec-0111"> <h3 class="title" id="CD011481-sec-0111">Summary of main results</h3> <p>We included 38 trials in this review, but were able to extract data from only 35 trials investigating a total of 18 different comparisons for the primary outcome of benzodiazepine discontinuation. Valproate and tricyclic antidepressants seemed to have a potentially positive effect on benzodiazepine discontinuation, whereas withdrawal symptoms seemed to be potentially ameliorated by pregabalin, captodiame, paroxetine, tricyclic antidepressants, and flumazenil. The following pharmacological agents seemed to potentially reduce symptoms of anxiety: carbamazepine, pregabalin, captodiame, paroxetine, and flumazenil. However, flumazenil seemed to be associated with a high risk of precipitating a severe withdrawal syndrome, since one of the trials was prematurely ended due to observation of unacceptable adverse events (severe panic reactions). Alpidem seemed to worsen both the probability of discontinuing benzodiazepines and the intensity of withdrawal symptoms and should not be further investigated for this use. Likewise, magnesium aspartate seemed to decrease the proportion of participants discontinuing benzodiazepines. </p> </section> <section id="CD011481-sec-0112"> <h3 class="title" id="CD011481-sec-0112">Overall completeness and applicability of evidence</h3> <p>A plethora of different drugs have been investigated in a number of small trials, many of which are of questionable quality, poorly reported, and thus difficult to extract data from. The data set is therefore not complete, but nevertheless judged by the review authors to give a full representation of the current body of evidence in this area. A substantial proportion of included trials were initiated and sponsored by the pharmaceutical industry. </p> </section> <section id="CD011481-sec-0113"> <h3 class="title" id="CD011481-sec-0113">Quality of the evidence</h3> <p>We generally rated the quality of the evidence as very low or low, representing small studies of generally poor methodology and poor reporting. Especially as many of the trials were of older date, modern standards of design and reporting were not fulfilled. As a result, the conclusions of this review should be considered tentative at best. Nonetheless, the review provides an overview of the current status of evidence and points to future directions for research on the development of pharmacotherapies for benzodiazepine dependence. </p> </section> <section id="CD011481-sec-0114"> <h3 class="title" id="CD011481-sec-0114">Potential biases in the review process</h3> <p>Some of the authors of this review also authored one of the included trials (<a href="./references#CD011481-bbs2-0002" title="BaandrupL , FagerlundB , GlenthojB . Neurocognitive performance, subjective well‐being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add‐on melatonin versus placebo. European Archives of Psychiatry and Clinical Neuroscience2017;267(2):163‐71. [PUBMED: 27400927] BaandrupL , GlenthojBY , JennumPJ . Objective and subjective sleep quality: melatonin versus placebo add‐on treatment in patients with schizophrenia or bipolar disorder withdrawing from long‐term benzodiazepine use. Psychiatry Research2016;240:163‐9. [PUBMED: 27107670] BaandrupL , LindschouJ , WinkelP , GluudC , GlenthojBY . Prolonged‐release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: a randomised, placebo‐controlled, blinded trial. World Journal of Biological Psychiatry2016;17(7):514‐24. [PUBMED: 26086792] ">Baandrup 2016</a>). Data extraction and risk of bias assessment of this particular trial was done by LB and JR, the latter of whom was not involved in the trial in any way. The trial examined melatonin for benzodiazepine discontinuation. The meta‐analysis showed no benefit of melatonin for any of the reported outcomes, and thus we do not believe that our involvement in one the included trials in any way biased the results. </p> <p>In our protocol, we planned to only focus our assessments on randomised controlled trials (<a href="./references#CD011481-bbs2-0062" title="BaandrupL , EbdrupBH , LindschouJ , GluudC , GlenthøjBY . Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database of Systematic Reviews2015, Issue 1. [DOI: 10.1002/14651858.CD011481] ">Baandrup 2015</a>). By doing so, we are well aware of the fact that we put an overemphasis on potential beneficial effects of the assessed interventions and ran the risks of overlooking harms. The reasons for these considerations are that harms are generally not well reported in randomised controlled trials, and that observational studies are usually needed to detect rare‐ and late‐occurring adverse events (<a href="./references#CD011481-bbs2-0088" title="IoannidisJP , EvansSJ , GotzschePC , O'NeillRT , AltmanDG , SchulzK , et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine2004;141(10):781‐8. [PUBMED: 15545678] ">Ioannidis 2004</a>; <a href="./references#CD011481-bbs2-0089" title="IoannidisJP . Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Archives of Internal Medicine2009; Vol. 169, issue 19:1737‐9. [PUBMED: 19858427] ">Ioannidis 2009</a>). </p> <p>We did not search relevant databases of regulatory authorities as this was not planned in our protocol. We could therefore have overlooked relevant trials that have not been published in the usual literature. In all likelihood, such trials are at high risk of showing neutral or negative intervention effects, but for completeness of literature searches such databases of regulatory authorities need to be searched in future updates of this review (<a href="./references#CD011481-bbs2-0107" title="SchrollJB , BeroL . Regulatory agencies hold the key to improving Cochrane Reviews of drugs [editorial]. Cochrane Database of Systematic Reviews2015; Vol. 4. [DOI: 10.1002/14651858.ED000098; PUBMED: 25904511] ">Schroll 2015</a>). </p> </section> <section id="CD011481-sec-0115"> <h3 class="title" id="CD011481-sec-0115">Agreements and disagreements with other studies or reviews</h3> <p>A number of other reviews have been published on similar topics. A Cochrane Review investigating pharmacological interventions for benzodiazepine mono‐dependence management in outpatient settings in 35 studies pointed to a potential value of carbamazepine, but concluded that larger, controlled studies were needed (<a href="./references#CD011481-bbs2-0077" title="DenisC , FatseasM , LavieE , AuriacombeM . Pharmacological interventions for benzodiazepine mono‐dependence management in outpatient settings. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD005194.pub2] ">Denis 2006</a>). The current review confirms the potential value of carbamazepine, but the body of evidence is too weak to translate this into a clinical recommendation. </p> <p><a href="./references#CD011481-bbs2-0119" title="VoshaarRC , CouveeJE , vanBalkomAJ , MulderPG , ZitmanFG . Strategies for discontinuing long‐term benzodiazepine use: meta‐analysis. British Journal of Psychiatry2006;189:213‐20. ">Voshaar 2006</a> found that augmentation of systematic benzodiazepine discontinuation with imipramine was superior to systematic discontinuation alone. This conclusion is in agreement with the current review, although we could only identify a possible beneficial effect of tricyclic antidepressant on benzodiazepine discontinuation at longest follow‐up, based on data from a single trial. Furthermore, we report a potential favour of tricyclic antidepressants regarding benzodiazepine withdrawal symptoms, but this was also based on only one trial with results that generally seemed biased. </p> <p>In <a href="./references#CD011481-bbs2-0103" title="ParrJM , KavanaghDJ , CahillL , MitchellG , McD YoungR . Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta‐analysis. Addiction2009;104(1):13‐24. ">Parr 2009</a>, gradual dose reduction plus substitutive pharmacotherapies was compared with gradual dose reduction alone, restricted to general practice and outpatient settings. An evaluation of benzodiazepine cessation rate in 18 studies found promise for a few substitutive pharmacotherapies (melatonin, paroxetine, trazodone, and valproate), but concluded that the current evidence was insufficient to support their use. Our review, which included several more studies, adds further value to the suggestion of further investigating this topic, potentially involving paroxetine (and/or other selective serotonin reuptake inhibitors (SSRIs)) and valproate. </p> <p><a href="./references#CD011481-bbs2-0073" title="DarkerCD , SweeneyBP , BarryJM , FarrellMF , Donnelly‐SwiftE . Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. The Cochrane Database of Systematic Reviews2015, Issue 5. [DOI: 10.1002/14651858.CD009652.pub2] ">Darker 2015</a> examined psychosocial interventions for benzodiazepine withdrawal, finding a short‐term beneficial effect of cognitive behavioural therapy that did not last beyond three months. Motivational interviewing had no effect on benzodiazepine discontinuation. Other promising interventions investigated in single trials included a tailored letter from the general practitioner, standardised interview, and relaxation technique. The evidence base for using non‐pharmacological interventions to facilitate benzodiazepine use is unfortunately thus not much more convincing than the evidence gathered in the current review on pharmacological interventions. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011481-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011481-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011481-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011481-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of comparison: 2 Carbamazepine versus placebo, outcome: 2.1 Benzodiazepine discontinuation. Trial Sequential Analysis on benzodiazepine discontinuation in three trials was performed based on the proportion with benzodiazepine discontinuation in the control group set at 48%, a relative risk reduction (RRR) of 20%, a type I error of 2.5%, a type II error of 10% (90% power), and diversity of 36% as observed in the trials. The diversity‐adjusted required information size (DARIS) was 2109 participants, and the Trial Sequential Analysis‐adjusted confidence interval is 0.24 to 2.38. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 5%. The cumulative Z‐curve (blue line) touches the conventional statistical boundaries, but does not cross the trial sequential monitoring boundaries, and the diversity‐adjusted required information size is not met, showing that insufficient information has been accrued." data-id="CD011481-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Trial Sequential Analysis of comparison: 2 Carbamazepine versus placebo, outcome: 2.1 Benzodiazepine discontinuation. Trial Sequential Analysis on benzodiazepine discontinuation in three trials was performed based on the proportion with benzodiazepine discontinuation in the control group set at 48%, a relative risk reduction (RRR) of 20%, a type I error of 2.5%, a type II error of 10% (90% power), and diversity of 36% as observed in the trials. The diversity‐adjusted required information size (DARIS) was 2109 participants, and the Trial Sequential Analysis‐adjusted confidence interval is 0.24 to 2.38. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 5%. The cumulative Z‐curve (blue line) touches the conventional statistical boundaries, but does not cross the trial sequential monitoring boundaries, and the diversity‐adjusted required information size is not met, showing that insufficient information has been accrued. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of comparison: 6 Paroxetine versus placebo, outcome: 6.1 Benzodiazepine discontinuation. Trial Sequential Analysis on benzodiazepine discontinuation in three trials was performed based on the proportion with benzodiazepine discontinuation in the control group set at 48%, a relative risk reduction of 20%, a type I error of 2.5%, a type II error of 10% (90% power), and diversity of 86% as observed in the trials. The diversity‐adjusted required information size was 9448 participants, and the Trial Sequential Analysis‐adjusted confidence interval could not be estimated due to lack of information. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 5%. The cumulative Z‐curve (blue line) does not cross the conventional statistical boundaries. The trial sequential monitoring boundaries and the diversity‐adjusted required information size are not shown as the accrued number of participants only amounted to 221/9448 (2.34%), showing that insufficient information has been accrued." data-id="CD011481-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Trial Sequential Analysis of comparison: 6 Paroxetine versus placebo, outcome: 6.1 Benzodiazepine discontinuation. Trial Sequential Analysis on benzodiazepine discontinuation in three trials was performed based on the proportion with benzodiazepine discontinuation in the control group set at 48%, a relative risk reduction of 20%, a type I error of 2.5%, a type II error of 10% (90% power), and diversity of 86% as observed in the trials. The diversity‐adjusted required information size was 9448 participants, and the Trial Sequential Analysis‐adjusted confidence interval could not be estimated due to lack of information. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 5%. The cumulative Z‐curve (blue line) does not cross the conventional statistical boundaries. The trial sequential monitoring boundaries and the diversity‐adjusted required information size are not shown as the accrued number of participants only amounted to 221/9448 (2.34%), showing that insufficient information has been accrued. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of comparison: 6 Paroxetine versus placebo, outcome: 6.2 Benzodiazepine withdrawal symptoms Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ). Trial Sequential Analysis on benzodiazepine withdrawal symptoms assessed with BWSQ assessing a minimal relevant clinical difference (MIREDIF) of 2.25 points, and a variance of 20 points (empirical data), was performed based on a type I error of 1.25%, a type II error of 10% (90% power), and diversity of 0%. The diversity‐adjusted required information size (DARIS) was 229 participants, and the Trial Sequential Analysis‐adjusted confidence interval is ‐7.18 to 0.05. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 0.05. The red inward‐sloping lines represent the trial sequential monitoring boundaries. The cumulative Z‐curve touches the trial sequential monitoring boundaries, indicating that sufficient information was provided." data-id="CD011481-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Trial Sequential Analysis of comparison: 6 Paroxetine versus placebo, outcome: 6.2 Benzodiazepine withdrawal symptoms Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ). Trial Sequential Analysis on benzodiazepine withdrawal symptoms assessed with BWSQ assessing a minimal relevant clinical difference (MIREDIF) of 2.25 points, and a variance of 20 points (empirical data), was performed based on a type I error of 1.25%, a type II error of 10% (90% power), and diversity of 0%. The diversity‐adjusted required information size (DARIS) was 229 participants, and the Trial Sequential Analysis‐adjusted confidence interval is ‐7.18 to 0.05. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 0.05. The red inward‐sloping lines represent the trial sequential monitoring boundaries. The cumulative Z‐curve touches the trial sequential monitoring boundaries, indicating that sufficient information was provided. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of comparison: 6 Paroxetine versus placebo, outcome: 6.3 Anxiety, Hamilton Anxiety Rating Scale (HAM‐A). Trial Sequential Analysis on anxiety evaluated with HAM‐A assessing a minimal relevant clinical difference (MIREDIF) of 5 points, and a variance of 103 points, was performed based on a type I error of 1.25%, a type II error of 10% (90% power), and diversity of 0%. The diversity‐adjusted required information size (DARIS) was 236 participants, and the Trial Sequential Analysis‐adjusted confidence interval is ‐12.72 to ‐0.80. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 0.05. The red inward‐sloping lines represent the trial sequential monitoring boundaries. The cumulative Z‐curve crosses the trial sequential monitoring boundaries, indicating that sufficient information was provided." data-id="CD011481-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Trial Sequential Analysis of comparison: 6 Paroxetine versus placebo, outcome: 6.3 Anxiety, Hamilton Anxiety Rating Scale (HAM‐A). Trial Sequential Analysis on anxiety evaluated with HAM‐A assessing a minimal relevant clinical difference (MIREDIF) of 5 points, and a variance of 103 points, was performed based on a type I error of 1.25%, a type II error of 10% (90% power), and diversity of 0%. The diversity‐adjusted required information size (DARIS) was 236 participants, and the Trial Sequential Analysis‐adjusted confidence interval is ‐12.72 to ‐0.80. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 0.05. The red inward‐sloping lines represent the trial sequential monitoring boundaries. The cumulative Z‐curve crosses the trial sequential monitoring boundaries, indicating that sufficient information was provided. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of comparison: 7 Tricyclic antidepressants versus placebo, outcome: 7.1 Benzodiazepine discontinuation. Trial Sequential Analysis on benzodiazepine discontinuation in two trials was performed based on the proportion with benzodiazepine discontinuation in the control group set at 48%, a relative risk reduction (RRR) of 20%, a type I error of 2.5%, a type II error of 10% (90% power), and diversity of 0% as observed in the trials. The diversity‐adjusted required information size (DARIS) was 1343 participants, and the Trial Sequential Analysis‐adjusted confidence interval is 0.20 to 7.55. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 5%. The cumulative Z‐curve (blue line) does not cross the conventional statistical boundaries or the trial sequential monitoring boundaries (red dotted lines), and the diversity‐adjusted required information size is not met, showing that insufficient information has been accrued." data-id="CD011481-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Trial Sequential Analysis of comparison: 7 Tricyclic antidepressants versus placebo, outcome: 7.1 Benzodiazepine discontinuation. Trial Sequential Analysis on benzodiazepine discontinuation in two trials was performed based on the proportion with benzodiazepine discontinuation in the control group set at 48%, a relative risk reduction (RRR) of 20%, a type I error of 2.5%, a type II error of 10% (90% power), and diversity of 0% as observed in the trials. The diversity‐adjusted required information size (DARIS) was 1343 participants, and the Trial Sequential Analysis‐adjusted confidence interval is 0.20 to 7.55. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 5%. The cumulative Z‐curve (blue line) does not cross the conventional statistical boundaries or the trial sequential monitoring boundaries (red dotted lines), and the diversity‐adjusted required information size is not met, showing that insufficient information has been accrued. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of comparison: 8 Alpidem versus placebo, outcome: 8.3 Anxiety, Hamilton Anxiety Rating Scale (HAM‐A). Trial Sequential Analysis on anxiety evaluated with HAM‐A assessing a minimal relevant clinical difference (MIREDIF) of 5 points, and a variance of 103 points (empirical data), was performed based on a type I error of 1.25%, a type II error of 10% (90% power), and diversity of 0%. The diversity‐adjusted required information size (DARIS) was 235 participants, and the Trial Sequential Analysis‐adjusted confidence interval is ‐6.28 to 3.08. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 0.05. The red inward‐sloping lines represent the trial sequential alpha‐spending monitoring boundaries, while the red outward‐sloping lines represent the beta‐spending (futility) boundaries. The cumulative Z‐curve crosses the beta‐spending (futility) boundaries, showing that an intervention effect, if any, is less than 5 points." data-id="CD011481-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Trial Sequential Analysis of comparison: 8 Alpidem versus placebo, outcome: 8.3 Anxiety, Hamilton Anxiety Rating Scale (HAM‐A). Trial Sequential Analysis on anxiety evaluated with HAM‐A assessing a minimal relevant clinical difference (MIREDIF) of 5 points, and a variance of 103 points (empirical data), was performed based on a type I error of 1.25%, a type II error of 10% (90% power), and diversity of 0%. The diversity‐adjusted required information size (DARIS) was 235 participants, and the Trial Sequential Analysis‐adjusted confidence interval is ‐6.28 to 3.08. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 0.05. The red inward‐sloping lines represent the trial sequential alpha‐spending monitoring boundaries, while the red outward‐sloping lines represent the beta‐spending (futility) boundaries. The cumulative Z‐curve crosses the beta‐spending (futility) boundaries, showing that an intervention effect, if any, is less than 5 points. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of comparison: 9 Buspirone versus placebo, outcome: 9.1 Benzodiazepine discontinuation. Trial Sequential Analysis on benzodiazepine discontinuation in four trials was performed based on the proportion with benzodiazepine discontinuation in the control group set at 48%, a relative risk reduction of 20%, a type I error of 2.5%, a type II error of 10% (90% power), and diversity of 60% as observed in the trials. The diversity‐adjusted required information size was 3381 participants, and the Trial Sequential Analysis‐adjusted confidence interval could not be estimated due to lack of information. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 5%. The cumulative Z‐curve (blue line) does not cross the conventional statistical boundaries. The trial sequential monitoring boundaries and the diversity‐adjusted required information size are not shown, as the accrued number of participants only amounted to 143/3381 (4.23%), showing that insufficient information has been accrued." data-id="CD011481-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Trial Sequential Analysis of comparison: 9 Buspirone versus placebo, outcome: 9.1 Benzodiazepine discontinuation. Trial Sequential Analysis on benzodiazepine discontinuation in four trials was performed based on the proportion with benzodiazepine discontinuation in the control group set at 48%, a relative risk reduction of 20%, a type I error of 2.5%, a type II error of 10% (90% power), and diversity of 60% as observed in the trials. The diversity‐adjusted required information size was 3381 participants, and the Trial Sequential Analysis‐adjusted confidence interval could not be estimated due to lack of information. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 5%. The cumulative Z‐curve (blue line) does not cross the conventional statistical boundaries. The trial sequential monitoring boundaries and the diversity‐adjusted required information size are not shown, as the accrued number of participants only amounted to 143/3381 (4.23%), showing that insufficient information has been accrued. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of comparison: 10 Melatonin versus placebo, outcome: 10.1 Benzodiazepine discontinuation. Trial Sequential Analysis on benzodiazepine discontinuation in four trials was performed based on the proportion with benzodiazepine discontinuation in the control group set at 48%, a relative risk reduction (RRR) of 20%, a type I error of 2.5%, a type II error of 10% (90% power), and diversity of 61% as observed in the trials. The diversity‐adjusted required information size (DARIS) was 3438 participants, and the Trial Sequential Analysis‐adjusted confidence interval is 0.11 to 6.25. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 5%. The cumulative Z‐curve (blue line) does not cross the conventional statistical boundaries or the trial sequential monitoring boundaries (red dotted lines), and the diversity‐adjusted required information size is not met, showing that insufficient information has been accrued." data-id="CD011481-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Trial Sequential Analysis of comparison: 10 Melatonin versus placebo, outcome: 10.1 Benzodiazepine discontinuation. Trial Sequential Analysis on benzodiazepine discontinuation in four trials was performed based on the proportion with benzodiazepine discontinuation in the control group set at 48%, a relative risk reduction (RRR) of 20%, a type I error of 2.5%, a type II error of 10% (90% power), and diversity of 61% as observed in the trials. The diversity‐adjusted required information size (DARIS) was 3438 participants, and the Trial Sequential Analysis‐adjusted confidence interval is 0.11 to 6.25. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries of P = 5%. The cumulative Z‐curve (blue line) does not cross the conventional statistical boundaries or the trial sequential monitoring boundaries (red dotted lines), and the diversity‐adjusted required information size is not met, showing that insufficient information has been accrued. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Valproate versus placebo or no intervention, Outcome 1 Benzodiazepine discontinuation, end of intervention." data-id="CD011481-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Valproate versus placebo or no intervention, Outcome 1 Benzodiazepine discontinuation, end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Valproate versus placebo or no intervention, Outcome 2 Relapse to benzodiazepine use, end of intervention." data-id="CD011481-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Valproate versus placebo or no intervention, Outcome 2 Relapse to benzodiazepine use, end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Valproate versus placebo or no intervention, Outcome 3 Benzodiazepine discontinuation, longest follow‐up." data-id="CD011481-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Valproate versus placebo or no intervention, Outcome 3 Benzodiazepine discontinuation, longest follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Valproate versus placebo or no intervention, Outcome 4 Relapse to benzodiazepine use, longest follow‐up." data-id="CD011481-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Valproate versus placebo or no intervention, Outcome 4 Relapse to benzodiazepine use, longest follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Valproate versus placebo or no intervention, Outcome 5 Anxiety: HAM‐A (Hamilton Anxiety Rating Scale), end of intervention." data-id="CD011481-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Valproate versus placebo or no intervention, Outcome 5 Anxiety: HAM‐A (Hamilton Anxiety Rating Scale), end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Valproate versus placebo or no intervention, Outcome 6 Benzodiazepine withdrawal symptoms, end of intervention." data-id="CD011481-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Valproate versus placebo or no intervention, Outcome 6 Benzodiazepine withdrawal symptoms, end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Valproate versus placebo or no intervention, Outcome 7 Discontinuation due to adverse events." data-id="CD011481-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Valproate versus placebo or no intervention, Outcome 7 Discontinuation due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Valproate versus placebo or no intervention, Outcome 8 Serious adverse events." data-id="CD011481-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Valproate versus placebo or no intervention, Outcome 8 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Carbamazepine versus placebo, Outcome 1 Benzodiazepine discontinuation, end of intervention." data-id="CD011481-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Carbamazepine versus placebo, Outcome 1 Benzodiazepine discontinuation, end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Carbamazepine versus placebo, Outcome 2 Benzodiazepine withdrawal symptoms." data-id="CD011481-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Carbamazepine versus placebo, Outcome 2 Benzodiazepine withdrawal symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Carbamazepine versus placebo, Outcome 3 Benzodiazepine discontinuation, longest follow‐up." data-id="CD011481-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Carbamazepine versus placebo, Outcome 3 Benzodiazepine discontinuation, longest follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Carbamazepine versus placebo, Outcome 4 Relapse to benzodiazepine use." data-id="CD011481-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Carbamazepine versus placebo, Outcome 4 Relapse to benzodiazepine use.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Carbamazepine versus placebo, Outcome 5 Serious adverse events." data-id="CD011481-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Carbamazepine versus placebo, Outcome 5 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Carbamazepine versus placebo, Outcome 6 Non‐serious adverse events." data-id="CD011481-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Carbamazepine versus placebo, Outcome 6 Non‐serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Carbamazepine versus placebo, Outcome 7 Anxiety, HAM‐A." data-id="CD011481-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Carbamazepine versus placebo, Outcome 7 Anxiety, HAM‐A.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Carbamazepine versus placebo, Outcome 8 Discontinuation due to adverse events." data-id="CD011481-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Carbamazepine versus placebo, Outcome 8 Discontinuation due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Lithium versus placebo, Outcome 1 Benzodiazepine discontinuation." data-id="CD011481-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Lithium versus placebo, Outcome 1 Benzodiazepine discontinuation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Lithium versus placebo, Outcome 2 Serious adverse events." data-id="CD011481-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Lithium versus placebo, Outcome 2 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Lithium versus placebo, Outcome 3 Non‐serious adverse events." data-id="CD011481-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Lithium versus placebo, Outcome 3 Non‐serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Lithium versus placebo, Outcome 4 Discontinuation due to adverse events." data-id="CD011481-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Lithium versus placebo, Outcome 4 Discontinuation due to adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Pregabalin versus placebo, Outcome 1 Benzodiazepine discontinuation, end of intervention." data-id="CD011481-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Pregabalin versus placebo, Outcome 1 Benzodiazepine discontinuation, end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Pregabalin versus placebo, Outcome 2 Benzodiazepine withdrawal symptoms (Physician Withdrawal Checklist), end of intervention." data-id="CD011481-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Pregabalin versus placebo, Outcome 2 Benzodiazepine withdrawal symptoms (Physician Withdrawal Checklist), end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Pregabalin versus placebo, Outcome 3 Anxiety, HAM‐A, end of intervention." data-id="CD011481-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Pregabalin versus placebo, Outcome 3 Anxiety, HAM‐A, end of intervention.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Pregabalin versus placebo, Outcome 4 Serious adverse events." data-id="CD011481-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Pregabalin versus placebo, Outcome 4 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Pregabalin versus placebo, Outcome 5 Non‐serious adverse events." data-id="CD011481-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Pregabalin versus placebo, Outcome 5 Non‐serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Pregabalin versus placebo, Outcome 6 Discontinuation due to adverse events." data-id="CD011481-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Pregabalin versus placebo, Outcome 6 Discontinuation due to adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Captodiame versus placebo, Outcome 1 Benzodiazepine withdrawal symptoms, BWSQ (Benzodiazepine Withdrawal Symptom Questionnaire), end of intervention." data-id="CD011481-fig-0038" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Captodiame versus placebo, Outcome 1 Benzodiazepine withdrawal symptoms, BWSQ (Benzodiazepine Withdrawal Symptom Questionnaire), end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Captodiame versus placebo, Outcome 2 Anxiety, HAM‐A, end of intervention." data-id="CD011481-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Captodiame versus placebo, Outcome 2 Anxiety, HAM‐A, end of intervention.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Captodiame versus placebo, Outcome 3 Serious adverse events." data-id="CD011481-fig-0040" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Captodiame versus placebo, Outcome 3 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Captodiame versus placebo, Outcome 4 Non‐serious adverse events." data-id="CD011481-fig-0041" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Captodiame versus placebo, Outcome 4 Non‐serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Paroxetine versus placebo or no intervention, Outcome 1 Benzodiazepine discontinuation, end of intervention." data-id="CD011481-fig-0042" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Paroxetine versus placebo or no intervention, Outcome 1 Benzodiazepine discontinuation, end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Paroxetine versus placebo or no intervention, Outcome 2 Benzodiazepine withdrawal symptoms: BWSQ, end of intervention." data-id="CD011481-fig-0043" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Paroxetine versus placebo or no intervention, Outcome 2 Benzodiazepine withdrawal symptoms: BWSQ, end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Paroxetine versus placebo or no intervention, Outcome 3 Anxiety: HAM‐A, end of intervention." data-id="CD011481-fig-0044" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Paroxetine versus placebo or no intervention, Outcome 3 Anxiety: HAM‐A, end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Paroxetine versus placebo or no intervention, Outcome 4 Benzodiazepine withdrawal symptoms: BWSQ, longest follow‐up: 6 months." data-id="CD011481-fig-0045" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Paroxetine versus placebo or no intervention, Outcome 4 Benzodiazepine withdrawal symptoms: BWSQ, longest follow‐up: 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Paroxetine versus placebo or no intervention, Outcome 5 Serious adverse events." data-id="CD011481-fig-0046" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Paroxetine versus placebo or no intervention, Outcome 5 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Paroxetine versus placebo or no intervention, Outcome 6 Non‐serious adverse events." data-id="CD011481-fig-0047" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Paroxetine versus placebo or no intervention, Outcome 6 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Tricyclic antidepressants versus placebo, Outcome 1 Benzodiazepine discontinuation, end of intervention." data-id="CD011481-fig-0048" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Tricyclic antidepressants versus placebo, Outcome 1 Benzodiazepine discontinuation, end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Tricyclic antidepressants versus placebo, Outcome 2 Anxiety: HAM‐A (change from baseline), end of intervention." data-id="CD011481-fig-0049" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Tricyclic antidepressants versus placebo, Outcome 2 Anxiety: HAM‐A (change from baseline), end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Tricyclic antidepressants versus placebo, Outcome 3 Benzodiazepine discontinuation, longest follow‐up." data-id="CD011481-fig-0050" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Tricyclic antidepressants versus placebo, Outcome 3 Benzodiazepine discontinuation, longest follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Tricyclic antidepressants versus placebo, Outcome 4 Benzodiazepine withdrawal symptoms (Physician Withdrawal Checklist), end of intervention." data-id="CD011481-fig-0051" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Tricyclic antidepressants versus placebo, Outcome 4 Benzodiazepine withdrawal symptoms (Physician Withdrawal Checklist), end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Tricyclic antidepressants versus placebo, Outcome 5 Relapse to benzodiazepine use, end of intervention." data-id="CD011481-fig-0052" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Tricyclic antidepressants versus placebo, Outcome 5 Relapse to benzodiazepine use, end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Tricyclic antidepressants versus placebo, Outcome 6 Discontinuation due to adverse events." data-id="CD011481-fig-0053" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Tricyclic antidepressants versus placebo, Outcome 6 Discontinuation due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Alpidem versus placebo, Outcome 1 Benzodiazepine discontinuation, end of intervention." data-id="CD011481-fig-0054" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Alpidem versus placebo, Outcome 1 Benzodiazepine discontinuation, end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Alpidem versus placebo, Outcome 2 Withdrawal syndrome (clinical diagnosis), end of intervention." data-id="CD011481-fig-0055" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Alpidem versus placebo, Outcome 2 Withdrawal syndrome (clinical diagnosis), end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Alpidem versus placebo, Outcome 3 Anxiety, HAM‐A, end of intervention." data-id="CD011481-fig-0056" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Alpidem versus placebo, Outcome 3 Anxiety, HAM‐A, end of intervention.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Alpidem versus placebo, Outcome 4 Relapse to benzodiazepine use, end of intervention." data-id="CD011481-fig-0057" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Alpidem versus placebo, Outcome 4 Relapse to benzodiazepine use, end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Alpidem versus placebo, Outcome 5 Serious adverse events." data-id="CD011481-fig-0058" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Alpidem versus placebo, Outcome 5 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Alpidem versus placebo, Outcome 6 Discontinuation due to adverse events." data-id="CD011481-fig-0059" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 Alpidem versus placebo, Outcome 6 Discontinuation due to adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Buspirone versus placebo, Outcome 1 Benzodiazepine discontinuation, end of intervention." data-id="CD011481-fig-0060" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Buspirone versus placebo, Outcome 1 Benzodiazepine discontinuation, end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Buspirone versus placebo, Outcome 2 Anxiety: HAM‐A/Hospital Anxiety Depression Scale, end of intervention." data-id="CD011481-fig-0061" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Buspirone versus placebo, Outcome 2 Anxiety: HAM‐A/Hospital Anxiety Depression Scale, end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Buspirone versus placebo, Outcome 3 Benzodiazepine withdrawal symptoms, end of intervention." data-id="CD011481-fig-0062" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Buspirone versus placebo, Outcome 3 Benzodiazepine withdrawal symptoms, end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-009-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-009-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Buspirone versus placebo, Outcome 4 Benzodiazepine discontinuation, longest follow‐up." data-id="CD011481-fig-0063" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-009-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 Buspirone versus placebo, Outcome 4 Benzodiazepine discontinuation, longest follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-009-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-009-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-009-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Buspirone versus placebo, Outcome 5 Benzodiazepine withdrawal symptoms, longest follow‐up." data-id="CD011481-fig-0064" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-009-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9 Buspirone versus placebo, Outcome 5 Benzodiazepine withdrawal symptoms, longest follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-009-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-009-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-009-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Buspirone versus placebo, Outcome 6 Anxiety, Hospital Anxiety Depression Scale, longest follow‐up." data-id="CD011481-fig-0065" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-009-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9 Buspirone versus placebo, Outcome 6 Anxiety, Hospital Anxiety Depression Scale, longest follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-009-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-009-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-009-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Buspirone versus placebo, Outcome 7 Discontinuation due to adverse events." data-id="CD011481-fig-0066" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-009-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9 Buspirone versus placebo, Outcome 7 Discontinuation due to adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-009-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Melatonin versus placebo, Outcome 1 Benzodiazepine discontinuation, end of intervention." data-id="CD011481-fig-0067" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Melatonin versus placebo, Outcome 1 Benzodiazepine discontinuation, end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Melatonin versus placebo, Outcome 2 Insomnia." data-id="CD011481-fig-0068" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Melatonin versus placebo, Outcome 2 Insomnia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Melatonin versus placebo, Outcome 3 Discontinuation due to adverse events." data-id="CD011481-fig-0069" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Melatonin versus placebo, Outcome 3 Discontinuation due to adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-010-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-010-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Melatonin versus placebo, Outcome 4 Benzodiazepine discontinuation, longest follow‐up." data-id="CD011481-fig-0070" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-010-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 Melatonin versus placebo, Outcome 4 Benzodiazepine discontinuation, longest follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-010-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-010-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-010-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Melatonin versus placebo, Outcome 5 Adverse events." data-id="CD011481-fig-0071" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-010-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10 Melatonin versus placebo, Outcome 5 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-010-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-010-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-010-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Melatonin versus placebo, Outcome 6 Relapse to benzodiazepine use, longest follow‐up." data-id="CD011481-fig-0072" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-010-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10 Melatonin versus placebo, Outcome 6 Relapse to benzodiazepine use, longest follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-010-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Flumazenil versus placebo, Outcome 1 Benzodiazepine withdrawal symptoms, end of intervention." data-id="CD011481-fig-0073" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Flumazenil versus placebo, Outcome 1 Benzodiazepine withdrawal symptoms, end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Flumazenil versus placebo, Outcome 2 Anxiety, HAM‐D (Hamilton Depression Rating Scale), end of intervention." data-id="CD011481-fig-0074" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Flumazenil versus placebo, Outcome 2 Anxiety, HAM‐D (Hamilton Depression Rating Scale), end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-011-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-011-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Flumazenil versus placebo, Outcome 3 Benzodiazepine mean dose, end of intervention." data-id="CD011481-fig-0075" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-011-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11 Flumazenil versus placebo, Outcome 3 Benzodiazepine mean dose, end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-011-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Propranolol versus placebo, Outcome 1 Relapse to benzodiazepine use, end of intervention: 2 weeks." data-id="CD011481-fig-0076" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Propranolol versus placebo, Outcome 1 Relapse to benzodiazepine use, end of intervention: 2 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Progesterone versus placebo, Outcome 1 Benzodiazepine discontinuation, end of intervention." data-id="CD011481-fig-0077" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 Progesterone versus placebo, Outcome 1 Benzodiazepine discontinuation, end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-013-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-013-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Progesterone versus placebo, Outcome 2 Non‐serious adverse events." data-id="CD011481-fig-0078" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-013-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13 Progesterone versus placebo, Outcome 2 Non‐serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-013-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-014-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-014-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Magnesium aspartate versus placebo, Outcome 1 Benzodiazepine discontinuation." data-id="CD011481-fig-0079" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-014-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 Magnesium aspartate versus placebo, Outcome 1 Benzodiazepine discontinuation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-014-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-014-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-014-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Magnesium aspartate versus placebo, Outcome 2 Anxiety." data-id="CD011481-fig-0080" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-014-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14 Magnesium aspartate versus placebo, Outcome 2 Anxiety.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-014-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-014-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-014-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Magnesium aspartate versus placebo, Outcome 3 Relapse to benzodiazepine use." data-id="CD011481-fig-0081" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-014-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14 Magnesium aspartate versus placebo, Outcome 3 Relapse to benzodiazepine use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-014-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-014-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-014-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Magnesium aspartate versus placebo, Outcome 4 Non‐serious adverse events." data-id="CD011481-fig-0082" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-014-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14 Magnesium aspartate versus placebo, Outcome 4 Non‐serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-014-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-014-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-014-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Magnesium aspartate versus placebo, Outcome 5 Discontinuation due to adverse events." data-id="CD011481-fig-0083" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-014-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.5</div> <div class="figure-caption"> <p>Comparison 14 Magnesium aspartate versus placebo, Outcome 5 Discontinuation due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-014-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-015-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-015-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Homéogène 46/Sedatif PC (homeopathic drugs) versus placebo, Outcome 1 Benzodiazepine discontinuation." data-id="CD011481-fig-0084" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-015-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15 Homéogène 46/Sedatif PC (homeopathic drugs) versus placebo, Outcome 1 Benzodiazepine discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-015-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-016-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-016-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Carbamazepine versus tricyclic antidepressant, Outcome 1 Benzodiazepine discontinuation, end of intervention." data-id="CD011481-fig-0085" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-016-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16 Carbamazepine versus tricyclic antidepressant, Outcome 1 Benzodiazepine discontinuation, end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-016-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-016-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-016-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Carbamazepine versus tricyclic antidepressant, Outcome 2 Relapse to benzodiazepine use." data-id="CD011481-fig-0086" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-016-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16 Carbamazepine versus tricyclic antidepressant, Outcome 2 Relapse to benzodiazepine use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-016-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-016-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-016-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Carbamazepine versus tricyclic antidepressant, Outcome 3 Serious adverse events." data-id="CD011481-fig-0087" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-016-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.3</div> <div class="figure-caption"> <p>Comparison 16 Carbamazepine versus tricyclic antidepressant, Outcome 3 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-016-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-017-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-017-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Cyamemazine versus bromazepam, Outcome 1 Relapse to benzodiazepine use, longest follow‐up." data-id="CD011481-fig-0088" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-017-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17 Cyamemazine versus bromazepam, Outcome 1 Relapse to benzodiazepine use, longest follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-017-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-017-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-017-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Cyamemazine versus bromazepam, Outcome 2 Anxiety: Maximum amplitude of rebound (HAM‐A), end of intervention." data-id="CD011481-fig-0089" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-017-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17 Cyamemazine versus bromazepam, Outcome 2 Anxiety: Maximum amplitude of rebound (HAM‐A), end of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-017-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-017-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-017-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Cyamemazine versus bromazepam, Outcome 3 Discontinuation due to adverse events." data-id="CD011481-fig-0090" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-017-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.3</div> <div class="figure-caption"> <p>Comparison 17 Cyamemazine versus bromazepam, Outcome 3 Discontinuation due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-017-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-017-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-017-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Cyamemazine versus bromazepam, Outcome 4 Non‐serious adverse events." data-id="CD011481-fig-0091" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-017-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.4</div> <div class="figure-caption"> <p>Comparison 17 Cyamemazine versus bromazepam, Outcome 4 Non‐serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-017-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011481-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/urn:x-wiley:14651858:media:CD011481:CD011481-CMP-018-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_t/tCD011481-CMP-018-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Zopiclone versus flunitrazepam, Outcome 1 Relapse to benzodiazepine use, longest follow‐up." data-id="CD011481-fig-0092" src="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-018-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18 Zopiclone versus flunitrazepam, Outcome 1 Relapse to benzodiazepine use, longest follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/media/CDSR/CD011481/image_n/nCD011481-CMP-018-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011481-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Valproate compared with placebo or no intervention for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Valproate compared with placebo or no intervention for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> valproate<br/> <b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Valproate</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.55</b> <br/> (1.08 to 6.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The required information size of 1918 participants was not met.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>679 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b><br/> (142 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.57</b> <br/> (0.80 to 3.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>785 per 1000</b><br/> (400 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean benzodiazepine withdrawal symptoms in the intervention groups was<br/> <b>0.15 standard deviations lower</b><br/> (0.68 lower to 0.37 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.15 (‐0.68 to 0.37).</p> <p>As a rule of thumb, 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio: <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No details provided regarding random sequence generation, allocation concealment, and blinding, leading to unclear risk of selection bias, performance and detection bias (downgraded one level).<br/> <sup>2</sup>Required information size not met (downgraded two levels due to serious imprecision: the sample size is far from the required one).<br/> <sup>3</sup>Unclear risk of selection bias, attrition bias, reporting bias and high risk of performance bias (downgraded one level).<br/> <sup>4</sup>Required information size not met (downgraded two levels due to serious imprecision). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Valproate compared with placebo or no intervention for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011481-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Carbamazepine compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Carbamazepine compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> carbamazepine<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Carbamazepine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.33</b> <br/> (0.99 to 1.8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>147<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis showed that only 7.0% of the required information size (2109) was reached, indicating that insufficient information has been obtained. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>480 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>638 per 1000</b><br/> (475 to 864) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.41</b> <br/> (0.86 to 2.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>40<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>524 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>739 per 1000</b><br/> (450 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean benzodiazepine withdrawal symptoms in the intervention groups was<br/> <b>1.14 standard deviations lower</b><br/> (2.43 lower to 0.16 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐1.14 (‐2.43 to 0.16).</p> <p>As a rule of thumb, 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio: <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection bias. One study with high risk of attrition, reporting, and other bias (downgraded one level).<br/> <sup>2</sup>Required information size not met (downgraded one level due to imprecision).<br/> <sup>3</sup>Unclear risk of selection and attrition bias (downgraded one level).<br/> <sup>4</sup>Required information size not met, and 95% CI includes both no effect and appreciable benefit (downgraded two levels due to imprecision).<br/> <sup>5</sup>Required information size not met (downgraded one level for imprecision).<br/> <sup>6</sup>Significant heterogeneity (downgraded one level for inconsistency). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Carbamazepine compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011481-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Lithium compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lithium compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> lithium<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Lithium</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.05</b> <br/> (0.86 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>230<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The required information size of 1918 participants was not met.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>617 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>648 per 1000</b><br/> (531 to 790) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection, attrition, and reporting bias (downgraded one level).<br/> <sup>2</sup>The required information size of 1918 participants was not met (downgraded one level due to imprecision). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Lithium compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011481-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Pregabalin compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pregabalin compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> pregabalin<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Pregabalin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.44</b> <br/> (0.92 to 2.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>106<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The required information size of 1918 participants was not met.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>360 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>518 per 1000</b><br/> (331 to 810) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, Physician Withdrawal Checklist (PWCL), end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean benzodiazepine withdrawal symptoms, PWCL, end of intervention in the intervention group was<br/> <b>3.10 lower</b><br/> (3.51 to 2.69 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐3.10 (‐3.51 to ‐2.69)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection bias and high risk of attrition and other bias (downgraded two levels).<br/> <sup>2</sup>Required information size not met (downgraded one level due to imprecision). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Pregabalin compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011481-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Captodiame compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Captodiame compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> captodiame<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Captodiame</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ), end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean benzodiazepine withdrawal symptoms, BWSQ, end of intervention in the intervention group was<br/> <b>1.00 lower</b><br/> (1.13 to 0.87 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐1.00 (‐1.13 to ‐0.87)</p> <p>The required information size of 229 participants was not met.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection and reporting bias. High risk of other bias (downgraded one level).<br/> <sup>2</sup>Required information size not met (downgraded two levels due to imprecision). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Captodiame compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011481-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Paroxetine compared with placebo or no intervention for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Paroxetine compared with placebo or no intervention for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> paroxetine<br/> <b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Paroxetine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.45</b> <br/> (0.88 to 2.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>221<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis showed that only 2.34% of the required information size (9448) was reached, indicating that insufficient information has been obtained. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>504 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>731 per 1000</b><br/> (444 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, BWSQ, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean benzodiazepine withdrawal symptoms, BWSQ, end of intervention in the intervention groups was<br/> <b>3.57 lower</b><br/> (5.34 to 1.8 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐3.57 (‐5.34 to ‐1.8). Trial Sequential Analysis showed that the required information size of 229 participants was not reached. However, the alpha‐spending boundaries for benefit were crossed, indicating that sufficient information was obtained, and the result was not due to random error. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, BWSQ, longest follow‐up: 6 months</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean benzodiazepine withdrawal symptoms, BWSQ, longest follow‐up: 6 months in the intervention group was<br/> <b>0.13 lower</b><br/> (4.03 lower to 3.77 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.13 (‐4.03 to 3.77)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BWSQ:</b> Benzodiazepine Withdrawal Symptom Questionnaire; <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection and attrition bias. High risk of performance, detection, reporting, and other bias (downgraded two levels).<br/> <sup>2</sup>Required information size not met (downgraded one level due to imprecision).<br/> <sup>3</sup>Unclear risk of selection bias. High risk of performance, detection, reporting, and other bias (downgraded two levels).<br/> <sup>4</sup>The required information size was not met (downgraded one level due to imprecision).<br/> <sup>5</sup>Unclear risk of selection bias. High risk of reporting and other bias (downgraded one level).<br/> <sup>6</sup>Required information size not met (downgraded two levels due to imprecision). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Paroxetine compared with placebo or no intervention for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011481-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Tricyclic antidepressants compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tricyclic antidepressants compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> tricyclic antidepressants<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tricyclic antidepressants</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.82</b> <br/> (0.52 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>105<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis showed that only 7.82% of the required information size (1343) was reached, indicating that insufficient information has been obtained. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>451 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>370 per 1000</b><br/> (235 to 577) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.2</b> <br/> (1.27 to 3.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>47<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>375 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>825 per 1000</b><br/> (476 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, Physician Withdrawal Checklist, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean benzodiazepine withdrawal symptoms in the intervention group was<br/> 19.78<b>lower</b><br/> (20.25 lower to 19.31 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐19.78 (‐20.25 to ‐19.31)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection bias and high risk of attrition and other bias (downgraded one level).<br/> <sup>2</sup>Required information size not met (downgraded one level due to imprecision).<br/> <sup>3</sup>Unclear risk of selection and attrition bias (downgraded one level).<br/> <sup>4</sup>Required information size not met (downgraded two levels due to imprecision).<br/> <sup>5</sup>High risk of performance, detection, and reporting bias (downgraded two levels). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Tricyclic antidepressants compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011481-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Alpidem compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Alpidem compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> alpidem<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Alpidem</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.41</b> <br/> (0.17 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>25<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The required information size of 1918 participants was not met.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>750 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>308 per 1000</b><br/> (128 to 743) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawal syndrome (clinical diagnosis), end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 4.86</b> <br/> (1.12 to 21.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>145<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b><br/> (33 to 622) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Required information size not met (downgraded two levels due to imprecision).<br/> <sup>2</sup>Required information size not met (downgraded one level due to imprecision). </p> <p><sup>3</sup>Unclear risk of selection and other bias, high risk of attrition bias (downgraded one level) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Alpidem compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011481-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Buspirone compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Buspirone compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> buspirone<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Buspirone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.82</b> <br/> (0.49 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>143<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis showed that only 4.23% of the required information size (3381) was reached, indicating that insufficient information has been obtained. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>563 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>462 per 1000</b><br/> (276 to 772) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.60</b> <br/> (0.34 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>23<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>917 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>550 per 1000</b><br/> (312 to 962) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean benzodiazepine withdrawal symptoms, end of intervention in the intervention groups was<br/> <b>4.69 higher</b><br/> (14.47 lower to 23.85 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 4.69 (‐14.47 to 23.87)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean benzodiazepine withdrawal symptoms, longest follow‐up in the intervention groups was<br/> <b>1.34 lower</b><br/> (14.31 lower to 11.63 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐1.34 (‐14.31 to 11.63)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection, performance, and reporting bias. High risk of attrition and other bias (downgraded one level).<br/> <sup>2</sup>Required information size not met (downgraded one level due to imprecision).<br/> <sup>3</sup>Unclear risk of selection and reporting bias. High risk of attrition bias (downgraded one level).<br/> <sup>4</sup>Reguired information size not met (downgraded two levels due to serious imprecision). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Buspirone compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011481-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Melatonin compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Melatonin compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients (3 studies), outpatients in methadone maintenance treatment (1 study)<br/> <b>Intervention:</b> melatonin<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Melatonin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.20</b> <br/> (0.73 to 1.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>219<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis showed that only 6.37% of the required information size (3438) was reached, indicating that insufficient information has been obtained. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>417 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b><br/> (304 to 817) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.03</b> <br/> (0.47 to 2.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>38<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>389 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>401 per 1000</b><br/> (183 to 883) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazpine withdrawal symptoms, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection, attrition, and reporting bias. High risk of other bias (downgraded one level).<br/> <sup>2</sup>Required information size not met, and the 95% CI includes both no effect and appreciable benefit (downgraded two levels due to imprecision).<br/> <sup>3</sup>Unclear risk of selection and reporting bias (downgraded one level).<br/> <sup>4</sup>Required information size not met (downgraded two levels due to imprecision). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Melatonin compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011481-tbl-0011"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Flumazenil compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Flumazenil compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients in methadone maintenance treatment (2 studies), outpatients (1 study)<br/> <b>Intervention:</b> flumazenil<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Flumazenil</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean benzodiazepine withdrawal symptoms, end of intervention in the intervention groups was<br/> <b>0.95 standard deviations lower</b><br/> (1.71 to 0.19 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.95 (‐1.71 to ‐0.19)</p> <p>As a rule of thumb, 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection bias and high risk of performance, detection, and other bias (downgraded one level).<br/> <sup>2</sup>Required information size not met (downgraded two levels due to imprecision). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Flumazenil compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011481-tbl-0012"> <div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Progesterone compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progesterone compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> progesterone<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Progesterone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.15</b> <br/> (0.52 to 2.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>35<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The required information size of 1918 participants was not met.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>417 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>479 per 1000</b><br/> (217 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection and attrition bias (downgraded one level).<br/> <sup>2</sup>Required information size not met, and the 95% CI includes both no effect and appreciable benefit (downgraded two levels due to imprecision). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Progesterone compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011481-tbl-0013"> <div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Magnesium aspartate compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Magnesium aspartate compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> magnesium aspartate<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Magnesium aspartate</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.80</b> <br/> (0.66 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>144<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The required information size of 1918 participants was not met.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>853 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>683 per 1000</b><br/> (563 to 819) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection, detection, and attrition bias (downgraded one level).<br/> <sup>2</sup>Required information size not met (downgraded two levels due to imprecision). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Magnesium aspartate compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011481-tbl-0014"> <div class="table-heading"><span class="table-label">Summary of findings 14.</span> <span class="table-title">Homéogène 46/Sedatif PC (homeopathic drugs) compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Homéogène 46/Sedatif PC (homeopathic drugs) compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> Homéogène 46/Sedatif PC (homeopathic drugs)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Homéogène 46/Sedatif PC (homeopathic drugs)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.79</b> <br/> (0.36 to 1.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>51<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The required information size was not met.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>381 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>301 per 1000</b><br/> (137 to 648) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection, attrition, and other bias (downgraded one level).<br/> <sup>2</sup>Required information size not met, and the 95% CI includes both no effect and appreciable benefit (downgraded two levels due to imprecision). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 14.</span> <span class="table-title">Homéogène 46/Sedatif PC (homeopathic drugs) compared with placebo for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011481-tbl-0015"> <div class="table-heading"><span class="table-label">Summary of findings 15.</span> <span class="table-title">Carbamazepine compared with tricyclic antidepressant for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Carbamazepine compared with tricyclic antidepressant for benzodiazepine discontinuation in chronic benzodiazepine users</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults who withdraw from chronic benzodiazepine use<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> carbamazepine<br/> <b>Comparison:</b> tricyclic antidepressant </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tricyclic antidepressant</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Carbamazepine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Benzodiazepine discontinuation, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.00</b> <br/> (0.78 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>48<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The required information size was not met.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>833 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>833 per 1000</b><br/> (650 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine discontinuation, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, end of intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine withdrawal symptoms, longest follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear risk of selection, detection, and attrition bias (downgraded one level).<br/> <sup>2</sup>Required information size not met (downgraded one level due to imprecision). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 15.</span> <span class="table-title">Carbamazepine compared with tricyclic antidepressant for benzodiazepine discontinuation in chronic benzodiazepine users</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/full#CD011481-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011481-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Valproate versus placebo or no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Benzodiazepine discontinuation, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.55 [1.08, 6.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Relapse to benzodiazepine use, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.11, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Benzodiazepine discontinuation, longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.80, 3.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Relapse to benzodiazepine use, longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.13, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Anxiety: HAM‐A (Hamilton Anxiety Rating Scale), end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐6.47, 5.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Benzodiazepine withdrawal symptoms, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.68, 0.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Physician Withdrawal Checklist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.77, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 CIWA‐B (Clinical Institute Withdrawal Assessment Scale ‐ Benzodiazepines)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐1.01, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Valproate versus placebo or no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011481-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Carbamazepine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Benzodiazepine discontinuation, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.99, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Benzodiazepine withdrawal symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.14 [‐2.43, 0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Physician Withdrawal Checklist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.82 [‐2.61, ‐1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Patient Withdrawal Checklist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐1.13, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Benzodiazepine discontinuation, longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.86, 2.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Relapse to benzodiazepine use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.08, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.39, 126.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Anxiety, HAM‐A <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.0 [‐9.58, ‐2.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Carbamazepine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011481-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Lithium versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Benzodiazepine discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.86, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.75, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.13, 15.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Lithium versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011481-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Pregabalin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Benzodiazepine discontinuation, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.92, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Benzodiazepine withdrawal symptoms (Physician Withdrawal Checklist), end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.1 [‐3.51, ‐2.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Anxiety, HAM‐A, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.8 [‐5.28, ‐4.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.16, 2.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.84, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.31, 2.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Pregabalin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011481-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Captodiame versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Benzodiazepine withdrawal symptoms, BWSQ (Benzodiazepine Withdrawal Symptom Questionnaire), end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐1.13, ‐0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Anxiety, HAM‐A, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.7 [‐6.05, ‐5.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Captodiame versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011481-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Paroxetine versus placebo or no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Benzodiazepine discontinuation, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.88, 2.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Benzodiazepine withdrawal symptoms: BWSQ, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.57 [‐5.34, ‐1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Anxiety: HAM‐A, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.75 [‐9.64, ‐3.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Benzodiazepine withdrawal symptoms: BWSQ, longest follow‐up: 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐4.03, 3.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.35, 5.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Paroxetine versus placebo or no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011481-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Tricyclic antidepressants versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Benzodiazepine discontinuation, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.52, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Anxiety: HAM‐A (change from baseline), end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.38 [‐25.96, 5.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Benzodiazepine discontinuation, longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [1.27, 3.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Benzodiazepine withdrawal symptoms (Physician Withdrawal Checklist), end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐19.78 [‐20.25, ‐19.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Relapse to benzodiazepine use, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.73, 5.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.42, 3.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Tricyclic antidepressants versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011481-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Alpidem versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Benzodiazepine discontinuation, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.17, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Withdrawal syndrome (clinical diagnosis), end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.86 [1.12, 21.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Anxiety, HAM‐A, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐4.64, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Relapse to benzodiazepine use, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.09, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.05, 4.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Alpidem versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011481-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Buspirone versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Benzodiazepine discontinuation, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.49, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Anxiety: HAM‐A/Hospital Anxiety Depression Scale, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐0.50, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Benzodiazepine withdrawal symptoms, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.69 [‐14.47, 23.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Benzodiazepine discontinuation, longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.34, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Benzodiazepine withdrawal symptoms, longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.34 [‐14.31, 11.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Anxiety, Hospital Anxiety Depression Scale, longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.75 [‐2.83, 8.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Buspirone versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011481-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Melatonin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Benzodiazepine discontinuation, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.73, 1.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Insomnia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.23 [‐2.70, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 PSQI (Pittsburgh Sleep Quality Index) global score (higher = worse), end of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.92, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Sleep quality (1 poorest, 10 excellent), end of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.34 [‐4.42, ‐2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [0.20, 22.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Benzodiazepine discontinuation, longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.47, 2.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.52, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Relapse to benzodiazepine use, longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.8 [0.37, 8.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Melatonin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011481-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Flumazenil versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Benzodiazepine withdrawal symptoms, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.95 [‐1.71, ‐0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Anxiety, HAM‐D (Hamilton Depression Rating Scale), end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.3 [‐2.28, ‐0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Benzodiazepine mean dose, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.70 [‐22.06, 14.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Flumazenil versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011481-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Propranolol versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Relapse to benzodiazepine use, end of intervention: 2 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.31, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Propranolol versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011481-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Progesterone versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Benzodiazepine discontinuation, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.52, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [1.15, 8.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Progesterone versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011481-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Magnesium aspartate versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Benzodiazepine discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.66, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Anxiety <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐2.73, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Relapse to benzodiazepine use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.46, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.18, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.13, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Magnesium aspartate versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011481-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Homéogène 46/Sedatif PC (homeopathic drugs) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Benzodiazepine discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.36, 1.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Homéogène 46/Sedatif PC (homeopathic drugs) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011481-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Carbamazepine versus tricyclic antidepressant</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Benzodiazepine discontinuation, end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.78, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Relapse to benzodiazepine use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.28, 3.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Carbamazepine versus tricyclic antidepressant</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011481-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Cyamemazine versus bromazepam</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Relapse to benzodiazepine use, longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.14, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Anxiety: Maximum amplitude of rebound (HAM‐A), end of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐1.23, 2.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [0.79, 10.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [1.01, 2.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Cyamemazine versus bromazepam</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011481-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Zopiclone versus flunitrazepam</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Relapse to benzodiazepine use, longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.23, 4.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Zopiclone versus flunitrazepam</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011481.pub2/references#CD011481-tbl-0033">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011481.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011481-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011481-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011481-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD011481-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD011481-note-0022">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011481-note-0004">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011481\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011481\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011481\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011481\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011481\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011481\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011481\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011481\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6XSHdtL3&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011481.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011481.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011481.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011481.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011481.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720349165"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011481.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720349169"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011481.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dfeff39c89377',t:'MTc0MDcyMDM0OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 